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Abstract
Self-immolative spacers are a unique class of molecules employed in a variety of
applications, particularly in the biomedical field.

Most commonly, they are molecules

containing two reactive termini with a capping group at one terminus and a substrate of
interest at the other.

Upon removal of the capping group, the spacer undergoes an

intramolecular reaction that results in its removal from the molecule and liberation of the
substrate. These spacers have been extensively studied in monomeric form within prodrugs,
as well as to form dendrimers that have been used for applications such as signal
amplification, molecular logic gates and amplified drug release. Their use to form polymeric
systems, however, remains largely unexplored and undeveloped. The work described in this
thesis serves to expand this particular area of research, exploring the use of amine-based selfimmolative spacers in the context of self-immolative polymers.
Two new polymeric systems were developed using N,N-dimethylethylenediamine in
conjunction with first 4-hydroxybenzyl alcohol and then 2-mercaptoethanol. In the first
example, when a poly(ethylene glycol) end cap was used a block copolymer was formed that
self-assembled in an aqueous environment and was capable of encapsulating a hydrophobic
molecule and releasing it upon polymer degradation. The second polymeric system was the
first fully aliphatic self-immolative polymer, and when a disulfide end cap was employed
polymer degradation could be triggered by the addition of dithiothreitol.
Following this work, a series of novel self-immolative spacers derived from 4aminobutyric acid were developed in efforts to gain access to more rapidly cyclizing aminebased spacers. Carrying out modifications to the N and ! positions, a series of spacers were
developed with half-lives of cyclization ranging from 2 – 39 s. Lastly, these spacers were
then combined with 4-hydroxybenzyl alcohol and 2’-hydroxyhydrocinnamic acid in efforts to
develop novel 4-aminobutyric acid-based self-immolative polymers.

Keywords
Self-immolative, monomer, polymer, block copolymer, spacer, cyclization, electronic
rearrangement, degradation, synthesis, kinetics.
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Chapter 1
Biodegradable and Self-Immolative Materials in Medical
Applications!

1.1 General Introduction
Biodegradable polymers are an important class of materials with applications in diverse
areas. With uses from bulk commercial items such as biodegradable plastics to highly
specialized drug delivery systems for the treatment of cancer, these polymers represent
one of the most broadly applicable classes of materials.

Predominantly, they are

polyesters such as polycaprolactone (PCL), poly(D/L-lactic acid) (PDLLA), poly(L-lactic
acid) (PLLA),

or poly(glycolic acid) (PGA) (Figure 1.1), owing to their ease of

synthesis, often in a single step through a ring-opening polymerization of readily
available monomers (Scheme 1.1). Additionally, other polyesters derived from diacids
and diols have been employed, along with other backbones such as polyamides,
polyanhydrides, polyphosphazenes, and more specialized polydisulfides, polyacetals, and
poly(ortho ester)s (Figure 1.2).

Of particular interest to this thesis is their use in

biomedical applications, including stents and sutures,1-3 tissue engineering4-9 and
particularly as drug delivery vehicles.10-33

Recent advancements in the use of

biodegradable polymers in each of these applications will be highlighted below.
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Figure 1.1. Chemical structures of the most common biodegradable polyesters.
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1.2 Biodegradable Polymers in Medical Applications
Poly(hydroxyacid)s have received substantial attention for applications in biomedical
devices.

They possess numerous desirable properties, such as biocompatibility,

maintenance of tensile strength over time, and eventual breakdown into nontoxic
degradation products. Additionally, each polymer has unique physical properties, such as
polymer morphology, glass transition temperature and melting point, as well as chemical
properties such as degradation kinetics.

Furthermore, by developing copolymers of

different monomeric units, the physical and chemical properties can be fine-tuned to fit a
host of potential applications.
Common polymers used in medical devices include PCL, PGA, PLLA, PDLLA,
and more recently polydioxanone (PDS), as well as various combinations of these in
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copolymers such as poly(D/L-lactic-coglyocolic acid) (PLGA). In vivo degradation times
of these polymers range from 1 – 2 months for 50/50 PLGA up to greater than two years
for PCL and PLLA, with homopolymers generally having longer lifetimes than
copolymers.1 This degradation timeline makes these materials well suited to a variety of
medical applications such as sutures or stents, as the extended timeline allows the
polymer to maintain tensile strength throughout the healing process while eventually
degrading into small molecules, eliminating the need for additional procedures to remove
the device.
Numerous polyesters, both homopolymers and copolymers, have already been
commercialized as degradable sutures. These include products such as Vicryl" and
Monocryl", copolymers of PGA-PLA and PCL-PLA, respectively, Dexon", a glycolic
acid homopolymer, and PDS II", made from polydioxanone.2 In a report highlighting the
development of Monocryl", the authors found that the material maintained approximately
25% breaking strength after two weeks compared to greater than 80% retention for PDS
II". Analyzing the degradation, Monocryl" was found to undergo complete degradation
in approximately 4 months.
In 2008, Pektok and coworkers evaluated PCL nanofiber as a vascular graft
material, comparing it to the more conventionally used expanded polytetrafluoroethylene
(ePTFE).3 They found that PCL nanofibers were superior to ePTFE in healing capability,
as faster endothelialization and extracellular matrix formation was observed.
Degradation studies proved that the polymer was being broken down, with approximately
20% reduction in molecular weight being observed after 24 weeks.
Taking advantage of the healing capabilities and prolonged degradation times of
these polymers, researchers have also investigated their potential application in scaffoldbased tissue engineering. Scaffold-based tissue engineering is a technique used to repair
a wide variety of damaged tissues in the body. It involves the use of a biocompatible and
degradable scaffold on which cells of a desired type can be seeded and then grown.
Upon maturation, the cells are implanted into the body at the site of the injury, proliferate
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and in turn heal the damaged site.

Throughout this process the polymer gradually

degrades, resulting in its complete removal from the matrix.
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Figure 1.3. Biodegradable polymers used in different tissue engineering applications.
The types of tissues engineered by this process have included soft tissue, bone,
smooth muscle, as well as cardiovascular tissues. Each of these tissues requires scaffolds
with different biocompatibilities, physical properties, and degradation timelines. To this
end, numerous biodegradable polymers have been developed which possess the
properties desirable for each application.

With their elastic properties, PGA/PCL

copolymers were found to be ideally suited to smooth muscle tissue engineering.8 For
soft tissue engineering, a polymer with a lower tensile strength is desired and thus
poly(ester urethane)ureas and similar polymers have been employed.7 Conversely, for
bone tissue engineering, materials with much higher tensile strength are required, and
materials such as poly(propylene fumarate)9 and a polycarbamate derived from lysine
diisocyanate and glucose6 have been employed (Figure 1.3).

5

1.3 Drug Delivery Systems
A very important and exciting application of biodegradable polymers is their use as drug
delivery vehicles.

These vehicles are designed to increase drug bioavailability and

effectiveness, particularly pertaining to more hydrophobic drugs, as well as reduce
toxicity, and help control the dosage and release rate of the drug. A number of polymeric
systems have been developed to achieve this task, which can be divided into two major
groups, both of which will be discussed in greater detail below. The first group involves
nonspecific biodegradable polymers, examples of which include polyesters,13,15-18,2022,32,33

polyphosphazenes,34-36 and polyanhydrides.19

The second group is stimuli

responsive polymers, including polyketals,29-31,37 poly(ortho esters),38 disulfide containing
polymers,28,39,40 polyelectrolytes,41-44 and a variety of others. This second group can be
further subdivided into two categories, degradable and non-degradable.

Degradable

stimuli responsive polymers will break down into smaller molecules upon triggering,
while non-degradable polymers, often referred to as bioresponsive polymers, will lose
any kind of supramolecular assembly upon triggering, but the polymer chains themselves
remain intact. There are many types of triggering mechanisms, but those used in the
context of drug delivery are primarily changes in pH and redox potential.

1.3.1 Biodegradable Homopolymers
Polymer
degradation
Drug
release

Particle
formation

Polymer and drug in solution

Drug loaded
particle

Partially degraded polymer
and resulting drug release

Scheme 1.2. Encapsulation & release from a biodegradable polymer particle.
Within the first class of nonspecific biodegradable polymers, there have been primarily
two approaches to using these as drug delivery agents. The first approach involves the

6

synthesis of a homopolymer of the degradable material and its assembly into a
nanoparticle or microparticle loaded with the drug to be delivered. This is an attractive
approach, as the polymers are formed in a single step from inexpensive starting materials,
and numerous methods exist to create particles of various sizes. A general method for
particle formation and drug release is shown in Scheme 1.2, where the polymer and the
drug are mixed together and then the particle is formed with the drug encapsulated.
Additionally, the exterior of the particles can be coated with different materials for
applications such as improved targeting or to promote cell adhesion. Once the particles
have been prepared, they can be injected into the body whereupon the polymer gradually
degrades, releasing its payload.
Particles of various sizes and compositions have been employed for a variety of
applications. For example, Benoit and coworkers demonstrated the capability of PCL
microparticles as agents for oral vaccine delivery.32 Under various conditions they were
able to synthesize particles ranging from 5 – 10 µm, a suitable size for oral delivery.
Using bovine serum albumin (BSA) as a water-soluble model antigen, they demonstrated
that the protein could be taken up inside the microparticle with loading efficiencies
ranging from 1 – 36%. Carrying out polymer degradation and release studies in vitro,
they found that there was an initial burst release of approximately 25% of the protein,
followed by the gradual release of a further 10% over the course of 80 h, leading to a
maximum release of approximately 35%. Analyzing the BSA released from the particles,
they found it to be unchanged throughout the course of encapsulation and release. While
the authors did not investigate their system in vivo, their in vitro analyses demonstrated
the proof of concept that their microparticles could be used for oral vaccine
administration.
Demonstrating that dual functions could be achieved, Newman and McBurney
developed porous PLA/PGA microspheres for the uptake and delivery of cells for tissue
engineering.18 In their study, they synthesized microspheres in the presence of retinoic
acid (RA), a molecule used to induce cell differentiation into neurons. Following this, the
microspheres were coated with laminin to promote cell adhesion and then added to P19
embryonal carcinoma cell culture, a model of embryonic stem cells. They found that
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after one day, cells had begun to attach themselves to the surface of the microspheres,
and by day four cells had encompassed many of the microspheres. They observed that
the cells exhibited a slight improvement in neuron formation when compared to cells
cultured in the presence of free RA. In studying biodegradation of the microspheres, the
percent release of RA was monitored over a course of 125 h, and was found to be 50 –
60%.
Similar materials have also been investigated for the treatment of vascular injury.
In a study performed by Chandy and coworkers, they demonstrated the ability of
PLA/PCL microspheres to encapsulate cisplatin and slowly release the drug over the
course of 30 days.22

They synthesized PLA/PCL microspheres in the presence of

cisplatin, encapsulating the drug, and then coated the microspheres with either poly(vinyl
alcohol) (PVA), poly(ethylene glycol) (PEG), chitosan or alginate. These coatings were
added to improve circulation time, as well as to slow the degradation time of the particle,
thus slowing the release of the drug. Carrying out release studies, they found that there
was an initial burst release of between 20 – 30% of the drug within the first day with a
more gradual release being observed over the remaining 29 days of the study. They
found that PVA-coated microspheres displayed the fastest release of cisplatin, with
greater than 90% of the drug released after 30 days. The remaining three coatings were
similar, exhibiting approximately 75 – 85% release over the same time period, with PEGcoated microspheres showing the slowest release profile. Based on these findings, the
authors demonstrated that PEG and alginate-coated PLA/PCL microspheres were indeed
viable candidates for cisplatin drug delivery vehicles.
While the above examples have demonstrated the effectiveness of micron-sized
particles for drug delivery applications, there has also been significant investigation of
similar materials on the nanoscale. Nano-sized particles have been found to be ideally
suited to traverse cellular membranes, making them extremely valuable as potential drug
delivery agents. Mu and Feng have demonstrated their potential in use in anti-cancer
therapy.17 In their study, they synthesized PLA/PGA nanoparticles loaded with Taxol"
(Tax), and demonstrated its controlled release from the nanoparticle. Under optimized
conditions, they were able to encapsulate Tax within the nanoparticles with 84%
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efficiency. In in vitro release studies, the results observed were similar to those of the
microparticle studies described above.

There was an initial burst release of

approximately 20% in the first day, and by day thirty 50 – 70% of the drug had been
released from the carrier.
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Figure 1.4. Various steroid-substituted polyphosphazenes.
Polyphosphazenes have also been investigated as different class of potential drug
delivery vehicles.35 Due to the possibility of varying the substituents on the phosphorus,
the degradation kinetics of these polymers can be readily tuned by incorporating
hydrophilic or hydrophobic substituents. Additionally, there exists the possibility of
incorporating the drug molecule directly onto the polymer backbone.

Provided the

linkage is hydrolytically sensitive, this should allow for its gradual release from the
polymer as the polymer breaks down. This proof of concept was first demonstrated by
Allcock and Fuller in 1980, when they synthesized a series of polyphosphazenes with
various steroidal substituents incorporated on the backbone (Figure 1.4).34 The steroids
were linked either through aryloxy or alkoxy groups to the phosphorus, and they found
that while aryloxy-based phosphazenes were stable, the alkoxy-substituted ones were not.
The authors did not carry out a thorough investigation of the release of the steroids upon
degradation, but they did demonstrate this as a possible mechanism for drug delivery.
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Figure 1.5. Polyphosphazenes synthesized for drug delivery.
Allcock and Fuller also later reported imidazole and methylphenoxy cosubstituted polyphosphazene 1.21 for release of noncovalent drug molecules.

They

varied the ratio of the two substituents to contain 20, 45 and 80% imidazole substitution,
and found that 20% imidazole content showed the best release kinetics.36 Carrying out in
vitro release studies on different compounds such as 4-nitroaniline, progesterone as well
as BSA, they observed that contrary to polyester-based drug carriers discussed thus far,
little or no burst release of the drug was observed. The timeline of release was also found
to be much faster than polyester-based delivery vehicles. 4-Nitroaniline was completely
released within approximately 10 days, while progesterone was fully released within 30
days. While the 30-day timeline was the same that from the polyester carriers previously
discussed, in those cases the drug continued to be released and the experiment was
simply terminated, whereas in the polyphosphazene case the drug had been fully released
from the polymer. The only exception was with BSA, which was found to have much
slower and incomplete release, as it began to level off at around 50% release after 3
weeks. These results have shown that polyphosphazenes represent a viable alternative to
polyester-based drug delivery systems, and have great potential for further applications.

1.3.2 Biodegradable Block Copolymer Assemblies for Drug Delivery
Self-assemblies are the arrangements of material, in this case polymers, into ordered
supramolecular structures. While there are numerous driving forces for these assemblies,
such as hydrogen bonding or charge-charge interactions, the driving force for the
assemblies to be detailed in this section is primarily entropic in nature and relies on the
hydrophobic and hydrophilic characteristics of the block copolymers. By preparing
polymers composed of a relatively hydrophobic polyester block connected to a more
hydrophilic block such as PEG and then immersing them in water, the polymers
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spontaneously arrange themselves in order to minimize contact of the hydrophobic blocks
with water. While these self-assemblies can vary in nature and size, to include spherical
and worm-like micelles, vesicles, toroids, and others, only spherical micelles and vesicles
(Figure 1.6) will be discussed here, as they have been most widely investigated for drug
delivery applications. A spherical micelle is an assembly where the hydrophobic chains
of the polymers aggregate at the core while the hydrophilic chains surround it on the
exterior, making up the corona. A polymer vesicle, also referred to as a polymersome, is
the macromolecular analogue of the liposome, an assembly composed of phospholipid
surfactants that forms the basis for the membranes in living cells. In this case, the
hydrophobic chains make up the interior of the membrane, while the hydrophilic block
contacts the water on both the interior and exterior of the vesicle. In general, the ability of
an amphiphilic block copolymer to form micelles, vesicles, or other assemblies can be
predicted based on the volume fractions of the hydrophobic and hydrophilic block,
although the structure of the polymer, its rigidity, and crystallinity can also play a role.
By selecting different polymers, varying the ratio between the hydrophilic and
hydrophobic blocks, and employing different assembly methods, researchers are can
obtain control over both the type of assembly formed, as well as its size.

Spherical Micelle

Figure 1.6. Spherical micelle and vesicle.

Polymer Vesicle
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1.3.2.1

Biodegradable Micelles for Drug Delivery
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Figure 1.7. Encapsulation & release of drug from micelle.
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Figure 1.8. Chemical structure of Doxorubicin.
Polymer micelles are ideally suited for the delivery of hydrophobic drugs. As shown in
Figure 1.7, the drug molecules can be encapsulated within the hydrophobic core of the
micelle and slowly leach out over time. This increases the bioavailability of these drugs,
which otherwise exhibit poor water solubility, and therefore limited efficacy within the
body. This is particularly relevant in anti-cancer therapy, as a number of drugs currently
employed in treatments are quite hydrophobic and therefore have poor bioavailability on
their own. Of particular interest is the anti-cancer drug doxorubicin (Dox), shown in
Figure 1.8. Several recent reports have highlighted the possibility of using PCL-PEG
block copolymer micelles as delivery vehicles for Dox.20,21,23
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Figure 1.9. #-(carbamic acid benzyl ester)-$-caprolactone-modified polycaprolactonepoly(ethylene glycol) micelle for Dox delivery.
Lang and coworkers have recently reported a modified PCL-PEG micelle for Dox
delivery.21 In addition to using $-caprolactone (CL), they incorporated #-(carbamic acid
benzyl ester)-$-caprolactone (CABCL) into the hydrophobic block in either 10:1 or 2.5:1
CL:CABCL ratio (Figure 1.9). CABCL was a monomer they had recently developed for
the purpose of encapsulating Dox, as it was found to have superior interactions with the
drug compared to conventional $-caprolactone.

Having synthesized their block

copolymers, they assembled them into micelles in the presence of Dox via dialysis and
observed loading efficiencies of 47 and 69% for 10:1 and 2.5:1 polymer blends,
respectively. Examining release kinetics, they obtained a slow release profile of Dox
from the micelles, with 10 – 15% of the payload being released over a course of 3 days
compared to a 30% release of Dox from unmodified PCL-PEG micelles. No substantial
burst release was observed.

Their findings demonstrated that the incorporation of

CABCL into the polymer backbone improved Dox internalization, making these potential
candidates for slow release treatments.
In a second example, Diao and coworkers tested their Dox-loaded PCL-PEG
micelles for treatment of resistant K562 tumor cells.23

Dox-loaded micelles were

prepared in this case through ultrasonication of a mixed organic-aqueous solution
followed by evaporation of the organic solvent, and a loading efficiency of 49% was
obtained.

In vitro release studies showed increased release relative to Lang and

coworkers, with approximately 70% of encapsulated Dox being released after 4 days
following an initial burst of approximately 20%. Most importantly, when they tested
their loaded micelles against Dox-resistant K562 tumor cells, they found that at dosages
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of both 6 and 12 µg/mL, approximately 80% of the cells had been killed after 3 days of
incubation, relative to just 50% when free Dox was used. Their work has effectively
demonstrated that the use of drug delivery vehicles is a potentially useful treatment
option for drug-resistant in tumor cells.
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Figure 1.10. Folate-terminated star-shaped polycaprolactone-poly(ethylene glycol)
micelles.

Figure 1.11. Folate-terminated micelles bind to a receptor and release a drug payload.
Hsieh and coworkers have very recently developed a method to improve the targeting of
tumor cells with Dox-loaded PCL-PEG star-shaped micelles.20 This may minimize the
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harmful side effects often associated with chemotherapy. Attaching folic acid to the end
of the PEG block (Figure 1.10), they sought to take advantage of the fact that several
tumor cell lines overexpress folate receptor proteins, whereas these proteins are expressed
to much less extent in healthy tissue. Thus, the folic acid-terminated micelles should
preferentially bind to cancerous cells, resulting in Dox being primarily administered to
these cells (Figure 1.11). Dox-loaded micelles were formed by dialysis in a similar
fashion to Lang’s work. Once formed, release studies showed that a significant amount
of the Dox was lost within the first hour, with approximately 30% release being observed.
An additional 10% leached out over the next 12 h, at which point a maximum release of
40% was obtained, and held constant over the course of 7 days. To test the targeting
efficiency of folic acid on the micelle, they incubated MCF-7 cells for 48 h in the
presence of free Dox, Dox-loaded folic acid-terminated micelles, Dox-loaded hydroxyterminated micelles, and finally Dox-loaded folic acid-terminated micelles in the
presence of free folic acid. They found that their folic acid-terminated micelles showed
the best cytotoxicity, with an observed cell viability of below 20%. They also found that
free folic acid indeed inhibited binding, with cell viability rising to approximately 25%.
Micelles lacking targeting groups resulted in approximately 35% viability.

These

findings verify that the addition of targeting groups can improve the delivery of anticancer drugs to tumor cells, thus improving the potency of the drug.

1.3.2.2

Biodegradable Vesicles for Drug Delivery

Vesicles possess an advantage over micelles, in that they are capable of not only
encapsulating hydrophobic molecules within the vesicle membrane, but also hydrophilic
drugs in the aqueous core. This allows greater flexibility in the choice of drug to be
administered, and also opens the possibility of combination therapy, simultaneously
releasing multiple drug molecules.
In a recent example by Lee and Feijen, a variety of biodegradable polymer
vesicles were synthesized and the hydrophobic membranes were loaded with fluoresceinlabeled Tax.16 Making use of different polyester groups as hydrophobic blocks, they
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synthesized four different vesicles containing PEG with either PCL, PDLLA, PCL-bPDLLA or a random PCL/PDLLA copolymer acting as the hydrophobic block (Figure
1.12). Using a solvent injection method to generate the vesicles, they were able to
achieve Tax loading efficiencies of 75 – 80%. They analyzed the release over the course
of 4 weeks, and found significant differences depending on the hydrophobic block. PCL
had the most rapid and complete release, resulting in nearly 100% release by the end of
the study. The random PCL/PDLLA copolymer released approximately 70% of its
payload, while the block PCL-PDLLA and PDLLA on their own exhibited the slowest
release rates, with approximately 50% of Tax release over 4 weeks in each case. These
findings demonstrate that the nature of the hydrophobic block plays a key role in the
release profile of the drug, and offers insight into the potential to tune these systems to
obtain controlled release of a drug.
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Figure 1.12. Structures of block copolymers with varying hydrophobic groups, which
were used for vesicle formation.
Hammer, Therien, and coworkers have also investigated the potential of PCLPEO (PEO = poly(ethylene oxide)) vesicles for drug delivery.15 Their vesicles were
formed through thin-film rehydration, followed by Dox incorporation into the core using
an ammonium sulfate gradient. Testing their release in vitro, they carried out studies at
both pH 7.4 and 5.5. In both cases an initial burst of approximately 20% was observed,
after which time the release slowed substantially at pH 7.4, reaching a maximum of
approximately 50%. At pH 5.5, release was found to be both more rapid and more
complete, with a maximum of approximately 70% release observed. They also analyzed
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the rate of Dox release, measured in % initial load/h. The authors found two distinct
release profiles, depending on the pH, and proposed two different release mechanisms,
shown in Scheme 1.3. At pH 7.4, a rapid release was observed initially, after which time
the remaining contents slowly leaked out. Throughout these domains, two different
release rate constants were observed. To account for this, they suggested that there was
an initial leaching out of the drug through the intact vesicle walls, after which the
remaining drug release occurred as a result of vesicle wall rupture as the polyester
component began to hydrolyze. At pH 5.5, a more steady release curve was observed,
with a rate constant similar to that of the second phase of release in pH 7.4. Therefore,
the authors suggested that ester hydrolysis had occurred much more rapidly at pH 5.5,
and all of the observed release was as a result of vesicle wall rupture.

Mechanism 1
Vesicle Leakage

Mechanism 2'

pH 7.4

pH 5.5

Vesicle degradation
and drug release

Mechanism 2
pH 7.4

Scheme 1.3. pH dependence on release mechanism from polymer vesicles.
As previously mentioned, the use of polymer vesicles allows for the possibility of
utilizing a single drug carrier for combination therapy. This potential was effectively
demonstrated by Discher and coworkers.13 They synthesized vesicles from a mixture of
PLA-PEO and polybutadiene (PBD)-PEO through thin film rehydration, after which they
loaded them with Dox using a pH gradient method. Tax was then incorporated by
injecting a solution of Tax in MeOH into a buffered solution containing the vesicles, after
which dialysis removed any unencapsulated drug. They carried out release studies and

17

found that over the course of 3 days nearly 100% of the Dox had been released, while
80% of Tax was released. More importantly, they carried out in vivo studies in mice
models and compared their drug-loaded vesicles to free Dox and Tax. They noted that
after 3 days the tumor volumes were reduced by 60% relative to untreated tumors and did
not increase in size for the remainder of the study. Comparatively, free Dox and Tax
reduced tumor size by approximately 45% after 3 days, but thereafter tumor volume
began to increase.

1.3.3 Advantages and Limitations of Polyesters in Drug Delivery
These past examples have highlighted how the use of biodegradable drug delivery
vehicles can offer significant advantages in therapeutic applications. Their effectiveness
at controlling dosage has been highlighted in multiple cases, and by using different
polyester blocks, further control over the release kinetics can be obtained. In therapeutic
applications, the use of drug delivery vehicles has proven to be more effective than using
the free drug, and in fact has even been shown to overcome resistance to a drug by
different cell lines. Lastly, the use of targeting groups on the periphery has also been
shown to be effective in increasing localized dosage, maximizing therapeutic effect while
minimizing side effects. Despite these numerous advantages, there is a major limitation
inherent to the use of these materials, namely that they all rely on uncontrolled hydrolysis
of the polymer backbone. While the overall rate can be affected by such parameters as
pH or the length and nature of the polymer chain, there is still no way to control when
and where hydrolysis occurs along the backbone.

1.3.4 Stimuli Responsive Polymers
To overcome the limitations of ester hydrolysis as a mechanism for the breakdown of
materials and the release of drugs, over the past couple of decades much research has
focused on the development of stimuli-responsive polymers.

These polymers are

synthesized with specific functional groups incorporated that are sensitive to certain
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changes in the environment. Upon exposure to these changes, the functional groups
react, triggering the breakdown of the structure and causing release of the payload
(Scheme 1.4). This section will discuss recent advances in this field, with the following
subsections focusing on prominent types of triggering mechanisms.

Polymer assembly

Stimulus

Drug encapsulation
Polymer and drug
in solution

Aseembly with
encapsulated drug

Polymer disassembly
and drug release

Scheme 1.4. Stimuli responsive polymers in drug delivery.

1.3.4.1

pH Responsive Polymers

The design of polymers responsive to changes in pH represents an important
advancement for drug delivery, as tumors and inflammatory tissues, as well as other
tissues, have been reported to be mildly acidic (ie. pH 5.8 – 7.4).45,46 The best types of
treatments are those that deliver the drug molecule selectively to the damaged tissue
while leaving healthy tissue untouched. Therefore, any significant differences between
healthy and damaged tissue can potentially be exploited for selective drug delivery. A
pH gradient is one such property. Because certain damaged tissues are moderately acidic
relative to healthy tissue, there exists the potential to utilize materials that break down
more rapidly in acidic medium for drug delivery applications. Much focus has been
placed on exploiting this difference in pH, and some of the findings both in the areas of
degradable and non-degradable materials will be highlighted below.
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Scheme 1.5. Polyacetals as acid sensitive drug delivery vehicles.
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Figure 1.13. Series of polyamidoamines containing acid-sensitive acetals and ketals.
The most widely used functional groups for degradable pH-sensitive materials are
acetals and ketals. These groups are well known to be stable under neutral or basic
media, but readily undergo hydrolysis under acidic conditions.

Therefore, they are

ideally suited for drug delivery applications, as they remain stable under physiological
conditions but can break down upon exposure to the more acidic medium encountered
within a tumor cell, triggering polymer degradation and release of the payload (Scheme
1.5). This concept was demonstrated by Fréchet and coworkers, through the synthesis of
polymers containing acetal, dimethylketal, or aromatic ketals (Figure 1.13).37 Comparing
relative hydrolysis rates at pH 7.4 and pH 5.0, they observed marked enhancements at
lower pH. The half-life of polymer 1.31 dropped from 161 to 81 days, while that of 1.32
went from 6 to 0.03 days, and lastly 1.33 decreased from 15 to 3 days at pH 5.0 relative
to pH 7.4. This demonstrates that the use of a ketal linkage within the backbone can
provide significant enhancement in degradation rates.
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Figure 1.14. Polyacrylamide with acetal crosslinking groups.
In a more recent example from the same group, crosslinked polyacrylamide 1.34,
shown in Figure 1.14, was investigated for use in protein delivery.29 Acrylamide and a
benzaldehyde acetal-containing bis(acrylamide) were copolymerized in the presence of
BSA, forming BSA-loaded crosslinked microparticles. To evaluate the release kinetics,
they carried out experiments at both pH 5.0 and 7.4. At pH 5.0 they observed complete
release of BSA after 7 h, while at pH 7.4 less than 20% release had occurred over a
period of 20 h, effectively demonstrating their potential applications in drug delivery.
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Scheme 1.6. Particle formation and release from polyketal 1.35.
In another example, Murthy and coworkers designed a ketal-containing polymer
as a drug delivery vehicle for the treatment of inflammatory diseases.30 They synthesized
polymers with the general structure 1.35 containing varying ratios of 1,4-
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cyclohexanedimethanol and 1,5-pentanediol linked via dimethylketal groups, and
prepared microparticles from these polymers. Testing their degradation rates, they found
that the ideal ratio was 2.5:1 1,4-cyclohexanedimethanol:1,5-pentanediol, and used this
polymer for in vitro and in vivo tests. Beginning with in vitro release of rhodamine B,
they observed complete release of the molecule within 4 days at pH 4.5, compared to
approximately 65% at pH 7.4. For in vivo studies, they tested mice suffering from liver
damage by treating them with imatinib-loaded microparticles, using alanine
aminotransaminase (ALT) levels in the mice to evaluate the therapeutic effects. They
found that at low concentrations the drug-loaded particles offered no improvement over
free imatinib, but as concentrations rose the drug-loaded particles became extremely
effective, reducing ALT to almost zero at the highest dosage, thus demonstrating the
potential of this strategy for further treatments.
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Figure 1.15. Acid-sensitive poly(ortho ester amide) 1.39.
While the previous examples have focused on acetal and ketal linkages as acidsensitive groups, there has also been some focus on utilizing ortho esters for this same
role.

Wang and coworkers demonstrated this possibility by developing a series of

poly(ortho ester amides) (Figure 1.15).38 Following polymer synthesis, they prepared
hydrogels containing FITC-labeled dextran, and tested the release kinetics.

They

measured both polymer mass loss as well as dextran release at pH 5.0 and 7.4. They
found that at pH 5.0, complete mass loss was observed after 10 days, corresponding to
full dextran release along the same timeline, while at pH 7.4 only approximately 25%
mass loss and 25% dextran release was observed. Thus, they showed that poly(ortho
esters) are also viable candidates for pH sensitive drug delivery.
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1.3.4.1.2

Non-Degradable pH Responsive Polymers

Kataoka and coworkers designed a polymer for drug delivery that itself is stable to pH,
but contains drug molecules covalently bound to the polymer via acid sensitive
linkages.25

Utilizing a PEG-poly(aspartic acid) block copolymer, they modified the

carboxylate sidechain and covalently bound Dox through a hydrazone linkage.

At

physiological pH, Dox remains bound to the block copolymer micelle, but upon exposure
to mild acid, the hydrazone was cleaved, releasing Dox from the micelle (Scheme 1.7).
To verify this, they incubated their micelles at a range of pHs from 7.5 down to 3.0, and
measured the release of Dox over a period of 3 days. At pH 7.5, no release was observed
throughout the course of the experiment, while at pH 3 they observed 100% release. At
the more relevant pH ranges of 4.5 – 6.5, the amount of released Dox ranged from 5 –
45% as the pH decreased. This demonstrates a highly effective and innovative technique
for anti-cancer treatment, as near complete selectivity was achieved for release in more
acidic environment versus in conditions mimicking those of healthy tissues.
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Scheme 1.7. Covalent binding of Dox to block copolymer 1.40 via hydrazone linkage
followed by acid catalyzed hydrolysis.
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Figure 1.16. a) poly(2-(dialkylamino)ethyl) methacrylate structure and b) poly(2(dimethylamino)ethyl)-b-(2-(diethylamino)ethyl) methacrylate.
A number of other examples that make use of non-degradable polymers as pH
responsive drug delivery vehicles have also been reported. For these systems, basic
functional groups have typically been employed.
investigated

classes

of

non-degradable

pH

One of the most extensively
responsive

polymers

is

poly((dialkylamino)ethyl methacrylate)s 1.42 (Figure 1.16a).41,43 For example, Armes
and coworkers developed the first block copolymer of 2-(dimethylamino)ethyl
methacrylate and 2-(diethylamino)ethyl methacrylate, shown in Figure 1.16b.43 They
performed a series of experiments at varying pHs and noted a significant drop in surface
tension of the solution in the pH range 6 – 8, corresponding to a change in polymer
morphology. Additionally, they found that the hydrodynamic size reached a maximum at
pH 9.5, indicating micellization of the block copolymer.
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Figure 1.17. Block copolymer of poly(2-vinylpyridine) and poly(ethylene oxide).
Another example by Webber and coworkers made use of poly(2-vinylpyridine)
and PEO as a pH-sensitive block copolymer (Figure 1.17).44 In their study, they found
that micellization occurred at approximately pH 5, while below that the polymer chains
existed as unimers. While no further drug release studies were carried out, this example
indeed shows great promise. At physiological pH, the block copolymer exists primarily
as micelles. However, if exposed to acidic tissue, the pyridine groups protonate in the
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mildly acidic medium, making them hydrophilic and rupturing the micelle, releasing its
contents.

1.3.4.2

Reduction Sensitive Polymers
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Scheme 1.8. Disulfide-containing polymers as drug delivery vehicles.
Reduction sensitive polymers have also been developed, and typically involve disulfide
linkages. This strategy takes advantage of the fact that the extracellular environment is
typically oxidizing with glutathione concentrations on the order of micromolar, while the
interior of a cell is reducing with millimolar concentrations of glutathione. Therefore, the
use of a disulfide-containing polymer offers stability of the delivery vehicle outside of the
cell, limiting the risk of unwanted degradation. Once inside the cell, the disulfide bond
will be reduced, breaking down the polymer and releasing the payload entirely within the
cell (Scheme 1.8).
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Figure 1.18. Disulfide-containing polyamidoamine 1.45.
A common backbone utilized for these polymers has been a disulfide-linked
polyamidoamine. In a study by Ferruti and coworkers, a polymer containing disulfidelinked cysteine groups and piperazine dicarboxylates, 1.45, was synthesized and its
breakdown in both the presence and absence of 2-mercaptoethanol as a reducing agent
was evaluated.39 They found that the polymer was susceptible to hydrolysis in buffered
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media, with 10 – 20% molecular weight (MW) reduction observed after 1 day and
complete degradation occurring within a week. However, this degradation rate was
substantially improved in the presence of 2-mercaptoethanol, with a 50% MW reduction
within a day, and 90% MW reduction occurring within 2 days.
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Figure 1.19. Disulfide-containing poly(amido ethyleneimine) 1.46.
Kim and coworkers sought to apply this general polymer backbone for gene
delivery, utilizing poly(amido ethyleneimine) 1.46 (Figure 1.19).28 Taking advantage of
the cationic ethyleneimine portion of the polymer backbone, they tested its ability to
complex DNA, and found that complete complexation occurred when a 1.5:1 or higher
w/w ratio of polymer:DNA was employed.

Testing complex stability using gel

electrophoresis, they found them to be stable in buffered solution in the absence of any
reducing agents. Upon addition of dithiothreitol (DTT), complete release of the DNA
was observed across all polymer:DNA ratios. Based on these results, polymer 1.46 has
shown good promise for applications in intracellular gene delivery.
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Figure 1.20. Poly(ethylene glycol)-polyaspartate copolymer linked via disulfide.
Looking at a different polymeric structure, Kataoka and coworkers designed
block copolymer micelles from PEG and diethylenetriamine-substituted poly(aspartic
acid) containing a disulfide group as the linker between the two blocks (Figure 1.20).40
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Similar to Kim’s work, they utilized the amino groups to form complexes with the DNA,
synthesizing a series of complexes with varying N/P ratios. They found that for N/P
ratios greater than 2:1 they achieved complete complexation of DNA. Carrying out in
vitro degradation studies, they found that at sufficiently low concentrations of DTT (10
µM), the micelle structure remained stable. At 10 mM DTT, complete rupture occurred
within 1 h. They also carried out cell transfection studies, and found that gene delivery
began to occur within 11 h and 16 h for HeLa and 293T cells, respectively. This result
effectively demonstrates the possibility of these systems for use in gene therapy.

1.3.4.3

Thermoresponsive polymers

Scheme 1.9. a) Polymer in solution below and above LCST. b) Thermoresponsive
polymer used for drug delivery.
n
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Figure 1.21. Chemical structure of poly(N-isopropylacrylamide).
The third and final major class of stimuli responsive polymers utilized for drug delivery
systems is thermoresponsive polymers. These polymers have the unique property of
possessing a lower critical solution temperature (LCST) in water. The lower critical
solution temperature is the maximum temperature at which the polymer is soluble, above
which it precipitates out of solution (Scheme 1.9a). This property has been exploited by
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using polymers possessing LCSTs at or near physiological temperatures in water for drug
delivery applications, with the basic principle being that the polymer-drug complex is
formed at room temperature when the polymer is soluble, and then after injection into the
body and upon warming, the polymer precipitates out and the drug contents are released
(Scheme 1.9b). The most thoroughly investigated thermoresponsive polymer, for drug
delivery as well as a host of other applications, has been poly(N-isopropylacrylamide)
(PNIPAm) (Figure 1.21).

More recently, however, additional methacrylate-based

polymers have also been investigated, and found to have similar thermoresponsive
properties.
Ge and coworkers studied a crosslinked PNIPAm network for drug delivery
applications.12

Following the synthesis of crosslinked networks by two methods,

conventional radical polymerization and frontal polymerization, they tested the products
of each for drug loading capacities and drug release kinetics. Using aspirin as a model
drug, they found a 30% increase in drug loading capacity using frontal polymerization.
To evaluate release kinetics, they studied both polymers at 25 °C and 37 °C, and found
that the polymer produced from frontal polymerization exhibited both a more rapid and
smoother release profile at 25 °C, reaching 100% release after 12 h versus 48 h for the
conventional polymer. Interestingly, the release slowed down drastically upon heating to
37 °C, with 3 weeks being required for both polymers to release 90% of their payloads.
While surprising, they attribute this slow release primarily to hydrophobic effects keeping
the drug trapped within the polymer network.
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Scheme 1.10. Conjugation and release of Dox from poly(N-isopropylacrylamide)
hydrogel.
NIPAm has also been combined with other monomers to form multifunctional
polymeric structures that are both thermo- and pH-responsive.

This strategy was

employed effectively by Zhao and coworkers, who prepared a crosslinked copolymer
composed of NIPAm, methacrylic acid, and N,N’-methylenebisacrylamide as a
crosslinker.11 Using this, they conjugated Dox to the acid groups through an acidsensitive hydrazone linkage (Scheme 1.10). In the evaluation of these Dox-conjugated
nanogels, they noted significant thermoresponsivity, with the size dropping from 375 nm
at 25 °C to 135 nm at 37 °C. This did not result in substantial release of Dox, as only
20% release was observed over a course of 6 days. When the pH was decreased to 5.3,
however, greater than 70% release of Dox was noted. They further tested their drug
delivery system in cell viability assays at pH 7.4 and 6.8 at 37 °C and 43 °C. It was
found that changing one of the variables did not lead to any significant changes, whereas
lowering the pH and heating the solution to 43 °C resulted in cell viability dropping to
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65%. While they did not carry out cell studies at lower pH, based on the release profile
they proposed that this would be an effective drug delivery vehicle for hyperthermal
cancer treatment.
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Figure 1.22. Thermoresponsive polymer 1.52, a proposed alternative to poly(Nisopropylacrylamide).
In addition to PNIPAm, other acrylate-based polymers have also been studied for
thermoresponsivity. Lutz and coworkers have recently developed methacrylate polymer
1.52, a random copolymer of 2-(2-methoxyethoxy)ethyl methacrylate and oligo(ethylene
glycol) methacrylate (Figure 1.22).47 Comparing its physical characteristics directly to
PNIPAm, they found that it was superior to PNIPAm in a variety of aspects of its LCST
behaviour. First, they found it had a smaller temperature gradient and hysteresis between
heating and cooling cycles. Additionally, it was found to consistently maintain a lower
LCST than NIPAm in a variety of scenarios, such as changing salt concentration,
polymer concentration, as well as polymer chain length. From these findings, the authors
suggest polymethacrylate 1.52 as a viable alternative to PNIPAm, though as of yet no
application studies have been carried out.

1.3.4.4

Polymers Responsive to Other Stimuli

While pH, reduction and thermosensitive polymers represent the bulk of stimuli
responsive materials studied for biological applications, there are some noteworthy
examples of polymers responsive to other stimuli being employed for biological
applications. The groups of Morris and Zhao have developed a light sensitive block
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copolymer micelle composed of PEG and polymethacrylate with photosensitive pendant
groups26. Upon exposure to either UV (365 nm) or NIR (794 nm) light, the ester group is
cleaved, making the methacrylate portion of the block copolymer hydrophilic and thus
rupturing the micelle (Scheme 1.11). Using Nile Red and a coumarin dye as model
drugs, they monitored the decrease in fluorescence over time upon exposure to both
wavelengths. Exposure to UV light resulted in much faster release, with the fluorescence
decreasing by 60% within 40 min. When the same copolymer micelle was exposed to
NIR light, the fluorescence decreased by 60% within 5 h.
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Scheme 1.11. Release of coumarin dye 1.55 from polymer 1.53 upon irradiation with UV
or NIR light.
In another example, Kataoka and coworkers have developed a thermoresponsive
polymer that is highly sensitive to glucose concentrations for the treatment of diabetes
(Scheme 1.12).24

Incorporating a small amount of phenylboronic acid-substituted

acrylamide into PNIPAm, they found that glucose concentration played a dramatic role in
determining the LCST of the polymer.

In the absence of glucose, the LCST was

approximately 22 °C. As the concentration of glucose was gradually increased up to 5
g/L, the LCST correspondingly increased to 35 °C. They then tested the polymer gel’s
potential for insulin delivery by carrying out release studies at 28 °C and pH 9.0 with
varying glucose concentration. With no glucose, approximately 10% insulin release was
observed after 24 h. At 1 g/L of glucose, 30% was released over the same time period.
Finally, at 3 g/L 80% was released. While the parameters for these tests were outside of
physiological temperature and pH, they still effectively demonstrate the possibility for a
system of this nature to be employed for diabetes treatment.
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1.3.4.5

Advantages and Limitations of Stimuli Responsive
Polymers

The examples described above highlight the effectiveness of stimuli responsive polymers
for biological applications.

Their main advantage is their ability to release their

therapeutic payload in response to changes in conditions, such as pH, reduction potential,
temperature or other stimuli. This can potentially allow for a more localized release,
providing enhanced efficacy in treatments, and minimal side effects. However, they do
possess limitations. For example, in the case of pH, there is only a small pH gradient that
exists within the body so it is difficult to synthesize materials that can be highly sensitive
within such a small range. While the research thus far has indeed been promising and
substantial increases in release rates have been obtained by slight decreases in pH, there
is invariably uncontrolled release occurring.

While disulfide-containing polymers

address the issue of nonspecific degradation to some degree, as degradation outside of a
cell is minimized, an additional targeting group is often required to preferentially deliver
drug payloads to diseased cells. Lastly, with body temperature remaining constant at 37
ºC, it is difficult to employ thermoresponsive polymers in vivo, unless their LCSTs can be
modulated by other chemical factors, such as was demonstrated with glucose-sensitive
thermoresponsive hydrogels.
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1.4 Introduction to Self-Immolative Materials
To address a number of the above challenges and to further develop the field of
polymeric materials in biomedical applications, there has been a recent focus on a new
class of degradable polymers called self-immolative polymers. Composed of a unique
class of monomers called self-immolative spacers that are capable of undergoing
intramolecular cleavage reactions, they are a new class of stimuli-responsive polymers
that require just a single triggering event to induce complete depolymerization.
Containing an end cap at one terminus, these polymers maintain their stability as long as
the end cap remains attached. Once the end cap is removed, a cascade of intramolecular
cleavage events ensues, resulting in stepwise, end-to-end degradation of the polymer. By
using different functional groups as an end cap, depolymerization can be triggered under
a variety of conditions or in response to a variety of different molecules present in
solution. Additionally, because only a single triggering event is required, the sensitivity
to stimuli is greatly increased, with only trace amounts of an effector being required to
induce depolymerization.
While the field of self-immolative polymers is relatively new and unexplored, that
of self-immolative spacers is much more widely studied. Beginning as a capping group
for prodrugs, their usage has gradually expanded to include short oligomeric species,
dendrimers, and most recently linear self-immolative polymers, for a variety of
applications such as drug delivery, signal amplification and logic gates. A review of
these areas is presented in the following sections.

1.5 Self-Immolative Spacers
A class of molecules termed self-immolative spacers has been a principle component in
the design of all self-immolative materials. Originally developed for the field of prodrug
chemistry, such linkers were designed to overcome steric limitations by increasing the
physical distance between the parent drug and the cleavage site as well as to alter the
inherent stability of this linkage.48 In the absence of a self-immolative spacer, prodrugs
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could be composed of a specifier conjugated directly to the parent drug by an enzymelabile linkage.49-52

Unfortunately, due to the demanding steric requirements of the

enzymatic cleavage step, such prodrugs were found to be relatively ineffective.53-55
Introduction of a spacer (Figure 1.24a) capable of undergoing a spontaneous
intramolecular reaction to release the drug in its parent, active form, increased the
accessibility of the cleavage site, enhancing drug release.56
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Figure 1.23. a) Schematic of a prodrug comprising a specifier/trigger, spacer and drug; b)
general structure of electronic cascade spacers; and c) general structure of cyclization
spacers.
The first self-immolative spacer introduced by Katzenellenbogen and coworkers
in 1981 was based on 4-aminobenzyl alcohol.48

Commonly referred to as a 1,6-

elimination spacer, it is an example of an electronic cascade spacer, where unmasking of
an aromatic amine,48 hydroxyl,57 or thiol58 moiety allows these chemical functionalities to
become electron-donating, initiating an electronic cascade leading to release of a free
drug or other leaving group, often following a subsequent decarboxylation reaction
(Figure 1.23b). As shown in Figure 1.23c, spacers based on cyclization reactions have
also been introduced, whereby the unmasking of a nucleophilic functional group permits
cyclization.59,60 In general, electronic cascade spacers react more rapidly than the
cyclization spacers. Since their introduction, a variety of spacers based on both electronic
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cascades and cyclization reactions have been developed and they have been applied in
various prodrug,58,61-70 sensor,71-81 and drug delivery systems.82-88

1.6 Self-Immolative Oligomers
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Figure 1.24. a) Spacers based on extended aromatic systems such as naphthyl and
biphenyl moieties that did not ungergo the desired electronic cascade eliminations; b)
Spacers based on multiple 1,6-elimination spacers in sequence; and c) Spacers based on
multiple 1,6-elimination spacers followed by a cyclization spacer (PG = protecting group,
D = drug).
Self-immolative oligomers were introduced by Scheeren and coworkers in 2001 as
potential improvements to the spacers previously employed in prodrug systems.89 It was
hypothesized that the use of elongated linkers might enhance the cleavage rates by further
separating the cleavage site from the sterically bulky parent drug. Linkers based on
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extended aromatic systems such as naphthyl and biphenyl moieties (Figure 1.24a) were
prepared. However, these systems failed to undergo the electronic cascade leading to
drug release, a result that was attributed to the high energetic cost of dearomatization
associated with the required 1,8- and 1,10-elimination reactions.

In addition, the

repulsion of ortho hydrogens in the biphenyl system would disfavor the planar
intermediate structure. In contrast, the combination of multiple 1,6-elimination spacers in
sequence (Figure 1.24b) linking a plasmin sensitive specifier and the drug Tax or Dox,
led to significantly enhanced drug release rates in the presence of the enzyme, when
compared with analogous systems containing only one linker.

In addition, it was

demonstrated that a diamine cyclization spacer (Figure 1.24c) could be incorporated into
the sequence of linkers, also resulting in enhanced enzymatic cleavage rates relative to
the single spacer system. In this work, the prodrugs containing only electronic cascade
spacers released the free drug more rapidly than those incorporating the cyclization
spacers. However, the diamine cyclization spacer provided the opportunity to conjugate
hydroxyl-containing parent drugs via stable carbamate linkages instead of the less stable
carbonate linkages that would be generated using the 1,6-elimination spacers alone.
While none of the above systems resulted in an amplification of the biological stiumulus,
the groundwork was laid for the synthesis of future linear and dendritic systems. It was
also demonstrated that the electronic cascade and cyclization reactions utilized in selfimmolative spacers could be extended to multimeric systems. Since then, several other
examples of oligomeric combinations of self-immolative spacers have been reported and
demonstrated to undergo reaction cascades to release reporter molecules.65,74,79,90-93
The first example of a self-immolative oligomer that led to chemical amplification
was reported several years later by Warnecke and Kratz.94 This molecule, termed a
"linear self-eliminating system", was composed of a sequence of three 1,6-elimination
spacers (Scheme 1.13). In contrast to the above oligomers, which only carried a drug
payload at one terminus of the oligomer, amplification was achieved in this case by the
conjugation of a model drug to aromatic moieties such that it could be released by a 1,4elimination reaction. Kinetic studies revealed that cleavage of the oligomer backbone by
the sequence of 1,6-elimination reactions was the faster process, while the release of
drugs via the 1,4-elimination occurred more slowly. In this system, tryptamine was used
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simultaneously reported the first examples of self-immolative dendrimers.99-101 While
similar in design, each dendrimer was unique in its chemical structure, release trigger and
potential applications.
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Scheme 1.14. a) A 2nd generation dendrimer that fragments from the periphery to the
focal point by a sequence of three 1,6-elimination reactions upon cleavage of the allyl
ether, leading to the release of 4-nitrophenol; and b) A 2nd generation dendrimer that
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fragments from the focal point to the periphery upon allyl ether cleavage, resulting in the
release of four molecules of 4-nitrophenol.
McGrath and coworkers described up to 2nd generation "linearly disassembling"
benzyl(aryl ether) dendrimers based on 4-hydroxybenzyl alcohol derivatives.100 In the
case of the 2nd generation dendrimer (Scheme 1.14a), cleavage of a peripheral 4allyloxybenzyl ether group initiated a sequence of three 1,6-elimination reactions leading
to the release of a 4-nitrophenol reporter at the dendrimer's periphery. Under optimized
conditions for removal of the allyl group, the release of the 4-nitrophenol was complete
in approximately 15 min and no significant generational differences were observed.
Interestingly, the fragmentation was much slower in THF with complete release of the
reporter requiring on the order of 10 h. A new UV absorbance band was observed during
degradation, and was used to monitor the reaction. This band increased rapidly upon the
dendrimer’s subjection to degradation conditions, and gradually decreased as the
experiment proceeded.

The authors attributed this absorbance band to phenoxide

intermediates, supporting the proposed fragmentation mechanism, as opposed to simple
cleavage of the ether linkages.
While the above linearly disassembling dendrimers did not technically lead to
signal amplification as only a single reporter molecule was released, this work was
followed

up

with

a

new

series

of

polyether

dendrimers

based

on

2,4-

bis(hydroxymethyl)phenol.102 In this case, cleavage of an allyl ether at the dendrimer's
focal point initiated a cascade of both 1,4- and 1,6-elimination reactions leading to
fragmentation of the dendrimer backbones and release of 4-nitrophenol from the
dendrimer peripheries (Scheme 1.14b). Generation 0, 1, and 2 dendrimers released 1, 2,
and 4 reporters respectively, demonstrating the utility of the dendrimer backbone for
signal amplification.

In subsequent work, it was demonstrated that the chemically

cleavable allyl ether at the dendrimer's focal point could be replaced with a photolabile 2nitrobenzyl derivative providing an alternative triggering mechanism.103
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The self-immolative dendrimers reported by Shabat and coworkers in 2003 were
polycarbamates based on the branching unit 2,6-bis(hydroxymethyl)-4-cresol and the
cyclization spacer N,N’-dimethylethylenediamine (Scheme 1.15).101 In the 1st and 2nd
generation dendrimers, cleavage of a photolabile 2-nitrobenzyl derivative at the focal
point enabled cyclization of the diamine. Subsequent 1,4-elimination-decarboxylation
reactions fragmented the branching units, regenerating the amines for cyclization and
thus the next phase of degradation. Two molecules of aminomethylpyrene were released
from the 1st generation dendrimer and four were released from the 2nd generation
dendrimer as detected by HPLC. Contrary to the results of McGrath and coworkers with
polyether dendrimers, these polycarbamate dendrimers exhibited significant differences
in release kinetics between dendrimer generations. Characterization of the intermediates
allowed the authors to determine that cyclization of the diamine spacer was the rate
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limiting step, and thus as more of these spacers were incorporated, the time required for
complete degradation correspondingly increased.
While use of the diamine spacer reduced steric crowding in the dendrimer
backbone, allowing for the preparation of the 3rd generation dendrimer backbone, it was
found that steric crowding at the dendrimer periphery prevented the conjugation of eight
aminomethylpyrene reporters.

Therefore, the reporter was changed to the smaller

molecule 4-nitroaniline. Using a chemically cleavable t-butyloxycarbonyl (Boc) group at
the focal point, this 3rd generation dendrimer was found to degrade as expected upon
removal of the Boc group by trifluoroacetic acid (TFA). While neither of the above
examples explicitly demonstrated the applicability of their systems in drug delivery
applications, using model systems they were able to demonstrate the potential of selfimmolative dendrimers in signal amplification and were able to identify degradation
intermediates that supported their proposed degradation pathways.
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Scheme 1.16. A 1st generation dendrimer that fragments via 1,8-eliminationdecarboxylation reactions upon focal point reductions to release two molecules of Tax.
The 2003 report of de Groot and coworkers was the first to explicitly demonstrate
the potential use of self-immolative dendrimers for amplified drug release.99
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The
2-(4-

aminobenzylidene)propane-1,3-diol. A nitro group was used to mask the focal point
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aniline in oxidized form and two molecules of Tax were conjugated to the periphery of
the 1st generation dendrimer (Scheme 1.16), while 4 molecules of 4-nitrophenol were
conjugated to the periphery in the 2nd generation dendrimer. Upon reduction of the nitro
group to the corresponding aniline with zinc metal in acetic acid, each branched
monomer underwent two 1,8-elimination-decarboxylation reactions, leading to dendrimer
fragmentation and release of the dendrimer's drug molecules or reporters.

As only

electronic cascade reactions were involved in this degradation process, the kinetics were
similar to those observed by McGrath and coworkers, with release of Tax occurring over
a period of 30 min as detected by NMR spectroscopy.
When carbonate-bound Tax was subjected to the nitro-reducing conditions, no
degradation of the material was observed, illustrating that the conditions for the reduction
of the nitro group did not effect cleavage of the carbonates by some other mechanism.
Thus, they demonstrated that release of Tax occurred only after the nitro group was
reduced to the corresponding amine and the electronic cascade reaction had taken place.
As this system was designed for prodrug therapy, the degradation product 2-(4aminobenzylidene)propane-1,3-diol was assayed for cytotoxicity in human tumor cell
lines, and found to have negligible adverse effects.
With the groundwork for self-immolative dendrimers laid in these seminal
contributions, emphasis shifted towards improvements, modifications, and applications of
these dendrimers.

McGrath and coworkers recently reported improvements to their

methods for synthesizing the linearly disassembling benzyl(aryl ether) dendrimers, and
were able to prepare 1st, 2nd, and 3rd generation dendrimers on a multigram scale.104 An
allyl ether was used at the dendrimer periphery, and its cleavage led to release of 4nitrophenol at the dendimer focal point. Using improved degradation conditions, the
disassembly was shown to proceed smoothly and more rapidly than previously reported.
McGrath and coworkers also reported a new convergent synthesis strategy
towards their signal amplifying dendrimers based on 2,4-bis(hydroxymethyl)phenol.105
Previous self-immolative dendrimer syntheses were divergent (i.e. synthesized outward
from the focal point), and in fact, a synthetic approach working from the periphery
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towards the core was not possible for other dendrimers due to the tendency of the selfimmolative units to disassemble. McGrath’s group was able to use a copper-mediated
coupling reaction to generate these unique ether linkages without revealing a free phenol,
which made a convergent synthesis feasible. Using this strategy, they were able to
synthesize 0th, 1st, and 2nd generation dendrimers containing an allyl ether focal point and
multiple peripheral 2,4-xylenol molecules that could be released in an amplified manner.
However, the use of these dendrimers for drug delivery applications has not been
explored to this point.
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Figure 1.25. a) A 1st generation dendrimer that releases anticancer drugs Dox and
camptothecin via a series of cyclization and elimination-decarboxylation reactions upon
focal point cleavage by a catalytic antibody; and b) a similar dendrimer for the release of
Dox, camptothecin and etoposide by the same mechanism as in a).
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Following their initial report on self-immolative dendrimers, Shabat and
coworkers have made several significant advancements in the application of their selfimmolative dendrimers for amplified detection and drug release. It was demonstrated
that a trigger sensitive to the catalytic antibody 38C2, which catalyzes a sequence of
retro-aldol, retro-Michael cleavage reactions could be introduced at the focal point of a 1st
generation dendrimer, while the periphery could be used to conjugate Dox and/or
camptothecin, providing both homodimeric and heterodimeric enzyme sensitive prodrugs
(Figure 1.25a).106 Cell-growth inhibition assays in MOLT-3 leukemia cells with a fixed
antibody concentration demonstrated that in each case, and particularly for the
heterodimer, the dimeric prodrug was more active than the corresponding monomeric
produg or combination thereof. This result was attributed mainly to the dendritic
amplification effect.
In an extension of this work, a modified branching unit capable of undergoing
three elimination-decarboxylation reactions was used with the same catalytic antibody
38C2 substrate as the focal point trigger to provide the nearly simultaneous release of
three different chemotherapeutic drugs, camptothecin, Dox, and etoposide, in response to
a single enzymatic cleavage event (Figure 1.25b).107

In a modified system, three

equivalents of the chemotherapeutic drug melphalan were conjugated to an enzyme-labile
trigger through purely elimination spacers. The use of a trigger and branching unit that
did not utilize a slow cyclization step for signal transmission allowed for rapid release of
all three drug molecules, leading to enhanced drug toxicity in the presence of the enzyme
penicillin-G-amidase.108

The disassembly rate of the system based on 2,6-

bis(hydroxymethyl)-4-cresol could also be enhanced by replacement of the methyl
substituent on the aromatic ring with a more electron-withdrawing ethylcarboxy-ester at
the sacrifice of one branching position.109 Most recently, a first generation dendrimer
fragmenting by the 1,6-elimination-decarboxylation cascade was used to conjugate Tax
to N-(2-hydroxyproyl)-methacrylamide (HPMA) via a focal point oligopeptide spacer
sensitive to cathepsin B.110 Cleavage of this peptidic spacer initiated the dendrimer
disassembly, resulting in the release of three equivalents of Tax. This new polymer-drug
conjugate exhibited enhanced cytotoxicity to murine prostate adenocarcinoma (TRAMP-
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C2) cells in comparison with the classic monomeric polymer-drug conjugate, again
demonstrating the advantage of dendritic amplification.
O
N

O
O
O
O

N
O

N

H
N

OH

O

n

N
O

O HN
O

O
O

O

N

O

N

N

N

N

N

N

O

N

O

O

O
O

O
O
O

O

H
N
O

N
N N

O

N

O

O
O

O

N

O

N
O

N

N

O

O

O
O

O

O

HN

N
O

N N
N

O
O

O
N
H

O

nOH

N
N
N

O

O
O

N

O
O
1.94

Figure 1.26. Chemical structure of a self-immolative dendrimer with water solubilizing
PEO moieties and camptothecin on the periphery, with a penicillin-G-amidase-sensitive
focal point.
While the above approaches were successful in demonstrating amplified
enzymatically-triggered drug release from 1st generation dendrimers, the enzymatic
activation generally failed for 2nd generation dendrimers. This was attributed to the high
hydrophobicity of the larger dendritic structures, which resulted in aggregation of the
molecules in aqueous solution and prevented access of the enzyme to its substrate. This
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problem was addressed by the conjugation of PEO chains to the dendrimer periphery.111
Using this strategy, 2nd generation dendrimers were synthesized that could be activated at
their focal point by the enzyme penicillin-G-amidase to release four molecules of
camptothecin (Figure 1.26). Assays in MOLT-3, JURKAT, and HEK-293 cells revealed
that the IC50 values for this prodrug were 2 – 3 orders of magnitude lower in the presence
of the enzyme, suggesting that high concentrations of prodrug could be applied in
chemotherapy with decreased side effects. An alternative approach to addressing the
aqueous solubility issue was the use of ionizable reporter groups.112 For example, the
reporter 5-amino-2-nitrobenzoic acid was utilized to improve solubility, and it was
possible to activate 0th to 2nd generation dendrimers with penicillin-G-amidase without
the need for PEO. However, this approach is limited in scope compared to the use of
PEO chains, as the structures of chemotherapeutic compounds cannot be altered as easily
as those of reporter molecules.

Figure 1.27. Schematics of dendrimer designs: a) Cleavage of either one of the two
different triggers leads to the release of a reporter/drug molecule (molecular OR logic
trigger); b) Cleavage of a single trigger leads to the release of multiple reporters
(amplifier); c) A receiver-amplifier dendrimer with high sensitivity and gain, whereby a
low intensity signal can be amplified via the release of multiple reporters.
In addition to the triggered release of drug molecules, self-immolative dendrimers
are also highly promising as sensor molecules, due to their ability to transmit and amplify
one or more signals. For example, by using two peripheral groups sensitive to different
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stimuli, and a self-immolative spacer designed to fragment towards the focal point, it was
possible to transmit a signal from the cleavage of either moiety to a reporter group at the
focal point (Figure 1.27a).113 When the moiety released from the focal point was a drug
molecule, the approach was referred to as “prodrug activation by a molecular OR logic
trigger”.114 While these dendrimers resembled antennae more than amplifiers, it is also
possible to provide amplification by transmitting a signal from the focal point to the
dendrimer periphery. For example, using a branching unit capable of undergoing six 1,8elimination-decarboxylation reactions, it was possible to release six tryptophan reporter
molecules in response to a single enzymatic cleavage event (Figure 1.27b).115 Dual
output dendrimers have also been synthesized, wherein two types of reporters are
conjugated to the dendrimer periphery. Such structures facilitate the use of orthogonal
spectroscopic techniques such as fluorescence and absorbance, and could be potentially
useful in cases where one signal is unreliable; for example in a case where fluorescence is
quenched.116 In an interesting combination of the antennae-amplifier approach, it was
possible to transmit a signal from the periphery of one “receiver” dendrimer to its focal
point following a single cleavage event, then out to all of the peripheral units of a
dendritic “amplifier”, leading to the release of multiple reporter molecules and providing
a response with high sensitivity and gain (Figure 1.27c).117
The most recent examples demonstrating the use of dendritic amplification for
detection purposes were sensors capable of detecting H2O2. Triacetone triperoxide is an
illicit explosive that decomposes to release H2O2 upon treatment with acid. Thus an
H2O2 sensor could potentially provide a means of detecting triacetone triperoxide. To
this end, a self-immolative dendrimer containing an arylboronate ester at the focal point
was synthesized. Reaction of this boronate ester with H2O2 led to a new borate that was
readily hydrolyzed to produce a phenol, initiating elimination-decarboxylation reactions
to release multiple fluorescent reporters from the dendrimer periphery (Scheme 1.17).118
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Scheme 1.17. Chemical structure of a H2O2 sensor. Decomposition of a borate ester by
H2O2 leads to fragmentation of the self-immolative dendrimer and the amplified release
of reporter chromophores 1.99.
Following this work, Shabat and coworkers introduced an approach to
exponentially amplify diagnostic signals using a dendritic chain reaction.119 Using a
phenylboronic acid at the focal point, H2O2 triggered the generation of the focal point
phenol followed by disassembly of the dendrimer by elimination-decarboxylation
reactions (Scheme 1.18). However, in this case the system was designed to release one
reporter and two molecules of choline from the dendrimer periphery. The released
choline reacted with choline oxidase in situ to produce four molecules of H2O2, which
were able to activate four additional dendrimers. Thus in principle, a single molecule of
H2O2 could initiate a chain reaction leading to disassembly of all dendrimers in the
solution and release of all reporter groups. At high analyte concentrations, this system
behaved similar to a conventional probe; however at lower analyte concentrations the
chain reaction led to a 53-fold increase in signal due to the exponential amplification
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provided by the dendritic chain reaction. It was also demonstrated that this approach
could be applied to the detection of proteases. In this case, penicillin-G-amidase cleaved
a substrate, resulting in the release of choline and subsequent activation of the dendritic
chain reaction. The H2O2 sensor was later improved via the replacement of choline with
methanol.120 The decreased acidity of methanol (pKa 15.5) relative to choline (pKa 13.9)
resulted in a more stable carbonate, and thus reduced spontaneous carbonate hydrolysis
that had previously resulted in a relatively high background signal and decreased
sensitivity. Generation of amplified concentrations of H2O2 in this system was achieved
via the oxidation of methanol by alcohol oxidase.
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Scheme 1.18. A dendrimer system capable of exponential signal amplification. Cleavage
of the focal point trigger by H2O2 releases a reporter molecule and choline molecules that
are converted to additional H2O2 via an enzymatic reaction with choline oxidase.
The dendritic chain reaction approach was also later extended to a two component
system wherein a dendritic amplifier moiety capable of releasing choline was combined
with a separate molecule containing a chromogenic or fluorescent reporter.121 Both
components were triggered by H2O2 such that some molecules of H2O2 generated from
the oxidation of choline could activate additional dendritic amplifiers while others could
activate the reporter. This two-component approach led to simplification of the synthetic
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strategy required for preparation of the dendrimers.

While all the above sensor

approaches focused on the detection of H2O2 and used this molecule in the signal
amplification cascade, it was also recently demonstrated that a similar system could be
generated using thiols.122 A dendrimer with a thiol sensitive benzoquinone trigger at its
focal point was designed to release two new thiol molecules upon self-immolative
disassembly. The combination of this dendron with a chromogenic reporter having a
benzoquinone trigger allowed for amplified sensing of the thiols using the twocomponent strategy. This demonstrated the versatility of the dendritic chain reaction
with respect to the incorporation of different chemistries.
As demonstrated by the examples above, due to their branched structures,
dendrimers can provide an ideal framework for amplified drug release and sensing. Their
step-wise synthesis provides well-defined molecules that are attractive for in vivo
applications and are ideal for detailed fundamental physical studies in molecular sensing.
However, these same attributes have also introduced some limitations. The step-wise
syntheses of the complicated dendritic structures used in the aforementioned applications
are tedious and likely expensive to perform on a large scale. In addition, the use of large
peripheral moieties such as drugs and chromophores has introduced significant steric
hindrance at the dendrimer peripheries. While the latter has been addressed to some
extent by the use of larger branching units and linkers, the vast majority of dendrimers
described above were limited to the 1st or 2nd generations, thus limiting the degree of
signal amplification that could be obtained from a single molecule. Nevertheless, as
demonstrated by the examples above, self-immolative dendrimers possess a great deal of
potential for a variety of applications. They can be effectively used for enhanced drug
delivery, both for increased dosage delivery as well as the potential to release a drug
cocktail from a single source.

Their effectiveness in biosensing has also been

demonstrated, with the detection of a specific biomolecule triggering the release of
multiple reporters. Lastly, their role in trace analyte detection was demonstrated by
making use of dendritic chain reactions to heighten probe sensitivity.
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1.8 Self-Immolative Linear Polymers
Following dendrimers and oligomers, the investigation of self-immolative linear
polymers was the next logical step in the evolution of self-immolative materials. While
linear polymers are not monodisperse like dendrimers and oligomers, with the
appropriate monomers in hand they are synthesized in a single step, making their
preparation both practical and scalable. In addition, as polymers are inherently composed
of many monomer units, the cleavage of the trigger has the potential to provide a higher
degree of amplification than the oligomeric or dendritic structures. This amplification
can potentially be achieved by fragmentation of the linear polymer backbone leading
directly to the release of drug molecules or reporters. Alternatively, as linear copolymers
are known to assemble into a variety of supramolecular structures such as micelles,123,124
vesicles,125,126 and nanoparticles127,128 capable of encapsulating drug molecules, the
disassembly of the polymer backbone in response to a stimulus can potentially lead to the
controlled release of drugs from these assemblies.
The first self-immolative linear polymer was reported in 2008 by Shabat and
coworkers (Scheme 1.19).129 An end cap sensitive to BSA was incorporated at the
polymer terminus such that upon cleavage, a series of 1,6-elimination-decarboxylation
reactions

resulted

in

depolymerization

of

the

polycarbamate

backbone.

Depolymerization was readily detected by the release of a fluorescent monomeric 4aminobenzyl alcohol derivative whereas its fluorescence was significantly reduced when
the amine was masked as a carbamate. The polymer backbone comprised approximately
15 – 20 units, providing significant amplification for each cleavage event.
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Scheme 1.19. A self-immolative linear polymer that depolymerizes upon cleavage of the
terminal end cap by BSA, releasing many fluorescent reporters, thus providing amplified
sensing of BSA activity.
The same polymer backbone was also later used by the same group for the
activity-linked labeling of enzymes.130 The concept behind this work was that if an
enzyme successfully cleaved the end cap of the polymer, depolymerization would
generate reactive azaquinone methide intermediates that could be trapped by proximal
nucleophilic moieties on the protein's amino acid side chains, resulting in labeling of the
active enzyme with fluorophores. Penicillin-G-amidase and the catalytic antibody 38C2
were successfully labeled in this study. It was found that while penicillin-G-amidase did
not exhibit a significant reduction in its enzymatic activity as a result of the labeling,
antibody 38C2 did show diminished catalytic activity post-labeling, which was attributed
to labeling of the active site lysine $-amine. Interestingly, in a comparison between selfimmolative polymers, oligomers, and monomers as labeling agents, it was demonstrated
that the polymeric agents could provide enhanced levels of labeling, while preserving
higher levels of enzymatic activity.

This was explained by the breakdown of the

polymeric species over a period from seconds to minutes, allowing the depolymerization
to release azaquinone methide species farther from the active site where they could be
trapped without affecting activity. Despite this potential for polymer diffusion, it was
shown that when the labeling was performed in the presence of an activating and a
nonactivating protein in solution, the labeling of the activating protein was more effective
than the non-activating protein by a factor of 8.
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Scheme 1.20. A water-soluble self-immolative polymer that depolymerizes by 1,6elimination-decarboxylation reactions following activation by penicillin-G-amidase to
release model drug 1.102 via additional 1,6-elimination-decarboxylation reactions at a
vinylogous benzylic site on the monomer.
While specific choices of monomer units can lead to the direct generation of
reporter molecules upon depolymerization, Shabat and coworkers have also reported a
water soluble linear polymer where backbone depolymerization occurs via a series of 1,6elimination-decarboxylation

reactions,

with

an

additional

1,6-elimination-

decarboxylation at a vinylogous 2-benzyl position to release a reporter group (Scheme
1.20).131 This polymer provided signal amplification in response to the cleavage of the
end cap by penicillin-G-amidase via the release of non-monomeric reporters. Although
4-nitroaniline was used in this case, the reporter could be replaced with a drug molecule
allowing end cap cleavage to trigger amplified drug release.
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Scheme 1.21. The use of self-immolative polymers to prepare crosslinked microcapsules
that rupture and release their contents upon cleavage of the polymeric end caps.
Expanding on the concept of amplified release of non-covalently encapsulated
molecules from self-immolative materials, Moore and coworkers used a self-immolative
polycarbamate backbone129 to prepare microcapsules (Scheme 1.21).132

This was

achieved by the cross-linking of the linear polymers using interfacial polymerization
conditions. Removal of Boc or fluorenylmethyloxycarbonyl (Fmoc) end caps stimulated
the release of the microcapsule contents via depolymerization and capsule rupture.
Although these capsules were not specifically targeted towards drug delivery
applications, it was suggested that they might be useful for the release of healing agents
in autonomous repair systems.
An alternative approach not technically involving a self-immolative polymer
backbone was the introduction of self-immolative spacers throughout a linear polymer by
Almutairi and coworkers (Figure 1.28).133 In this case, cleavage of a 4,5-dimethoxy-2nitrobenzylcarbamate using either a one- or two-photon process led to unmasking of an
amine followed by cyclization and 1,4-elimination reactions to cleave the polymer
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backbone.

The polymers were used to prepare nanoparticles by a single emulsion

method. It was demonstrated that encapsulated Nile Red was released from the particles
following irradiation at 350 nm or 750 nm. The initial burst, followed by slower release
suggested that the mechanism of release likely involved both the rapid change in
hydrophilicity of the nanoparticles resulting from removal of the hydrophobic
photochemical trigger, as well as a slower breakdown of the nanoparticles resulting from
chain cleavage.

Figure 1.28. Self-immolative spacers lead to cleavage of a polymer backbone upon
removal of a trigger moiety photochemically.

The polymer was used to prepare

photoresponsive nanoparticles.
End
cap

O

O

O

n
1.111

Figure 1.29. General structure of polyphthalaldehyde.
In addition to 4-aminobenzyl alcohol spacers used thus far, Phillips and
coworkers have recently explored polyaldehydes as self-immolative polymers (Figure
1.29).134,135

Utilizing polyphthalaldehyde (PPHA) capped with different functional

groups, they developed stimuli-responsive patterned plastics as well as self-powered
microscale pumps.134,135 In the first scenario, they synthesized allyloxycarbonyl (Alloc)and tert-butyldimethylsilyl (TBS)-capped polymers sensitive to Pd0 and F-, respectively,
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and cast them onto a thin film surrounded by nondegradable polymer. Exposure to
stimuli resulted in rapid degradation of the polymer, with complete erosion of the film
occurring within 5 min following exposure of Alloc-terminated PPHA to 0.4 eq of
Pd(PPh3)4, and within 1 min after exposing TBS-capped PPHA to 0.5 eq
tetrabutylammonium fluoride (TBAF).134 Utilizing the same TBS-capped scaffold they
generated a thin film and measured velocity of the tracers following exposure to cleavage
conditions, and were able to generate average flow rates of 1.0 µm/s in the presence of
TBAF, and 12 µm/s in pH 14 solution.135
All of the above oligomers, dendrimers, and linear polymers used the electronic
cascade reactions in their backbones.

These reactions have been attractive for the

development of self-immolative materials due to their rapid degradation rates.

In

addition, they are relatively straightforward to work with synthetically as they are
unreactive when the aromatic amines or alcohols are masked.

However, the

biocompatibility of the quinone methide and azaquinone methide intermediates generated
during the disassembly process is currently debated, making the potential of these
systems for in vivo applications questionable. While studies of some prodrug systems
involving electronic cascade reactions have suggested that the byproducts are nontoxic,136 other studies have demonstrated toxicity of quinone methides.137-139 The work by
Shabat and coworkers on the activity-linked labeling of enzymes by self-immolative
polymers demonstrated that azaquinone methides can react with proteins in their vicinity
and such reactivity certainly raises concerns.130
While linear polymers do not possess the well-defined structures of dendrimers or
oligomers, as demonstrated above they exhibit other advantages such as simplified
synthetic approaches. In addition, they can provide a high degree of signal amplification
due to a high reporter to trigger ratio. This amplification has been achieved thus far by
use of the polymer backbone monomers as reporters, or by the conjugation of reporters
along the polymer backbone that are released through the disassembly process.
Alternatively, the non-covalent encapsulation of materials in nanoparticles or capsules
composed of self-immolative polymers can provide amplified release upon stimulustriggered depolymerization. Considering that the first examples of self-immolative linear
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polymers were reported only recently, significant progress has already been made and it
is likely that there will be considerable progress in the application of these materials for a
variety of drug delivery, sensing, and materials science applications over the years to
come.

1.9 Scope of This Thesis
When work began on this thesis, no prior publications on self-immolative linear polymers
had been reported. We, alongside Shabat and other research groups, sought to develop
this new class of materials. In addition to employing 4-aminobenzyl alcohol derivatives,
focus was placed on utilizing additional spacers previously used in small molecule
prodrugs and self-immolative dendrimers in an effort to build up a library of these
polymers with unique physical characteristics, cleavage mechanisms and degradation
profiles. The goal in doing so was to develop materials for a wide array of applications,
including dug delivery vehicles responsive to many potential stimuli and possessing a
broad range of release profiles, as well as more materials-based applications such as
tissue engineering. The general goal was to design and synthesize polymers from selfimmolative spacers either previously reported in the literature or developed within our
lab, and attach them to a variety of end caps. Once synthesized, the polymers were then
tested for self-assembly properties, if applicable, and then study the kinetics of
depolymerization and release of analytes.
Chapter two focuses on the development of a self-immolative polymer derived
from N,N-dimethylethylenediamine and 4-hydroxybenzyl alcohol. By attaching a PEG
end cap, this polymer will be shown to self-assemble in aqueous solution and to
encapsulate and release a model drug molecule.
Chapter three describes the synthesis of a self-immolative polymer derived from
the same diamine spacer in conjunction with 2-mercaptoethanol. Possessing a disulfide
end cap, this polymer will be shown to be stable to buffered solution in an oxidizing
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environment, but exposure to a reducing agent cleaves the disulfide and triggers polymer
degradation.
Chapter four discusses the development of 4-aminobutyric acid derivatives as a
new class of rapidly cyclizing self-immolative amine-based spacers as an alternative to
the previously employed diamine. Results will highlight the effect of various substituents
at the N and % positions on the observed cyclization rates.
Chapter five builds upon the results of chapter four and discusses the development
of self-immolative polymers derived from 4-aminobutyric acid. Two polymers were
developed utilizing different phenolic spacers in conjunction with 4-aminobutyric acid,
and the different strategies and synthetic routes to make these polymers will be discussed.
Lastly the degradation kinetics of the monomer will be reported.
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Chapter 2
A Self-Immolative Polymer Based on Alternating Cyclization
and Elimination Reactions!

2.1 Introduction
In recent years there has been significant interest in the development of biodegradable
polymers and in their application to areas as diverse as food sciences,1 medical devices,2,3
drug delivery,4-6 and tissue engineering.7,8 In particular, polyesters such as PLA,9,10
PGA,11-13 and PCL14-16 have been extensively used in biomedical applications and have
also been proposed as environmentally friendly replacements for traditional plastics such
as polyethylene. While the biodegradation rates of these polymers can be controlled to
some extent by tuning their composition, solubility and processing, they typically
degrade by random hydrolytic cleavages throughout the backbone, a process that is
relatively unregulated.17,18 For many applications, it would be desirable to use polymers
that can be degraded in a controlled manner in a specified environment or in response to a
stimulus. To address this, polymers with many acetal19-22 or disulfide linkages23,24 in
their backbones have been developed.

These polymers have been demonstrated to

degrade under mildly acidic and reducing conditions respectively, but the mechanism of
degradation still involves random chain scissions throughout the polymer backbone, and
many environmentally mediated cleavage events are required to completely degrade the
polymer.
Another interesting class of molecules that is under development is stimuli
responsive polymers.

For example, polymers based on NIPAM25 or oligo(ethylene

glycol) methacrylates26,27 have been demonstrated to be thermally responsive, with high
aqueous solubilities below their LCST and precipitation above the LCST. Polymers

!

This chapter contains work that has been published: DeWit, M. A.; Gillies, E. R. J. Am. Chem. Soc. 2009,
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65

containing pendant amines or carboxylic acids are typically responsive to pH, being
soluble within specified pH ranges.28-30 In addition, hydrophobic groups and drugs have
been appended to polymer backbones by pH sensitive acetals,31,32 hydrazones,33 or
photochemically cleavable linkages,34,35 such that the solubilities of the polymers are
significantly altered upon the removal of these groups. Other systems responsive to
stimuli such as sugar concentration36,37 and redox potential38-40 have also been reported.
These stimuli responsive polymers have increasingly been used in recent years to prepare
assemblies such as micelles, vesicles, and nanoparticles that are capable of releasing
molecules in response to changes in environmental conditions.34,35,38,40-47 However, the
design of systems capable of responding within the relatively narrow range of
biologically accessible conditions is still a significant challenge.
A new and attractive concept for the design of materials that are both degradable
and stimuli responsive is end capped self-immolative polymers. As illustrated in Figure
2.1, these polymers comprise a backbone that is stable when the end cap is intact, but
upon removal of the end cap via a single bond cleavage, a functionality is revealed at the
polymer terminus that initiates a cascade of intramolecular reactions leading to complete
depolymerization from end to end. This concept was initially introduced in dendritic
systems that upon removal of a focal point group were demonstrated to degrade by an
intramolecular cascade, releasing multiple molecules from the dendrimer periphery.48,49
Such systems were then further developed to provide for the simultaneous release of
multiple different drug molecules, the incorporation of tumor targeting groups, and focal
point groups that were sensitive to reducing conditions or enzymes.50-53

Figure 2.1. Schematic of a self-immolative linear polymer, where removal of a
stabilizing end cap initiates a cascade of reactions leading to depolymerization.
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The application of this concept to linear self-immolative polymers has the
potential to dramatically expand their utility. For example, such materials may be used
for the assembly of supramolecular aggregates such as micelles, vesicles, and
nanoparticles or for the fabrication of medical devices or tissue engineering scaffolds,
where they can impart several unique and advantageous properties. For example, the use
of end caps responsive to different conditions could allow the degradation of a single
polymer to be triggered under a wide range of conditions, while the composition of the
polymer backbone itself would determine the rate of degradation. By tuning the length of
the polymer backbone, the time required for polymer degradation can potentially be
controlled, as a longer polymer should take longer to completely depolymerize than a
shorter polymer. In addition, due to the end-to-end degradation mechanism resulting in a
controlled and gradual reduction of polymer molecular weight, the physical properties of
the polymer should be retained longer during the degradation process in comparison with
a traditional degradable polymer such as a polyester, where a single cleavage event may
decrease the molecular weight by up to 50%. Despite these attractive features, only one
self-immolative linear polymer backbone has been reported to date.54,55 This backbone
was a polycarbamate based on 4-aminobenzyl alcohol derivatives, which degrades
entirely

by

intramolecular

1,6-elimination

reactions

via

azaquinone

methide

intermediates. It has been demonstrated that by using enzyme sensitive end caps this
backbone can be used as an amplifying sensor,54 or to release multiple model drugs
conjugated along the polymer backbone.55 The development of alternative backbones
and cascade degradation mechanisms will be necessary in order to tune the properties and
degradation rates, opening the way for new applications of this class of materials.
Inspired by the incorporation of alternating cyclization and 1,6-elimination
spacers into a dendritic system,52 reported here is the first example of a linear selfimmolative polymer that degrades by alternating elimination and cyclization reactions.
The degradation rate and mechanism were studied using NMR spectroscopy and size
exclusion chromatography (SEC) and it was demonstrated that the incorporation of a
monomer that induces depolymerization by a cyclization mechanism provides an
effective means of tuning the degradation rate. Furthermore, by conjugating PEG to the
terminus of the self-immolative polymer as an end cap, an amphiphilic block copolymer
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was obtained, which assembled into nanoparticles in aqueous solution. Hydrolysis of the
ester linkage between the blocks initiated the cascade degradation process under
physiological conditions. These nanoparticles were found to encapsulate a hydrophobic
dye and release it upon depolymerization, thus demonstrating for the first time the utility
of this class of molecules in the development of functional polymer assemblies and
nanomaterials.

2.2 Results and Discussion
2.2.1 Design
The use of monomers such as hydroxybenzyl alcohol and aminobenzyl alcohol
derivatives in the development of self-immolative polymers is attractive as the presence
of the free aromatic alcohol or amine functionalities that normally trigger quinone
methide mediated elimination reactions can be masked when they are activated, thus
providing relatively stable polymerization monomers and synthetic intermediates.
Another potential class of monomers for self-immolative polymers is those capable of
undergoing intramolecular cyclization reactions.56

One example is a carbamate

derivative of N,N'-dimethylethylenediamine, which spontaneously cyclizes to form N,N'dimethylimidazolidinone, releasing the alcohol.57 This spacer has been incorporated into
some of the previously reported self-immolative dendrimers,48,52,53,58 where protecting
groups can be carefully manipulated during the step-wise dendrimer synthesis; however,
the synthesis of linear polymers based on this class of monomers presents a significant
challenge, as the requisite activation of the monomer for polymerization introduces the
possibility for an intramolecular cyclization to occur much more rapidly than the
intermolecular polymerization (Figure 2.2a). For this work, it was proposed that by
incorporating alternating N,N'-dimethylethylenediamine units with 4-hydroxybenzyl
alcohol units linked via carbamates as shown in Figure 2.2b, the site of the monomer
activation for polymerization could be moved distal to the diamine, thus significantly
slowing the intramolecular cyclization, allowing effective polymerization of the activated
heterodimer. Upon removal of the end cap from the amine polymer terminus, cyclization
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of the diamine should occur, releasing N,N'-dimethylimidazolidinone and revealing the
phenol.

The phenol should then undergo a 1,6-elimination, ultimately releasing 4-

hydroxybenzyl alcohol, CO2, and another amine terminus, from which the cascade can
continue until depolymerization is complete.
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Figure 2.2. a) A competing intramolecular cyclization makes the incorporation of
cyclizing monomers into a self-immolative linear polymer challenging. b) By using
alternating monomers, the activating leaving group can be moved distal to the cyclization
monomer, thus facilitating polymerization.

End cap removal then allows for

depolymerization by alternating cyclization and 1,6-elimination reactions.

2.2.2 Monomer Synthesis
The synthesis of the target monomer began by the reaction of 4-hydroxybenzyl alcohol
with tert-butyldimethylchlorosilane in the presence of imidazole to provide compound
2.6, with selective protection on the aliphatic alcohol as shown in Scheme 2.1. The
phenol of 2.6 was then activated using 4-nitrophenyl chloroformate to provide the
activated carbonate 2.8. Tri(ethylene glycol) monomethyl ether (TEGMME) was added
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to the reaction mixture upon completion of the activation in order to quench the
remaining chloroformate, which was otherwise inseparable from 2.8.

N,N’-

Dimethylethylenediamine (2.9) was converted to the mono Boc-protected derivative 2.10
by reaction with di-tert-butyldicarbonate, and then the other amine was reacted with the
activated carbonate 2.8 in the presence of 4-(dimethylamino)pyridine (DMAP) and N,Ndiisopropylethylamine (DIPEA) to provide the carbamate 2.11. Removal of the TBS
protecting group was accomplished with 1 vol% HCl in EtOH, conditions under which
the Boc protecting group remained intact, to give 2.12.

Finally, the protected

polymerization monomer 2.13 was prepared by activation of 2.12 with 4nitrophenylchloroformate.
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2.2.3 Polymer Synthesis
Removal of the Boc protecting group from compound 2.13 using TFA provided the
monomer 2.2a&TFA, capable of self-condensing via reaction of the amine with the
activated carbonate to form a polycarbamate, releasing 4-nitrophenol (Scheme 2.2).
When isolated as the TFA salt, the amine was sufficiently stable that as long as the
deprotection was performed within hours prior to the polymerization reaction it could be
isolated and transferred to the polymerization conditions without premature
polymerization or cyclization. Compound 2.13 with the Boc-capped amine also served as
a convenient end cap in the synthesis of the initial model polymer. Although a Boc group
cannot be readily cleaved under any known physiological conditions, it can be easily
cleaved with TFA under non-aqueous conditions, allowing the depolymerization process
to be studied independently of the end cap cleavage. Thus, monomer 2.2a was reacted
with 0.05 equivalents of the end cap 2.13 in the presence of DMAP and DIPEA to
provide the polymer 2.3a. Based on the synthesis of 2.11 from 2.8 it had already been
determined that the reaction of the secondary amines with 4-nitrophenyl carbonates was a
rapid and very high yielding process, thus favoring its use as the key polymerization
reaction. Indeed the crude polymer was isolated in 92% yield following extraction to
remove the 4-nitrophenol, DIPEA, and DMAP, and less than 5% of the monomer had
been converted into the cyclic urea byproduct as determined by 1H NMR spectroscopy.
This indicated that the polymerization reaction successfully competed with potential
intramolecular cyclizations under the reaction conditions. It is also noteworthy that
although each monomer had a 4-nitrophenyl end group at the beginning of the
polymerization, no 4-nitrophenyl groups were observed in the polymer product. This
indicates that this group was lost during the polymerization, in the reaction medium upon
completion of the polymerization, or during workup, leaving a benzylic alcohol terminus.
This is not surprising considering the high reactivity of this group under these conditions.
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Scheme 2.2. Deprotection and polymerization of monomer 2.13.
SEC analysis of polymer 2.3a showed a relatively broad distribution of molecular
weights and some low MW oligomers (see appendix), some of which might be cyclic
oligomers, consistent with the expected result for a condensation type polymerization.
Therefore, in order to facilitate the degradation studies, the higher MW fraction was
isolated in 45% yield by preparative SEC in DMF to provide a monomer to end cap ratio
of approximately 16:1 based on 1H NMR analysis. This value corresponds to a number
average molecular weight (Mn) of approximately 4600. A number average molecular
weight of 17 000 and polydispersity index (PDI) of 1.6 was determined based on SEC
relative to polystyrene standards (Figure 2.3). The overestimation of the MW by SEC
using a conventional calibration can be attributed to the contracted conformation of
polystyrene relative to polymer 2.3a in DMF as DMF is a relatively poor solvent for
polystyrene.59

Polymer 2.3a did not provide a light scattering signal of sufficient

intensity to allow for absolute MW determination by multi-angle light scattering, likely
due to its relatively low MW, but the 1H NMR analysis should provide an accurate
measurement of the average degree of polymerization. Preparative SEC could be easily
performed on 200 mg batches of polymer, which was suitable for the current study, but
for scale up it is anticipated that dialysis using a membrane with an appropriate MW cutoff can likely be used.
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Figure 2.3. Size exclusion chromatograms of polymer 2.3a prior to degradation (after
preparative SEC), after 24 h of degradation and after 4 days of degradation (eluent =
DMF with 10 mM LiBr and 1% (v/v) NEt3; detection by differential refractive index).

2.2.4 Degradation Kinetics for Polymer 2.3a
While the rate of the 1,6-elimination reaction has previously been reported and was found
to be very rapid,54,55 the diamine cyclization was expected to be much slower.52,57 As this
was anticipated to be the rate-limiting step in the polymer degradation it was important to
investigate its rate under the same conditions to be used in the polymer degradation study
in order to gain insight into the time scale expected for the depolymerization.

To

accomplish this, the Boc protecting group was removed from compound 2.12 by
treatment with 1:1 TFA:CH2Cl2, and the product was incubated in a pH 7.4 0.1 M
phosphate

buffer:acetone

(3:2)

at

37

°C.

The

appearance

of

N,N'-

dimethylimidazolidinone and 4-hydroxybenzyl alcohol were quantified by 1H NMR
spectroscopy.

Mass spectrometry was used to further support the identities of the

proposed degradation products (see appendix). As shown in Figure 2.4a, the cyclization
was complete after approximately 3 h, and fitting of the data to a first order rate law
provided a half-life of approximately 35 min, very close to that measured by Saari et al.
in a fully aqueous system.57 It is noteworthy that although quantitative kinetic studies
were not carried out in other solvents, it was found that the cyclization was generally
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slower in less polar solvents. The pH 7.4 0.1 M aqueous phosphate buffer:acetone (3:2)
mixture was selected for the above kinetic study as it was found to be the most polar one
capable of fully dissolving polymer 2.3a.
a)

b)

Figure 2.4. a) Kinetics of cyclization of compound 2.12 following Boc group removal, as
measured by 1H NMR spectroscopy in pH 7.4 0.1 M phosphate buffer (D2O):acetone-d6
(3:2) at 37 °C, following removal of the Boc protecting group.

b) Kinetics of

depolymerization of polymer 2.3a, as measured by 1H NMR spectroscopy in pH 7.4 0.1
M phosphate buffer (D2O):acetone-d6 (3:2), following removal of the Boc end cap.
To study the degradation of polymer 2.3a, the polymer was treated with 1:1
TFA:CH2Cl2 to remove the Boc end cap, and then the polymer was incubated in pH 7.4
0.1 M phosphate buffer:acetone (3:2). The degree of degradation was quantified by 1H
NMR spectroscopy. As shown in Figure 2.5, peaks corresponding to 4-hydroxybenzyl
alcohol and N,N'-dimethylimidazolidinone emerged as the degradation progressed. This
supports that the degradation occurred by the proposed depolymerization mechanism as a
degradation mechanism based primarily on random chain scission of the carbamate
linkages

in

the

polymer

backbone

would

generate

primarily

N,N'-

dimethylethylenediamine rather than the cyclic urea. As predicted based on the half-life
for the cyclization, and the approximate length of the polymer, the degradation was 50%
complete in less than one day, and complete degradation was observed after 4 – 5 days
(Figure 2.4b). In comparison, a control sample of polymer 2.3a in which the Boc end cap
was left intact exhibited only trace levels of degradation after 4 days (see appendix). The
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fact that the depolymerization reached completion also indicates that there was no
significant amount of nondegradable cyclic polymers in this high MW fraction that was
subjected to degradation. The degradation was also monitored by SEC and it was found
that after 24 h of degradation, as shown in Figure 2.3, there was a significant increase in
the retention time of the polymer, corresponding to a decrease in the polymer MW. After
4 days, no polymeric material could be detected by SEC.
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Figure 2.5. 1H NMR spectra of a) polymer 2.3a following end cap removal in pH 7.4 0.1
M phosphate buffer (D2O):acetone-d6 (3:2) at t = 0 in the degradation process; and b) the
same polymer solution after 5 days at 37 °C, showing complete depolymerization into
small molecules.

2.2.5 Synthesis of a PEG End Cap
The development of an end cap based on PEG was motivated by the possibility of
forming an amphiphilc block copolymer capable of assembling into self-immolative
aggregates in aqueous solution. In this study, an ester linkage that could readily be
hydrolyzed under neutral physiological conditions was selected for the conjugation of the
PEG block to the terminus of the self-immolative block, but this concept could readily be
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extended to pH or redox sensitive linkages in order to initiate the degradation cascade
under a wide range of conditions. In contrast to a traditional polyester, only one ester
cleavage should be required to initiate the degradation cascade.
As shown in Scheme 2.3, the synthesis of the PEG end cap began by reaction of
the commercially available acid terminated PEG monomethyl ether 2.14 having a MW of
approximately 5000 g/mol, with 4-nitrophenyl chloroformate to provide the active ester
2.15. This active ester was reacted with the phenol 2.6 in the presence of triethylamine to
provide the ester 2.16. The TBS protecting group of 2.16 was then removed by treatment
with 1 vol% HCl in a 3:1 mixture of EtOH:CH2Cl2 and the resulting alcohol 2.17 was
activated with 4-nitrophenyl chloroformate to provide the activated end cap 2.18.
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Scheme 2.3. Synthesis of poly(ethylene glycol) end cap 2.18.

2.2.6 Synthesis and Assembly of the PEG-Polycarbamate Block
Copolymer
Polymerization of the deprotected monomer 2.2a with the end cap 2.18 was carried out
under the same polymerization conditions described above to provide the block
copolymer 2.3b in 76% yield (Scheme 2.4). Like polymer 2.3a, this polymer was further
purified by preparative SEC for kinetic studies. 1H NMR analysis in CDCl3 indicated that
the ratio of monomer to end cap in the resulting polymer was approximately 15:1,
corresponding to an Mn of 9100, while an Mn of 28 700 and a PDI of 1.2 was measured
by SEC relative to polystyrene standards. When polymer 2.3b was added to pure water
or pH 7.4 0.1 M phosphate buffer, the polymer did not immediately dissolve, but with
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sonication it readily dispersed. Transmission electron microscopy (TEM) performed
using phosphotungstic acid as a stain revealed the presence of nearly spherical aggregates
with a relatively broad distribution of diameters ranging from less than 100 nm to a few
hundred nm (Figure 2.6). The light corona surrounding the darker core suggests that the
hydrophobic aromatic polycarbamate block forms the cores of the nanoparticles while the
hydrophilic PEG coats their surfaces. TEM performed using osmium tetroxide to stain
the polycarbamate block also revealed the presence of spherical aggregates (see
appendix). Assemblies in water were also detected by dynamic light scattering (see
appendix). The extreme broadness and very low intensities of the peaks corresponding to
the hydrophobic polycarbamate block of 2.3b in its 1H NMR spectrum in D2O is
additional evidence of the polymer's assembly (Figure 2.7a).
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Scheme 2.4. Synthesis of poly(ethylene glycol)-capped polymer 2.3b.

Figure 2.6. Transmission electron microscopy image of nanoparticles formed by the
assembly of polymer 2.3b in water. Staining was performed with phosphotungstic acid.
Scale bar = 100 nm.
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2.2.7 Degradation Kinetics for Polymer 2.3b.
Prior to evaluating the degradation rate of the end capped polymer 2.3b, it was of interest
to determine the rate at which the ester linkage of the end cap would be hydrolytically
cleaved under physiological conditions, as this was the essential first step in initiating the
degradation cascade. Thus, the PEG derivative 2.17 was incubated in pH 7.4 0.1 M
phosphate buffered D2O at 37 °C, and the release of the hydrolysis product 4hydroxybenzyl alcohol was quantified by 1H NMR spectroscopy. As shown in Figure
2.8a, the hydrolysis occurred over a period of approximately 1 – 2 days, with a calculated
half-life of 15 h.
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Figure 2.7. 1H NMR spectra of a) polymer 2.3b in pH 7.4 0.1 M phosphate buffered
D2O; and b) the same polymer solution after 29 days at 37 °C, showing complete
depolymerization.
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b)

a)

Figure 2.8. a) Ester hydrolysis kinetics for compound 2.17 in pH 7.4 0.1 M phosphate
buffered D2O at 37 °C as measured by 1H NMR spectroscopy.

b) Kinetics of

depolymerization of polymer 2.3b in pH 7.4 0.1 M phosphate buffered D2O at 37 °C as
measured by 1H NMR spectroscopy.
To measure the rate of degradation of the assemblies formed from polymer 2.3b,
the polymer was dispersed using sonication in pH 7.4 0.1 M phosphate buffered D2O and
incubated at 37 °C. The depolymerization was monitored by 1H NMR spectroscopy. As
described above for polymer 2.3a, peaks corresponding to 4-hydroxybenzyl alcohol and
N,N'-dimethylimidazolidinone emerged as the degradation progressed (Figure 2.7b) and
the kinetic data are shown in Figure 2.8b. As shown, the depolymerization rate is clearly
slower than that observed for polymer 2.3a. This can likely be attributed to the formation
of the above-described nanoparticles from polymer 2.3b in aqueous solution. While the
depolymerization of 2.3a was carried out in a water:acetone mixture in which the
polymer was fully dissolved, the depolymerization of 2.3b occurred at the hydrophobic
core of the nanoparticles. A slowing of reactions with polar transition states in the
hydrophobic cores of micelles has been previously reported32,60 and is consistent with the
observation that the diamine cyclization was quite dependent on the polarity of the
solvent. These results indicate that the rate of the cascade degradation can be modulated
not only by incorporating new monomers with different depolymerization rates, but also
by modulating the hydrophobicity of the materials and controlling their assembly into
nanoaggregates.
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It is also of interest to note that the depolymerization kinetics for both polymer
2.3a and 2.3b are significantly slower than those of the previously reported backbone
based entirely on 1,6-elimination spacers.54,55

While a rapid depolymerization is a

definite asset for the previously reported application of amplified sensing, the availability
of a polymer degrading in a controlled manner but at a slower rate opens up many new
potential applications such as drug carrier systems or biomedical devices where more a
prolonged degradation or release of molecules is required.

2.2.8 Evaluation of Controlled Release Properties

Figure 2.9. Fluorescence decrease of Nile Red corresponding to its release from
nanoparticles comprising polymer 2.3b, as a function of time incubated in pH 7.4 0.1 M
phosphate buffer at 37 °C.
To evaluate the potential utility of this new polymer system for encapsulation and
controlled release applications, the dye Nile Red was encapsulated and its release was
studied. Nile Red was chosen as a hydrophobic dye because its fluorescence is negligible
in aqueous solutions but is known to increase substantially in the hydrophobic
compartments of polymer assemblies.61,62

The encapsulation was performed by

sonicating the polymer in pH 7.4 0.1 M phosphate buffer in the presence of insoluble
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Nile Red. As the nanoparticles formed, Nile Red was taken up as evidenced by a '20
fold increase in the fluorescence of the solution in comparison with the minimal
fluorescence of Nile Red which was sonicated in phosphate buffer alone. The loaded
nanoparticles were then incubated in this buffer at 37 °C, allowing depolymerization of
the polymers to occur. Over a time period of two weeks, the fluorescence of the dye
relative to a control solution of Nile Red, decreased to less than 15% of its initial
fluorescence, consistent with its release from the nanoparticles (Figure 2.9). The time
scale of this release was similar to that of the polymer degradation. This experiment
therefore suggests that nanoparticles comprising self-immolative polymers can provide
well-controlled release properties that depend on the rate of depolymerization.

2.3 Conclusions
In conclusion, a new approach was developed for the incorporation of spontaneously
cyclizing monomers into linear polymers, providing a new class of self-immolative linear
polymers.

This approach was based on the use of activated heterodimers as

polymerization monomers, leading to polymers degrading by alternating elimination and
cyclization reactions.

Kinetics studies were carried out on both the monomer and

corresponding polymer and the data supported the proposed route of degradation via endto-end depolymerization.

This work therefore demonstrated that cyclization spacers

could be incorporated to control the rate of degradation, and as a number of different
cyclization spacers have previously been reported,56 this approach should allow for the
depolymerization rate to be readily tuned according to the desired application, while the
choice of the end cap can be used to determine under which conditions the degradation
will be initiated. In addition, using a PEG end cap, an amphiphilic block copolymer was
developed and was demonstrated to assemble into self-immolative nanoparticles in
aqueous solution. It was possible to encapsulate the hydrophobic fluorescent dye Nile
Red into these nanoparticles and to subsequently release it over the time scale of the
depolymerization.

This ability of the block copolymers to form functional
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nanoassemblies in aqueous solution is highly promising as it opens up many new and
exciting applications of the materials.

2.4 Experimental
General procedures and materials:
All reagents were purchased from commercial suppliers and used without further
purification unless otherwise noted. Anhydrous DMF and CH2Cl2 were obtained from a
solvent purification system.

Pyridine and NEt3 were distilled from CaH2.

Unless

otherwise stated, all reactions were performed under a N2 atmosphere using flame or
oven dried glassware. Column chromatography was performed using silica gel (0.0630.200 mm particle size, 70-230 mesh). Thin layer chromatography was performed using
Macherney-Nagel Polygram® SIL G/UV254 plates. 1H NMR spectra were obtained at 400
MHz and 13C NMR spectra were obtained at 100 MHz using a Varian Mercury or Varian
Inova spectrometer. NMR chemical shifts are reported in ppm and are calibrated against
residual solvent signal of CDCl3 (! 7.27, 77.00). Coupling constants (J) are expressed in
Hertz (Hz). Infrared spectra were obtained as films from CH2Cl2 on NaCl plates using a
Bruker Tensor 27 instrument.

High-resolution mass spectrometry (HRMS) was

performed using a Finnigan MAT 8400 electron impact (EI) or a Micromass LCT
electrospray ionization time-of-flight (ESI) mass spectrometer. Matrix assisted laser
desorption ionization time of flight (MALDI-TOF) MS was performed on a Bruker
Reflex IV instrument using trans-3-indoleacrylic acid as a matrix.

Size exclusion

chromatography (SEC) was carried out at a flow rate of 1 mL/min in N,Ndimethylformamide (DMF) with 10 mM LiBr and 1% (v/v) NEt3 at 85 °C using a Waters
2695 separations module equipped with a Waters 2414 differential refractometer and two
PLgel 5 !m mixed-D (300 mm " 7.5 mm) columns from Polymer Laboratories connected
in series. The calibration was performed using polystyrene standards. Preparative size
exclusion chromatography was performed in DMF at 3 mL/min using a Waters 515 pump
equipped with an Optilab Rex refractive index detector from Wyatt Technology and 100
Å and 500 Å PLGel columns from Polymer Laboratories.
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Synthesis of compound 2.6: tert-Butyldimethylsilyl chloride (3.38 g, 22.4 mmol) and
imidazole (3.01 g, 44.3 mmol) were dissolved in DMF (20 mL), and the solution was
stirred for 10 min. 1.97 (2.50 g, 20.1 mmol) was then added, and the reaction mixture
was stirred at room temperature overnight. The solvent was evaporated under reduced
pressure, and then the crude material was partitioned between CH2Cl2 and 0.1 M HCl.
The aqueous layer was further extracted with CH2Cl2 and the combined organic layers
were dried over MgSO4, filtered, and the solvent was removed in vacuo. The product
was purified by column chromatography (9:1 hexanes:EtOAc followed by 1:1
hexanes:EtOAc), yielding 2.6 (3.49 g, 71%) as a colourless oil. 1H NMR (CDCl3): ! 7.20
(d, J = 8.1, 2H), 6.79 (d, J = 8.6, 2H), 4.95 (s, 1H), 4.67 (s, 2H), 0.94 (s, 9H), 0.10 (s,
6H).

13

C NMR (CDCl3): ! 154.8, 133.9, 128.0, 115.3, 65.0, 26.2, 18.7, -5.0. IR (cm-1):

3405, 2955, 2855. HRMS: calcd [M]+ (C13H22O2Si): 238.1389. Found: (EI) 238.1385.
Synthesis of compound 2.8: To a flask containing CH2Cl2 (45 mL) was added the
phenol 2.6 (2.0 g, 8.5 mmol) in 5 mL of anhydrous CH2Cl2, followed by freshly distilled
NEt3 (6.0 mL, 43 mmol). 4-Nitrophenyl chloroformate (3.4 g, 17 mmol) was added
slowly to the reaction flask, and the solution was stirred until the reaction was complete
as determined by thin layer chromatography (TLC) (30 min). To consume the excess 4nitrophenyl chloroformate and facilitate product isolation, distilled TEGMME (2.0 mL,
13 mmol) was added and the reaction was stirred until all 4-nitrophenyl chloroformate
was consumed as determined by TLC (20 min). The solution was then diluted with
CH2Cl2 and washed with 1 M HCl. The organic phase was dried over MgSO4, filtered,
and the solvent was removed in vacuo. The crude product was purified with column
chromatography (9:1 CH2Cl2:hexanes), yielding 2.8 (2.5 g, 75%) as a white powder. 1H
NMR (CDCl3): ! 8.33 – 8.30 (m, 2H), 7.51 – 7.47 (m, 2H), 7.41 – 7.37 (m, 2H), 7.26 –
7.21 (m, 2H), 4.75 (s, 2H), 0.96 (s, 9H), 0.11 (s, 6H).

13

C NMR (CDCl3): ! 155.3, 151.1,

149.5, 145.6, 140.1, 127.2, 125.4, 121.7, 120.4, 64.2, 25.9, 18.4, -5.3. IR (cm-1): 2925,
2856, 1770, 1637, 1527. HRMS: calcd [M]+ (C20H25NO6Si): 404.1524 Found: (ESI)
404.1516.
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Synthesis of compound 2.10: Under air atmosphere, a flask containing diamine 2.9
(4.06 g, 46.0 mmol) in 7:1 MeOH:NEt3 (120 mL) was cooled to 0 °C in an ice bath. A
solution of di-tert-butyl dicarbonate (10.04 g, 46.0 mmol) in MeOH (20 mL) was added
dropwise to the reaction over approximately 1 h via a dropping funnel. The reaction
mixture was allowed to warm to room temperature and the reaction was stirred overnight.
The solvent was removed, and the resulting residue was purified by column
chromatography (10:3:87 MeOH:NEt3:EtOAc followed by 20:3:77 MeOH:NEt3:EtOAc),
yielding 2.10 (3.34 g, 39%) as a yellow oil. 1H NMR (CDCl3): ! 3.33 (t, J = 6.2, 2H),
2.87 (s, 3H), 2.72 (t, J = 6.5, 2H), 2.45 (s, 3H), 1.44 (s, 9H).

13

C NMR (CDCl3): ! 155.8,

-1

79.2, 70.5, 48.4, 36.2, 34.6, 28.3. IR (cm ): 3410, 2975, 1650. HRMS: calcd [M]+
(C9H20N2O2): 188.1525 Found: (EI) 188.1524.
Synthesis of compound 2.11: Nitrophenyl carbonate 2.8 (2.53 g, 6.28 mmol) was
dissolved in toluene (20 mL). Amine 2.10 (1.42 g, 7.53 mmol) was added, followed by
DIPEA (1.64 mL, 9.42 mmol) and DMAP (0.077g, 0.63 mmol), and the reaction mixture
was stirred at room temperature for 24 h. The solution was then diluted with EtOAc, and
washed with 1 M HCl, followed by 1 M Na2CO3. The organic layer was dried over
MgSO4, filtered, and the solvent was removed in vacuo. The resulting pale yellow oil
was used in the next step without further purification. 1H NMR (CDCl3): ! 7.30 (d, J =
7.6, 2H), 7.05 (d, J = 8.2, 2H), 4.71 (s, 2H), 3.63 – 3.40 (m, 4H), 3.12 & 3.03 (2 s, 3H
total (rotamers)), 2.95 – 2.86 (m, 3H (rotamers)), 1.50 – 1.42 (m, 9H (rotamers)), 0.93 (s,
9H), 0.09 (s, 6H).
Synthesis of compound 2.12: Compound 2.11 (2.84 g, 6.28 mmol) was dissolved in a
solution of 1 vol% 12M HCl in EtOH (20 mL) and the solution was stirred for 1 h at
room temperature under air atmosphere. The solution was then diluted with CH2Cl2 and
washed with saturated NaHCO3 solution. The organic phase was dried over MgSO4,
filtered, and the solvent was removed in vacuo. The crude material was purified by
column chromatography (3:2 hexanes:EtOAc followed by 3:1 EtOAc:hexanes), yielding
2.12 (1.97 g, 93% over two steps) as a colourless oil. 1H NMR (CDCl3): ! 7.35 (d, J =
8.2, 2H), 7.09 (dd, J = 2.3 & 8.6, 2H), 4.66 (s, 2H), 3.62 – 3.39 (m, 4H), 3.12 & 3.03 (2 s,
3H total (rotamers)), 2.94 – 2.87 (m, 3H (rotamers)), 1.76 (br. s, 1H), 1.50 – 1.42 (m, 9H
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(rotamers)).

13

C NMR (CDCl3): ! 155.5, 154.7, 150.7, 138.4, 127.9, 127.6, 79.8, 64.2,

46.8, 35.8, 28.3. IR (cm-1): 3430, 2927, 2243, 1677. HRMS: calcd [M]+ (C17H26N2O5):
338.1842 Found: (ESI) 338.1838.
Synthesis of compound 2.13: Compound 2.12 (1.09 g, 3.22 mmol) was dissolved in a
mixture of CH2Cl2 (10 mL) and freshly distilled pyridine (0.80 mL, 9.9 mmol). 4Nitrophenyl chloroformate (1.29 g, 6.41 mmol) was added and the reaction mixture was
stirred for 2 h. The solution was then diluted with CH2Cl2 and washed with 1 M HCl.
The organic layer was dried over MgSO4, filtered, and the solvent was removed in vacuo.
Column chromatography (CH2Cl2 followed by 1:1 EtOAc:CH2Cl2) was used to purify the
material, yielding 2.13 (1.48 g, 91%) as a pale yellow oil. 1H NMR (CDCl3): ! 8.30 –
8.26 (m, 2H), 7.44 (d, J = 8.6, 2H), 7.41 – 7.35 (m, 2H), 7.19 – 7.12 (m, 2H), 5.27 (s,
2H), 3.61 – 3.42 (m, 4H), 3.13 & 3.04 (2 s, 3H total (rotamers)), 2.94 – 2.87 (m, 3H
(rotamers)), 1.50 – 1.42 (m, 9H (rotamers)).

13

C NMR (CDCl3): ! 155.5, 154.3, 152.3,

151.9, 145.3, 131.2, 129.9, 125.2, 122.2, 122.0, 121.8, 79.6, 70.3, 46.8, 45.5, 35.1, 34.5,
28.4. IR (cm-1): 2914, 1775, 1720, 1689, 1525. HRMS: calcd [M]+ (C24H29N3O9):
503.1904 Found: (EI) 503.1909.
Synthesis of polymer 2.3a and general polymerization procedure: The protected
monomer 2.13 (1.04 g, 2.07 mmol) was dissolved in a 1:1 mixture of CH2Cl2:TFA (5
mL) under air atmosphere and the solution was stirred for 2 h. The solvent was removed
in vacuo, and CH2Cl2 was successively added and evaporated to remove residual TFA, to
provide the deprotected monomer 2.2a&TFA. The end cap 2.13 (0.055, 0.109 mmol) was
then added, and the resulting mixture was dissolved in anhydrous toluene (10 mL). To
this was added freshly distilled NEt3 (1.55 mL, 11.1 mmol) and DMAP (0.0254 g, 0.208
mmol), and the reaction was stirred for 24 h at room temperature. The solution was
diluted with CH2Cl2 and washed once with 1 M HCl, then twice with 1 M Na2CO3. The
organic layer was dried over MgSO4 and the solvent was removed in vacuo to provide
0.643 g (91% crude yield) of 2.3a as a yellow solid. The crude polymer was then further
purified using preparative SEC to remove lower molecular weight oligomers for the
degradation study. An optimized yield for the preparative SEC was approximately 45%.
1

H NMR (CDCl3): ! 7.35 (br s, 2H), 7.12 – 7.00 (m, 2H), 5.15 – 5.03 (m, 2H), 3.66 –
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3.41 (m, 4H), 3.15 – 2.83 (m, 6H), 1.50 – 1.40 (m, 0.5H). SEC: Mn = 17 000, Mw = 26
900, PDI = 1.58.
Synthesis of compound 2.15: Acid terminated poly(ethylene glycol) methyl ether (2.01
g, 0.401 mmol) with a peak molecular weight of 5017 g/mol (n = 113) as determined by
MALDI-TOF MS was dissolved in CH2Cl2 (20 mL), and freshly distilled pyridine (0.65
mL, 8.04 mmol) was added. 4-Nitrophenyl chloroformate (0.805 g, 3.99 mmol) was
added and the reaction was stirred for 24 h. The product was then partitioned between 1
M HCl and CH2Cl2 and the aqueous solution was extracted twice with CH2Cl2. The
combined organic layers were dried over MgSO4, and the volume was reduced in vacuo
to approximately 5 mL. The product was precipitated in 200 mL of cold Et2O, yielding
2.15 (1.87 g, 90%) as a white powder. 1H NMR (CDCl3): ! 8.28 (d, J = 9.2, 2H), 7.33 (d,
J = 9.2, 2H), 4.47 (s, 2H), 3.85 – 3.47 (m, 450H), 3.37 (s, 3H). IR (cm-1): 2880, 2692,
1765, 1650, 1590. MS calcd. for [M+Na]+ based on conjugation to the starting polymer
with a peak MW of 5017 g/mol (n = 113): 5160. Found (MALDI-TOF): 5162.
Synthesis of compound 2.16: Phenol 2.6 (0.839 g, 3.52 mmol) was dissolved in CH2Cl2
(20 mL) and freshly distilled NEt3 (0.95 mL, 6.83 mmol) was added. To this, activated
PEG derivative 2.15 (1.80 g, 0.351 mmol) was slowly added and the reaction mixture
was stirred at room temperature for 24 h. The product was then partitioned between 1 M
HCl and CH2Cl2 and the aqueous solution was extracted twice with CH2Cl2.

The

combined organic layers were dried over MgSO4, and the volume was reduced in vacuo
to approximately 5 mL. Precipitation into 150 mL of cold Et2O yielded 2.16 (1.40 g,
77%) as a white powder. 1H NMR (CDCl3): ! 7.33 (d, J = 8.8, 2H), 7.07 (d, J = 8.6, 2H),
4.73 (s, 2H), 4.42 (s, 2H), 3.86 – 3.42 (m, 450 H), 3.38 (s, 3H), 0.94 (s, 9H), 0.10 (s, 6H).
IR (cm-1): 2880, 2692, 1757, 1615. MS calcd. for [M+Na]+ based on conjugation to the
starting polymer with a peak MW of 5017 g/mol (n = 113): 5260. Found (MALDI-TOF):
5259.
Synthesis of compound 2.17: Under air atmosphere, 2.16 (1.53 g, 0.292 mmol) was
dissolved in a solution of 1 vol% 12 M HCl in 3:1 EtOH:CH2Cl2 (20 mL) and the
reaction mixture was stirred for 1 h. The resulting mixture was then partitioned between
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CH2Cl2 and saturated NaHCO3 solution, and the aqueous layer was further extracted with
CH2Cl2. The combined organic layers were dried over MgSO4, and the volume was
reduced in vacuo to approximately 5 mL. Precipitation of the CH2Cl2 solution into 150
mL cold Et2O yielded 2.17 (1.15 g, 77%) as a white powder. 1H NMR (CDCl3): ! 7.38
(d, J = 8.8, 2H), 7.10 (d, J = 8.8, 2H), 4.68 (s, 2H), 4.41 (s, 2H), 3.84 – 3.45 (m, 450H),
3.37 (s, 3H). IR (cm-1): 3550, 2880, 2692, 2240, 1760, 1625. MS calcd. for [M+Na]+
based on conjugation to the starting polymer with a peak MW of 5017 g/mol (n = 113):
5146. Found (MALDI-TOF): 5146.
Synthesis of compound 2.18: 2.17 (1.12 g, 0.220 mmol) was dissolved in CH2Cl2 (15
mL). To this was added freshly distilled pyridine (0.36 mL, 4.5 mmol), followed by 4nitrophenyl chloroformate (0.446 g, 2.21 mmol), and the solution was stirred for 24 h.
The resulting mixture was then partitioned between CH2Cl2 and 1 M HCl, and the
aqueous layer was further extracted with CH2Cl2. The combined organic layers were
dried over MgSO4, and the volume was reduced in vacuo to approximately 5 mL.
Precipitation of the CH2Cl2 solution into 150 mL of cold Et2O yielded 2.18 (0.412 g,
79%) as a white powder. 1H NMR (CDCl3): ! 8.28 (d, J = 9.2, 2H), 7.48 (d, J = 8.8, 2H),
7.39 (d, J=9.2, 2H), 7.17 (d, J = 8.8, 2H), 5.29 (s, 2H), 4.44 (s, 2H), 3.89 – 3.43 (m,
450H), 3.38 (s, 3H). IR (cm-1): 2870, 1760, 1640. MS calcd. for [M+Na]+ based on
conjugation to the starting polymer with a peak MW of 5017 g/mol (n = 113): 5311.
Found (MALDI-TOF): 5312.
Synthesis of Polymer 2.3b: This polymer was prepared by the same procedure described
above for the synthesis of polymer 2.3a, except 2.18 was used as the end cap. Yield =
76%. 1H NMR (CDCl3): ! 7.34 (br s, 2H), 7.12 – 7.01 (m, 2H), 5.16 – 5.05 (m, 2H), 4.42
(s, 0.1H), 3.85 – 3.41 (m, 71H), 3.38 (s, 0.3H), 3.15 – 2.89 (m, 6H). SEC: Mn = 28 700,
Mw = 35 000, PDI = 1.21.
Degradation studies
Buffer Preparation: NaH2PO4&H2O (0.069 g, 0.5 mmol) was dissolved in D2O (5 mL).
To this, a saturated solution of NaOH in D2O was added dropwise with stirring, while
monitoring with a pH meter until the desired pH of 7.4 was obtained.
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Degradation of deprotected monomer 2.12: Under air atmosphere, monomer 2.12
(0.020 g, 0.059 mmol) was dissolved in 1:1 TFA:CH2Cl2 (1 mL), and the solution was
stirred for 2 h at room temperature. The solvent was removed in vacuo, and then the
material was taken up in CH2Cl2 and washed with saturated NaHCO3 solution to remove
all residual TFA. The organic layer was dried over MgSO4, filtered, and the solvent was
removed in vacuo. The product was then taken up in pH 7.4 0.1 M phosphate buffer
(D2O):acetone-d6 (3:2) (1 mL), and the solution was incubated at 37 °C. The extent of
cyclization was quantified using 1H NMR by integrating the benzylic methylene peak on
the liberated 4-hydroxybenzyl alcohol relative to that on the starting material.
Degradation of polymer 2.3a: Under air atmosphere, polymer 2.3a (0.030 g) was
dissolved in 1:1 TFA:CH2Cl2 (1 mL), and the solution was stirred for 2 h at room
temperature. The solvent was removed in vacuo, and then the material was taken up in
CH2Cl2 and washed with saturated NaHCO3 solution to remove all residual TFA. The
organic layer was dried over MgSO4, filtered, and the solvent was removed in vacuo.
The product was then taken up in pH 7.4 0.1 M phosphate buffer (D2O):acetone-d6 (3:2)
(1 mL), and the solution was incubated at 37 °C. The extent of depolymerization was
quantified using

1

H NMR by integrating the methylene peak of the N,N'-

dimethylimidazolidinone a degradation product relative to residual DMF in the sample.
Hydrolysis of PEG derivative 2.17: Compound 2.17 (0.040 g, 7.6 µmol) was dissolved
in pH 7.4 0.1 M phosphate buffer (D2O) (1 mL) and was incubated at 37 °C. The extent
of hydrolysis was quantified using 1H NMR by integrating the benzylic methylene peak
on the liberated 4-hydroxybenzyl alcohol relative to that on the ester.
Degradation of polymer 2.3b: Polymer 2.3b (0.040 g) was dissolved in pH 7.4 0.1 M
phosphate buffer (D2O) (1 mL), and the solution was sonicated for 30 s.

The solution

was then incubated at 37 °C, and the extent of depolymerization was quantified using 1H
NMR by integrating the methylene peak of the N,N'-dimethylimidazolidinone
degradation product relative to residual DMF in the sample.
Transmission electron microscopy (TEM)
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Sample preparation: Polymer 2.3b (0.2 mg) was dissolved in CH2Cl2, and the solution
was passed through a 0.2 !m syringe filter. The solvent was removed in vacuo, 0.5 mL
of H2O was filtered into the flask, and the mixture was sonicated for 30 s. A single drop
of solution was added to a carbon formvar grid and was left for 1 min. The excess
solution was then removed using a kimwipe.

The grid was stained with either

phosphotungstic acid (PTA) or OsO4.
PTA Staining: Immediately following removal of the excess polymer 2.3b solution from
the TEM plate, a drop of 2% aqueous PTA solution was added and left for between 1 and
2 min. The excess solution was then removed using a kimwipe.
OsO4 Staining: The sample grid containing polymer 2.3b was stored in a sealed
container, exposing it to the vapors of aqueous OsO4, and after 7 h the sample was
removed.
Imaging: Images were obtained using a Phillips CM10 microscope operating at 80kV
with a 40 µm aperture.
Encapsulation and release of Nile Red: Polymer 2.3b (2 mg) and Nile Red (0.2 mg)
were dissolved in 1 mL of CH2Cl2 and mixed thoroughly.

The solvent was then

removed, first under a stream of nitrogen then under vacuum. pH 7.4 0.1 M phosphate
buffer solution (2 mL) was added, and the mixture was sonicated for 2 h.

The

fluorescence was measured immediately after sonication, after which the sample was
incubated at 37 °C. A second sample, containing only Nile Red, was treated in exactly
the same manner as the polymer solution to obtain a background fluorescence value for
Nile Red in phosphate buffer. A control sample of Nile Red was also prepared by
dissolving 0.1 mg in THF (1 mL) and diluting by 1500x to obtain a fluorescence value
similar to that of the polymer. The fluorescence of the degrading sample relative to the
control sample was measured daily to determine the percentage of the initial fluorescence
while correcting for instrumental fluctuations. The fluorescence spectra were obtained on
a QM-4 SE spectrometer from Photon Technology International (PTI), equipped with
double excitation and emission monochromators. An excitation wavelength of 550 nm
was used for Nile Red and the emission spectra were recorded from 565 and 700 nm.
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Chapter 3
A Reduction Sensitive Self-Immolative Linear Polymer!

3.1 Introduction
Biodegradable polymers have been of significant interest in recent years for a wide range
of applications. For example, they can serve as environmentally friendly substitutes for
nondegradable polymers in materials such as food and beverage containers.1 They have
also been developed for biomedical materials such as sutures,2 stents,3 and tissue
engineering scaffolds,4,5 thus allowing the materials to degrade during the natural healing
or tissue regeneration process, preventing the need for further interventions to remove the
foreign material. Furthermore, their incorporation into drug delivery systems such as
micelles,6,7 worms,8,9 vesicles10-12 and nanoparticles13-15 facilitates the release of
encapsulated drug molecules throughout the degradation process. Thus far, significant
progress has been made in these areas using polymers such as PCL,16-18 PLA,19,20 and
PGA.21-23 However, the ability to "turn on" the degradation of these polymers under
specific physiological conditions has not been demonstrated as these polymer backbones
exhibit gradual degradation under most physiological conditions.24,25
The ability to trigger the degradation of a polymer backbone under specified
conditions such as photochemical or enzymatic stimuli, or changes in pH or redox
potential offers the possibility to utilize polymer backbones that will be stable for
extended periods but that will degrade under the desired conditions, resulting in a
controlled disintegration of biomedical materials or release of drug molecules from the
drug delivery system. Thus far, several polymer backbones containing acetal26-29 or
disulfide30,31 linkages have been developed to degrade under mildly acidic or reducing

This chapter contains work that has been published: DeWit, M. A.; Beaton, A.; Gillies, E. R. J. Polym.
Sci., Part A: Polym. Chem. 2010, 48, 3977-3985. See Co-Authorship Statement for specific contributions
from each author.
!

93

conditions respectively. However, the mechanisms of degradation for these polymers
involve random chain scissions throughout the polymer backbone, and many
environmentally mediated cleavage events are required to completely degrade the
polymer.
Inspired by elegant work on dendrimer systems that were designed to degrade by
a cascade of reactions upon removal of a single trigger moiety,32-41 the group of
Shabat42,43 as well as our group44 have recently developed end capped self-immolative
linear polymers. These polymers comprise backbones that are stable when the end cap is
intact, but upon removal of the end cap via a single bond cleavage, a functionality is
revealed at the polymer terminus that initiates a cascade of intramolecular reactions
leading to complete depolymerization from end to end. Like the dendrimer systems, both
of these systems have used self-immolative linkers previously developed for prodrugs.4550

Shabat's group reported the use of a polycarbamate based on 4-aminobenzyl alcohol

derivatives, that depolymerized to fluorescent monomers via a series of rapid 1,6elimination reactions in response to an enzyme mediated end cap cleavage, thus serving
as a sensor for the enzyme.42 Our group developed a polycarbamate that degraded by
alternating cyclization and 1,6-elimination reactions and incorporated this polymer into
an amphiphilic block copolymer by using a PEG derivative as an end cap.44 It was
demonstrated that the cyclization reaction could be used to control the overall rate of
depolymerization and also that the block copolymer could be assembled into
nanoparticles in aqueous solution. These nanoparticles were capable of encapsulating
and releasing a model drug molecule in a controlled manner, thus demonstrating the
promise of self-immolative linear polymers in drug delivery applications.
In order to fully exploit this new class of polymers, it will be necessary to develop
a series of polymer backbones with different depolymerization rates and also a series of
end caps that can be removed under different conditions. This will allow for the selection
of the appropriate backbone and end cap combination for the desired application.
Furthermore, it has been suggested that the quinone methide intermediates involved in
the 1,6-elimination reactions can potentially lead to toxicity,51-53 so it would be desirable
to develop new backbones that do not involve hydroxybenzyl alcohol or aminobenzyl
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alcohol. Towards this goal we report here the first example of a self-immolative linear
polymer that degrades entirely by cyclization reactions. Furthermore, we describe the
first incorporation of a disulfide end cap that can be cleaved under mildly reducing
conditions. Such conditions can be encountered in hypoxic tumor tissue54 where the
concentration of the reducing agent glutathione is at least 4-fold higher than in normal
tissues55 or within the intracellular environment where the concentration of glutathione is
approximately 0.5 - 10 mM relative to 2 - 20 µM in the extracellular environment.56,57

3.2 Results and Discussion
3.2.1 Design
A diverse array of intramolecular cyclization reactions have been reported, potentially
allowing the rate of depolymerization to be controlled by the choice of the cyclization
reaction.48,59,60 In this particular work, the cyclizations of 2-mercaptoethanol derivatives
to the corresponding cyclic thiocarbonate (Figure 3.1a) were of interest as they have been
recently reported as components of traceless self-immolative spacers in fluorescent
protease sensors.59
The development of monomers capable of undergoing polymerization to form
self-immolative polymers requires careful design. In particular, in the preparation of
polymers designed to degrade by cyclization mechanisms, cyclization of the activated
monomer (Figure 3.1b) must be avoided. In our previous work, it has been found that the
synthesis and polymerization of activated dimers is an effective approach, as the
activated leaving group is distant from the nulceophilic moiety such that the resulting
ring size is not particularly favourable for cyclization.44 This allows polymerization to be
a highly competitive reaction at high concentrations. In particular, the use of alternating
monomers, and thus the preparation of activated heterodimers as polymerizable
"monomers" has been found to be an effective strategy for overcoming the challenges
associated with the synthesis of both the activated monomers and their corresponding
polymers.44 Therefore, an activated heterodimer based on 2-mercaptoethanol and N,N'dimethylethylenediamine units was proposed.

Carbamate derivatives of N,N'-
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dimethylethylenediamine are known to spontaneously cyclize to form N,N'dimethylimidazolidinone49 and this spacer has been incorporated into our previously
reported linear self-immolative polymer44 as well and some of the previously reported
self-immolative dendrimers.32,36,39,40 As shown in Figure 3.1c, polymerization of this
activated heterodimer in the presence of an end cap should lead to a polymer based on 2mercaptoethanol and N,N'-dimethylethylenediamine with alternating carbamate and
thiocarbamate linkages. Removal of an end cap would lead to alternating cyclization
reactions resulting in end to end depolymerization with the release of N,N'dimethylimidazolidinone and 1,3-oxathiolan-2-one.
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The end cap selected for the target polymer was a disulfide (Figure 3.1d).
Disulfide linkages are known to be cleaved by biological reducing agents such as
glutathione, and it has been shown that the incorporation of disulfide linkages into gene
and drug delivery systems can provide a selective release of the cargo under the reducing
conditions within cells, leading to enhanced therapeutic efficacy.61-66

In addition,

because of the incorporation of the 2-mercaptoethanol cyclization reaction in the
degradation cascade, the disulfide was a natural choice for an end cap as the thiol moiety
can be readily converted to a disulfide which upon cleavage can directly initiate the
depolymerization cascade.

3.2.2 Boc-Capped Polymer Synthesis
As shown in Scheme 3.1, the synthesis of the target activated heterodimer began by the
selective protection of the alcohol group on 2-mercaptoethanol (3.8) using tertbutyldiphenylchlorosilane in the presence of imidazole to provide the tertbutyldiphenylsilyl (TBDPS) protected derivative 3.9. The thiol of 3.9 was then treated
with 4-nitrophenylchloroformate to provide the activated thiocarbonate 3.10. The mono
Boc protected derivative of N,N’-dimethylethylenediamine44 (2.10) was reacted with 3.10
using DMAP as a catalyst and DIPEA as a base to give the thiocarbamate 3.11, and then
the TBDPS protecting group was removed using TBAF in THF to provide the alcohol
3.12. The alcohol was then converted to the activated carbonate 3.13 by reaction with 4nitrophenyl chloroformate, providing the protected version of the polymerization
monomer.
Prior to incorporating the desired disulfide end cap, it was prudent to investigate
polymer synthesis and degradation using a model Boc end cap, provided by active
monomer 3.13. This allowed the polymerization procedure to be tested and optimized
with materials already on hand prior to investing synthetic efforts into the more valuable
disulfide end cap. Furthermore, the Boc group can be cleanly removed by treatment with
TFA, allowing the kinetics of depolymerization to be assessed independently. To this
end, compound 3.13 was first deprotected in a mixture of TFA and CH2Cl2, affording
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3.4a as its TFA salt.

While relatively stable in its salt form, upon deprotonation

compound 3.4a readily undergoes self-condensation via attack of the amine on the
nitrophenyl carbonate moiety, forming the desired polycarbamate. This process was
triggered by addition of NEt3 and catalytic DMAP to a solution of 3.4a&TFA in toluene,
with 0.05 equivalents of 3.13 added to serve as an end cap. Following reaction workup,
purification of the crude polymer mixture was carried out using preparative SEC in DMF
to remove lower MW oligomers and small molecule byproducts. Following purification,
analytical SEC in THF revealed an Mn of 1650 g/mol, an Mw of 2200 g/mol (relative to
polystyrene standards), and a resultant PDI of 1.3.
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3.2.3 Polymer Degradation
To study the kinetics of depolymerization, polymer 3.5a was first deprotected using 1:1
TFA:CH2Cl2, and the resulting material was incubated at 37 ºC in pH 7.4 0.1M phosphate
(D2O):acetone-d6 (3:2).
spectroscopy,

measuring

The progress of degradation was monitored using NMR
the

integration

of

peaks

arising

from

N,N'-

dimethylimidazolidinone. As shown in Figure 3.2, depolymerization was monitored over
a course of 7 days, resulting in approximately 60% degradation. While the study was not
followed to completion, it demonstrated that depolymerization indeed occurred as
predicted, and furthermore it gave an approximate timeline for future studies with a more
relevant end cap.

Figure 3.2. Kinetics of depolymerization of polymer 3.5a as determined by 1H NMR
spectroscopy in pH 7.4 0.1 M phosphate (D2O):acetone-d6 (3:2).

3.2.4 Disulfide-Capped Polymer Synthesis
For the synthesis of the target end cap, the alcohol group of the previously reported
thiopyridyl derivative 3.1458 was treated with 4-nitrophenyl chloroformate to provide the
activated carbonate 3.7a as shown in Scheme 3.3. This activated carbonate allows for
incorporation of the end cap onto the polymer. TEGMME was used to quench the excess
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chloroformate in this reaction as it was otherwise chromatographically inseparable from
the product.
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Scheme 3.3. Synthesis of disulfide end cap 3.7a.
Polymerization of 3.13 with end cap 3.7a was carried out in an analogous fashion
to formation of 3.5a, except that the monomer:end cap ratio was modified to 98:2. To
this end, 3.13 was first deprotected with TFA, after which the solvent was removed and
the material redissolved in toluene. NEt3 and catalytic DMAP were then added to initiate
polymerization in the presence of 2 mol% of 3.7a.
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Scheme 3.4. Polymerization of 3.13 utilizing disulfide end cap 3.7a.
The resulting polymer 3.5b was purified by dialysis in DMF using a regenerated
cellulose membrane with a MW cutoff of 3500 g/mol to remove small molecule
byproducts. The material isolated from the dialysis was pure and free of low MW
impurities as determined by 1H NMR and SEC.

In the analysis of the dialysate,

cyclization products were not detected (see appendix), indicating that the cyclization of
the monomer was not a competing reaction during the polymerization. In addition, no
monomer was detected, indicating that the polymerization proceeded to completion.
However, some polymeric material was lost into the dialysate. It should be noted that the
MW cutoff of 3500 g/mol is an estimate as it depends on the macromolecule's size and
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shape. In addition, the MW cutoff corresponds to aqueous conditions and is likely lower
in DMF due to the decreased swelling of the membrane in DMF. However, we have
routinely observed that linear polymers above the MW cut-off can pass through the
membrane.67 Although the yield for this polymer following dialysis was relatively low,
approximately 35%, this method is much less labour intensive than preparative SEC,
which was previously used to purify our self-immolative linear polymers, including 3.5a.
Using 1H NMR spectroscopy a ratio of end cap to monomer of approximately 35:1 was
determined, corresponding to an Mn of 7800 (see appendix). Using SEC the polymer was
found to have an Mn of 1800 g/mol, an Mw of 2950 g/mol, and a PDI of 1.6 relative to
polystyrene standards.

3.2.5 Polymer degradation
To study the depolymerization initiated by end cap cleavage, polymer 3.5b was dissolved
in pH 7.4 0.1M phosphate (D2O):acetone-d6 (3:2). DTT was added to cleave the disulfide
end cap, thus initiating the degradation cascade and the sample was incubated at 37 °C.
The reducing conditions were maintained by periodic additions of fresh DTT, as gradual
oxidation of the DTT within the buffered solution was observed. The degradation was
monitored by 1H NMR spectroscopy. As shown in Figure 3.3, over time, characteristic
peaks appeared corresponding to N,N'-dimethylimidazolidinone at 2.8 and 3.4 ppm and
1,3-oxathiolan-2-one at 3.2 and 3.7 ppm. The presence of these products is a strong
indicator that the degradation proceeds by the proposed cascade of cyclization reactions
as random chain scissions would lead to N,N’-dimethylethylenediamine and 2mercaptoethanol, products that were not detected in the NMR spectra. It is noteworthy
that in addition to the thiol cyclizing to form 1,3-oxathiolan-2-one, a competing
cyclization reaction to form thiirane could also be occurring, as evidenced by the
apparent

lower

integration

dimethylimidazolidinone.

of

1,3-oxathiolan-2-one

relative

to

N,N'-

In addition, a control sample incubated under the same

conditions except in the absence of DTT did not reveal the appearance of any degradation
products, thus indicating the end cap cleavage was required to initiate the degradation
(see appendix). Furthermore, an additional control polymer having a Boc end cap was
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also prepared and was demonstrated to undergo depolymerization in pH 7.4 0.1 M
phosphate (D2O):acetone-d6 (3:2) following prior treatment with 1:1 TFA:CH2Cl2 to
remove the Boc group. This confirmed that the polymer degradation could not be
attributed to random polymer backbone cleavage by the DTT (see appendix).

Figure 3.3. 1H NMR spectra of polymer 3.5b and its degradation products in pH 7.4 0.1
M phosphate (D2O):acetone-d6 (3:2) at different time points following the addition of
DTT: a) immediately following DTT addition; b) after 4 days; c) after 8 days.
The percentage of degradation was determined by the relative integration of the
peak at 4.3 ppm assigned to the methylene group adjacent to the oxygen in the polymer
and the peak at 3.4 ppm corresponding to the methylene unit of N,N'dimethylimidazolidinone.

As shown in Figure 3.4, the degradation reached 80%

completion after 10 – 14 days.

However, no significant further degradation was
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observed, even after 30 days. Size exclusion chromatograms were also obtained at
different time points during the degradation process. As shown in Figure 3.5, prior to
degradation, the chromatogram exhibited a peak at an elution volume of 16.7 mL as well
as a distinct shoulder at 18.5 mL. As the degradation progressed, the peak at 16.7 mL
decreased in intensity, consistent with the degradation progress observed by 1H NMR
spectroscopy. On the other hand, no change in the intensity of the peak at 18.5 mL was
observed. Therefore, it is possible that the peak at 18.5 mL corresponds to cyclic
polymers. These cyclic species would not be end capped and thus degradation would
only be initiated by a random chain scission of the polymer backbone. As observed for
the control sample such cleavages are extremely slow under the degradation conditions.
This may explain why the depolymerization did not reach 100% completion according to
1

H NMR spectroscopy.

Figure 3.4. Kinetics of depolymerization of polymer 3.5b, as measured by 1H NMR
spectroscopy in pH 7.4 0.1 M phosphate (D2O):acetone-d6 (3:2), following addition of
DTT.
It should also be noted that the cyclic polymers would not be distinguishable from
the linear end capped polymers by NMR spectroscopy.

Therefore, based on the

degradation plateau at 80% completion, it is possible that the ratio of monomer to end cap
in the linear polymers is closer to 30:1 than the 35:1 ratio mentioned above. Altering the
concentration of the polymerization reaction did not appear to change the content of the
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possible cyclic species significantly, nor the polymer MW.

Interestingly, such

nondegradable species were not observed in our previously reported self-immolative
polymers based on N,N’-dimethylethylenediamine and 4-hydroxybenzyl alcohol.44 This
may be explained by the increased rigidity imparted by the aromatic groups of 4hydroxybenzyl alcohol, making cyclization less favourable. Nevertheless, this somewhat
unexpected result provides additional evidence of the polymer backbone’s inherent
stability and the specificity of the degradation process mediated by end cap cleavage. It
is possible that in the future, the extent of the possible cyclic species could be decreased
by tuning the reactivity of the activated carbonate in the polymerization monomer.

Figure 3.5. Size exclusion chromatograms of polymer 3.5b before degradation and after
1 day, 4 days, and 8 days of incubation in pH 7.4 0.1M phosphate (D2O):acetone-d6 (3:2)
in the presence of DTT (detection by refractive index).

3.3 Conclusions
In conclusion, a new polymer designed to degrade by a cascade of intramolecular
cyclization reactions was prepared for the first time.

A disulfide end cap was

incorporated such that the degradation could be selectively initiated under reducing
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conditions. The degradation was initiated by the addition of DTT, a known thiol-based
reducing agent and was monitored by 1H NMR and size exclusion chromatography. The
data supported the proposed degradation mechanism, and also suggested that the polymer
likely contained approximately 20% of a proposed cyclic species that did not degrade as
they were lacking the labile linkage to the end cap. Overall, this new class of polymers
offers a high degree of control over the degradation process as the polymer backbone is
very stable under physiological conditions (pH 7.4 buffer) in the absence of the trigger
required to cleave the end cap. In addition, the degradation mechanism of this polymer
avoids the potentially undesirable quinone methide species generated in the degradation
of the previously reported self-immolative linear polymers. Future work on this polymer
will focus on its biological properties and applications in biomedical materials.

3.4 Experimental
General Procedures and Materials:
Solvents used were anhydrous and obtained from a solvent purification system.
Chemicals were obtained from Sigma Aldrich and Alfa Aesar and were used without
further purification unless otherwise noted. Unless otherwise stated, all reactions were
performed under a N2 atmosphere using flame or vacuum-dried glassware. Silica used
for column chromatography was 70-230 mesh, 0.063-0.200mm particle size.

1

H NMR

13

spectra were obtained at 400 MHz and C NMR spectra were obtained at 100 MHz using
a Varian Mercury or Varian Inova spectrometer. NMR chemical shifts are reported in
ppm and are calibrated against residual solvent signal of CDCl3 (! 7.27, 77.00).
Chemical shifts are reported in ppm. Coupling constants (J) are reported in Hz. Infrared
spectra were obtained as films from CH2Cl2 on NaCl plates using a Bruker Tensor 27
instrument. ESI mass spectrometry was performed using a PE-Sciex API 365 triple
quadrupole instrument. Analytical size exclusion chromatography was performed using a
Waters 515 HPLC pump, equipped with Wyatt miniDawnTREOS and Wyatt Optilab Rex
detectors, and two ResiPore 300x7.5mm, 3µm particle size columns from Polymer
Laboratories. The eluent used was THF and the calibration was performed using
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polystyrene standards. Preparative size exclusion chromatography was carried out in
DMF at 3 mL/min using a Waters 515 pump equipped with an Optilab Rex refractive
index detector from Wyatt Technology and 100 Å and 500 Å PLGel columns from
Polymer Laboratories.
Synthesis of compound 3.9: To a solution of imidazole (3.84 g, 56.3 mmol) in DMF (40
mL) was added a solution of tert-butyldiphenylchlorosilane (7.75 g, 28.2 mmol) in DMF
(30 mL) and the resulting solution was stirred for 10 min. 2-Mercaptoethanol (2.04 g,
26.1 mmol, 1.00 eq.) in DMF (8 mL) was then added and the reaction mixture was stirred
at room temperature for 24 h. The DMF was then removed in vacuo and the crude
product was taken up in CH2Cl2, filtered, and washed with H2O to remove the imidazole.
The organic layer was dried with MgSO4, filtered, and the solvent was removed in vacuo.
The residue was purified by silica gel chromatography (97:3 hexanes:EtOAc) to provide
3.9 (7.74 g, 94%) of as a clear colourless oil. 1H NMR (CDCl3): ! 7.71 – 7.67 (m, 4H),
7.48 – 7.37 (m, 6H), 3.79 (t, J = 6.35 Hz, 2H), 2.68 (dt, J = 8.30 & 6.30 Hz, 2H), 1.60 (t,
J = 8.30 Hz, 1H), 1.08 (s, 9H).

13

C NMR (CDCl3): ! 135.2, 133.1, 129.4, 127.4, 65.3,

26.8, 26.5, 18.9. IR (cm-1): 3070, 2970, 1930, 1770, 1685, 1650,1520. HRMS: calcd [MH]+ (C18H24OSSi): 315.1239 Found: (ESI) 315.1230.
Synthesis of compound 3.10: Compound 3.9 (1.01 g, 3.20 mmol) was dissolved in
CH2Cl2 (40 mL).

NEt3 (2.2 mL, 15 mmol) was added followed by 4-nitrophenyl

chloroformate (1.30 g, 6.39 mmol) and the reaction mixture was stirred at room
temperature for 18 h. The reaction mixture was then poured onto 1 M HCl and the
product was extracted twice into CH2Cl2. The combined organic layers were dried over
MgSO4, filtered, and the solvent was removed in vacuo. The product was purified by
silica gel chromatography (1:1 CH2Cl2:hexanes) to provide 3.10 (1.52 g, 99%) as a clear,
colourless oil. 1H NMR (CDCl3): ! 8.28 (d, J = 9.4 Hz, 2H), 7.69 (dd, J = 7.9 & 1.5 Hz,
4H), 7.37 – 7.50 (m, 6H), 7.32 (d, J = 9.4 Hz, 2H), 3.91 (t, J = 6.1 Hz, 2H), 3.18 (t, J =
6.1 Hz, 2H), 1.06 – 1.11 (m, 9H).

13

C NMR (CDCl3): ! 169.5, 155.6, 135.6, 133.1,

129.8, 127.7, 125.2, 122.0, 62.2, 34.3, 26.8, 19.2. IR (cm-1): 3050, 2930, 2850, 1725,
1590, 1520. HRMS: calc’d [M+H]+ (C25H27NO5SSi): 482.1457 Found: (ESI) 482.1461.
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Synthesis of compound 3.11: To a solution of compound 3.10 (3.17 g, 6.58 mmol) in
toluene (60 mL) was added DMAP (0.077 g, 0.63 mmol), DIPEA (1.72 g, 13.3 mmol),
and diamine 2.10 (1.81 g, 9.63 mmol). The reaction mixture was heated at reflux for 5 h.
The reaction mixture was then washed 1 M HCl, followed by two washes with saturated
Na2CO3 solution. The organic layer was dried with MgSO4, filtered, and the solvent was
removed in vacuo to provide 3.11 (3.48 g, 99%) as a clear pale yellow oil.

1

H NMR

(CDCl3): ! 7.68 (dd, J = 7.9 & 1.7Hz, 4H), 7.47 – 7.34 (m, 6H), 7.30 – 7.14 (m, 3H), 3.82
(m, 2H), 3.57 – 3.32 (m, 4H, (rotamers)), 3.18 – 3.08 (m, 2H), 3.02 (br s, 3H), 2.94 –
2.81 (m, 3H), 1.46 (d, J = 8.40 Hz, 9H), 1.06 (s, 9H, CH3).

13

C NMR (CDCl3): ! 168.2

(rotamer), 167.5 (rotamer), 155.7, 155.4, 135.5, 133.6, 129.6, 127.6, 125.3, 115.6, 79.7,
63.3, 47.6 (rotamer), 46.7 (rotamer), 45.8 (rotamer), 35.7 (rotamer), 35.3 (rotamer), 34.8
(rotamer), 34.6 (rotamer), 32.99 (rotamer), 32.93 (rotamer), 28.4, 26.8, 19.2. IR (cm-1):
3060, 2925, 2850, 1690, 1650.

HRMS: calcd [M+H]+ (C28H42N2O4SSi): 531.2707

Found: (ESI) 531.2691.
Synthesis of compound 3.12: To a solution containing 3.11 (1.18 g, 2.22 mmol) in THF
(20 mL) was added TBAF (1.0 M solution in THF, 4.43 mL, 4.43 mmol) and the reaction
mixture was stirred at room temperature for 2 h. The solvent was then removed in vacuo
and the resulting residue was purified by silica gel chromatography (85:15
hexanes:EtOAc) to provide 3.5 (0.50 g, 78%) as a clear, pale yellow oil.

1

H NMR

(CDCl3): ! 3.75 (t, J = 5.8 Hz, 2H), 3.54 – 3.33 (m, 4H (rotamers)), 3.05 (t, J = 5.6 Hz,
2H), 2.99 (br s, 3H), 2.90 – 2.78 (m, 3H), 2.00 (s, 1H), 1.42 (s, 9H).

13

C NMR (CDCl3):

! 168.9 (rotamer), 168.7 (rotamer), 155.5, 80.0 (rotamer), 79.7 (rotamer), 79.5 (rotamer),
62.1 (rotamer), 61.8 (rotamer), 48.1 (rotamer), 47.8 (rotamer), 47.4 (rotamer), 47.4
(rotamer), 46.7 (rotamer), 46.5 (rotamer), 45.6 (rotamer), 35.7 (rotamer), 35.4 (rotamer),
35.1 (rotamer), 34.9 (rotamer), 34.7 (rotamer), 34.4 (rotamer), 33.2 (rotamer), 32.8, 28.2.
IR (cm-1): 3400, 2960, 2930, 2850, 1680, 1650. HRMS: calc’d [M]+ (C12H24N2O4S):
292.1457 Found: (ESI) 292.8123.
Synthesis of compound 3.13: To a solution containing 3.12 (0.45 g, 1.5 mmol) in
CH2Cl2 (10 mL) was added pyridine (0.37 mL, 4.6 mmol), followed by 4-nitrophenyl
chloroformate (0.62 g, 3.1 mmol), and the reaction mixture was stirred for 20 h. The
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reaction mixture was then washed with 1 M HCl, then the organic layer was dried over
MgSO4, filtered, and the solvent was removed in vacuo. The resulting residue was
purified by silica gel chromatography (1:1 CH2Cl2:EtOAc) to provide 3.13 (0.60 g, 85%)
as a clear, pale yellow oil. 1H NMR (CDCl3): ! 8.33 – 8.25 (m, 2H), 7.46 – 7.37 (m, 2H),
4.42 (t, J = 6.5 Hz, 2H) 3.61 – 3.50 (m, 2H (rotamer)), 3.40 (d, J = 6.1 Hz, 2H), 3.27 (d, J
= 5.5 Hz, 2H (rotamer)), 3.04 (s, 3H), 2.89 (br s, 3H), 1.47 (br. s. 9H).

13

C NMR

(CDCl3): ! 167.0 (rotamer), 166.8 (rotamer), 166.2 (rotamer), 155.6 (rotamer), 155.4,
155.2 (rotamer), 152.1, 145.3, 125.1, 121.7, 79.7 (rotamer), 79.52 (rotamer), 79.45
(rotamer), 88.0, 53.4, 47.9 (rotamer), 47.5 (rotamer), 46.7 (rotamer), 46.4 (rotamer), 45.6
(rotamer), 35.5 (rotamer), 35.2 (rotamer), 34.7 (rotamer), 34.3 (rotamer), 28.5 (rotamer),
28.3 (rotamer). IR (cm-1): 3105, 3070, 2964, 2920, 1770, 1690, 1650. HRMS: calc’d
[M+H]+ (C19H27N3O8S): 458.1597 Found: (ESI) 458.1599.
Synthesis of polymer 3.5a and general polymerization procedure: Under air
atmosphere, compound 3.13 (1.9 g, 4.2 mmol) was dissolved in 1:1 CH2Cl2:TFA (20 mL)
and the reaction mixture was stirred at room temperature for 2 h. The solvent was
evaporated in vacuo, and then CH2Cl2 was added and evaporated five times to remove
residual TFA, providing 3.4a&TFA. The residue was dissolved in toluene (40 mL) and
NEt3 (2.9 mL, 21 mmol), DMAP (0.056 g, 0.46 mmol) and end cap 3.13 (0.096 g, 0.21
mmol) were added. The resulting solution was stirred at room temperature for 18 h. The
reaction was quenched with 1 M HCl, and the product was extracted three times into
CH2Cl2.
removed.

The organic layers were dried over MgSO4, filtered, and the solvent was
Purification via preparative SEC afforded polymer 3.5a (0.44 g, 45%).

1

H

NMR (CDCl3): ! 4.27 – 4.13 (m, 2H), 3.60 – 3.33 (m, 4H), 3.22 – 3.10 (m, 2H), 3.02 (s,
3H), 2.97 – 2.89 (m, 3H), 1.46 (s, 0.5H). SEC: Mn = 1650 g/mol, Mw = 2200 g/mol, PDI
= 1.3.
Synthesis of compound 3.7a: Compound 3.1458 (0.24 g, 1.3 mmol) was dissolved in
CH2Cl2 (6 mL) and pyridine (0.30 mL, 3.8 mmol), then 4-nitrophenyl chloroformate
(0.51 g, 2.5 mmol) was added and the reaction mixture was stirred for 4 h. NEt3 (0.34
mL, 2.5 mmol) and TEGMME (0.30 mL, 1.9 mmol) were then added and the reaction
mixture was stirred for an additional 10 min. The reaction mixture was then poured into
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1 M HCl and the product was extracted twice into CH2Cl2. The combined organic layers
were dried with MgSO4, filtered, and the solvent was removed. The residue was purified
by silica gel chromatography (9:1 hexanes:EtOAc) to provide 3.7a (0.33 g, 74%) as a
pale yellow oil. 1H NMR (CDCl3): ! 8.53 - 8.48 (m, 1H), 8.32 - 8.26 (m, 2H), 7.70 - 7.63
(m, 2H), 7.42 - 7.36 (m, 2H), 7.15 - 7.12 (m, 1H), 4.57 (t, J = 6.4, 2H), 3.17 (t, J = 6.4,
2H).

13

C NMR (CDCl3): ! 159.1, 155.3, 152.1, 149.8, 145.4, 137.1, 125.3, 121.7, 121.1,

120.2, 66.6, 36.7. IR (cm-1): 3115, 3080, 3045, 2960, 2855, 1760, 1615, 1590, 1570,
1520. HRMS: calc’d [M]+ (C14H12N2O5S2): 352.0188 Found: (ESI) 352.0184.
Synthesis of polymer 3.5b: This polymer was prepared by the same procedure described
above for the synthesis fo polymer 3.5a except that 3.7a was used as the end cap. The
polymer was purified by dialysis against DMF (200 mL, 1 solvent change) using a
regenerated cellulose membrane (Spectrum Laboratories Spectra/Por, 3500 MW cutoff).
The DMF was then removed in vacuo to provide polymer 3.5a (0.10 g, 34%). 1H NMR
(CDCl3): ! 8.48 (d, J = 4.7 Hz, 0.2H), 8.28 (d, J = 9.0 Hz, 0.2H) 7.74 – 7.61 (m, 0.4H),
7.41 (d, J = 9.0 Hz, 0.2H), 7.10 (br s, 0.2H), 4.39 – 4.28 (m, 2H), 4.27 – 4.07 (m, 2H),
3.61 – 3.34 (m, 4H), 3.23 – 3.10 (m, 2H), 3.02 (br S, 3H), 2.98 – 2.89 (m, 3H). SEC: Mn
= 1800 g/mol, Mw = 2950 g/mol, PDI = 1.6.
Degradation Study
Buffer Preparation: NaH2PO4&H2O (0.069 g, 0.5 mmol) was dissolved in D2O (5 mL).
To this, a saturated solution of NaOH in D2O was added dropwise with stirring, while
monitoring with a pH meter until the desired pH of 7.4 was obtained.
Degradation of polymer 3.5a: Under air atmosphere, 12 mg of polymer 3.5a was
dissolved in 1:1 TFA:CH2Cl2 (1 mL) and the solution was stirred 2 h. The solvent was
removed, and then CH2Cl2 was added and removed five times to azeotrope residual TFA.
The material was then dissolved in pH 7.4 0.1 M phosphate (D2O):acetone-d6 (3:2) (1
mL), and the solution was incubated at 37 °C. The extent of depolymerization was
quantified using 1H NMR by integrating the methylene peak corresponding to the N,N'dimethylimidazolidinone a degradation product (3.4 ppm) relative to the peak
corresponding to the methylene group adjacent to the oxygen in the polymer (4.3 ppm).
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A control sample with the Boc group still attached was monitored under the same
conditions as above.
Degradation of polymer 3.5b: Under air atmosphere, 15 mg of polymer 3.5b was
dissolved in pH 7.4 0.1 M phosphate buffered D2O:acetone-d6 (3:2) (1 mL), and the
solution was incubated at 37 °C.

3 mg of DTT was added at the beginning and

subsequently every 7 days to maintain reducing conditions. Extent of depolymerization
was monitored as described above for degradation of 3.5a. A control sample was
monitored under the same conditions as above, but without DTT. For SEC samples, a
0.25 mL aliquot was dried and the resulting residue was taken up in THF. The salts were
removed by filtration through a 0.2 µm filter.
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Chapter 4
Design, Synthesis and Cyclization of 4-Aminobutyric Acid
Derivatives: Potential Candidates as Self-Immolative
Spacers!

4.1 Introduction
Chemical moieties capable of undergoing rapid and spontaneous intramolecular reactions
in response to the cleavage of a capping or triggering unit are commonly referred to as
self-immolative spacers.1 In their typical form, these moieties comprise two reactive
termini with a capping group or trigger as one terminus and the substrate of interest, such
as a drug, fluorophore, or an additional spacer on the other terminus. Removal of the
capping group results in an intramolecular reaction that ultimately results in the liberation
of the substrate. As shown in Figure 4.1, these intramolecular reactions generally involve
electronic rearrangements such as 1,4, 1,6, or 1,8 elimination reactions2,3 or cyclizations
to form highly favored five- or six-membered rings.4,5
In recent years, the interest in self-immolative spacers has grown significantly as
their application in various prodrug, sensor, and drug delivery systems has been explored.
For example, the conjugation of self-immolative spacers to drug molecules has created
inactive prodrugs that are converted to the free and active drugs by cleavage of the trigger
upon exposure to an external stimulus.6-15 They have also been used in the linkage of
drug molecules to small molecule or antibody targeting moieties.16-23 Sensors have been
developed by using self-immolative spacers to conjugate reporter molecules such as
fluorophores or imaging agents to peptide or enzyme sensitive triggers.24-32 The use of
these linkers in dendrimeric33-37 and oligomeric38,39 systems has also been explored,
leading to an amplified release of drugs or reporter molecules.

!

This chapter contains work that has been published: Dewit, M. A.; Gillies, E. R. Org. Biomol. Chem.
2011, 9, 1846-1854. See Co-Authorship Statement for specific contributions from each author.
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Figure 4.1. a) Schematic of a self-immolative spacer; b) example of a 1,6 elimination
reaction; c) example of a cyclization reaction.
Recently, our group and others have explored the development of linear polymers
comprising self-immolative spacers.

Shabat and coworkers have explored polymers

based entirely on 1,6-elimination reactions as amplified reporters,40 enzyme sensors,41
and enzyme labels.42 Moore and coworkers have prepared microcapsules based on crosslinked versions of similar polymers.43 Our group has introduced cyclization spacers in
alternation with elimination spacers as a means of controlling the polymer degradation
rate, and have demonstrated that amphiphilic block copolymers such as 2.3b (Figure 4.2)
comprising one self-immolative block are capable of assembling into nanoparticles that
degrade in a controlled manner to release their cargo.44 Furthermore, we have also
developed linear polymers such as 3.5b,45 capable of degrading entirely by cyclization
reactions in order to address the potential toxicity of the quinone methide intermediates
that are produced during the 1,6-elimination reaction.46
In order to fully exploit self-immolative spacers in these materials and other new
applications, it is essential to have access to spacers that react at different rates. For
example, the N,N’-dimethylethylenediamine spacer used in both polymers 2.3b and 3.5b
cyclized slowly at pH 7.4, which resulted in polymer degradation over a period of days to
weeks. While several self-immolative spacers based on cyclization reactions have been
reported, there are very few that cyclize rapidly under mild conditions.1,4,47,48 To address
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this need and to develop a spacer that could potentially replace the N,N’dimethylethylenediamine spacer in polymers such as 2.3b or 3.5b, we have investigated
4-aminobutyric acid derivatives as a potential new class of rapidly cyclizing selfimmolative spacers. The recent incorporation of a 4-aminobutyric acid unit into an
enzymatic detection probe suggested that this class of molecules may serve as rapidly
cyclizing spacers.24 However, there has not been a versatile synthetic strategy developed
for the preparation of various analogues, nor a comprehensive study of their cyclization
rates. Thus, described here is the design and synthesis of eleven different derivatives of
4-aminobutyric acid, and studies of their cyclizations.
O

O

O

O

n O

O

N

N

OH
O

O

m

2.3b
N

O
S

S

O

N

N

S
O

OH
n

3.5b

Figure 4.2. Chemical structures of previously reported self-immolative polymers
incorporating cyclization spacers.44,45

4.2 Results and discussion
4.2.1 Design
O
R1HN
R2

R3

OPh

4.1a R1 = R2 = R3 = H
4.1b R1 = Me R2 = R3 = H
4.1c R1 = R2 = Me R3 = H
4.1d R1 = Me R2 = allyl R3 = H
4.1e R1 = Me R2= Bn R3 = H
4.1f R1 = R2 = R3 = Me
4.1g R1 = Me R2 = R3 = allyl
4.1h R1 = Me R2 = R3 = Bn
4.1i R1 = Me R2 = -CH2(CH2)2CH2- = R3 (cyclopentyl)
4.1j R1 = R2 = H R3 = OH
4.1k R1 = Me R2 = H R3 = OH

Figure 4.3. Target 4-aminobutyric acid derivatives for kinetic studies.
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The targets shown in Figure 4.3 were designed with several aspects in mind. First, a
phenyl ester was selected, as it would serve as a good model system for future
applications. Many dyes, such as fluorescein, Hoechst stain and umbelliferone, contain
phenolic groups, along with the chemotherapy drug Topotecan. In addition, many other
self-immolative spacers involve phenols,1,3,5 thus allowing the new spacer to be readily
alternated with other spacers, and incorporated into polymers analogous to 2.3b.
Secondly, some N-methylated derivatives were targeted as this has previously been
reported to significantly enhance the cyclization rate in the case of ethylenediamine
derivatives.49 Finally, substitution at the # position allowed us to examine the ThorpeIngold effect.50,51 and/or the reactive rotamer effect52 on these compounds. It was also
expected to slow any competing ester hydrolysis. To test the scope of these effects, the
substitution pattern and the size of the substituents were varied from unsubstituted to an
#,#-dibenzyl derivative. A single cyclopentyl ring was also incorporated to test the effect
of a conformationally locked system.

The 2-hydroxy derivatives were designed to

provide insight into inductive effects.

4.2.2 Synthesis
PhOH
DCC
DMAP

O
BocHN

OH

CH2Cl2

4.2
2. LiOH.H2O
THF/H2O
73%

1. MeI, NaH
DMF

O
BocN

OH

R
BocN
PhOH
DCC
DMAP

O
OPh

4.4a R = H 95%
4.4b R = Me 79%

CH2Cl2

4.3

Scheme 4.1. Synthesis of #-unsubstituted derivatives.
The synthesis of targets 4.1a-j began with the previously reported Boc-protected 4aminobutyric acid 4.2.53 As shown in Scheme 4.1, the phenyl ester 4.4a was obtained by
coupling the acid 4.2 to phenol using N,N’-dicyclohexylcarbodiimide (DCC) in the
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presence of DMAP. The N-methyl derivative was prepared by treating 4.2 with MeI and
NaH, immediately followed by hydrolysis of the resulting methyl ester with LiOH. The
resulting free acid 4.3 was then coupled to phenol using DCC and DMAP to obtain the
desired Boc-protected phenyl ester 4.4b.
NH
O

4.2

CCl3

4.5
BF3.Et2O

R
BocN

CH2Cl2

O
OtBu

4.6a R = H 96%
4.6b R = Me 84%

MeI, NaH
DMF, 0°C

OH

O
BocN
R

2. Boc2O, NaOH
H2O/dioxane

O
BocN

NEt3
CH2Cl2

R

1. TFA/CH2Cl2
OtBu

4.7a R = Me 88%
4.7b R = allyl 69%
4.7c R = Bn 70%

Piv-Cl
PhOH, DMAP

O
BocN

R-X
LiCl
LHMDS
THF
-78°C

4.8a R = Me 91%
4.8b R = allyl 99%
4.8c R = Bn 96%

OPh
R

4.9a R = Me 78%
4.9b R = allyl 86%
4.9c R = Bn 82%

Scheme 4.2. Synthesis of #-monosubstituted derivatives.
To prepare the #-monosubstituted compounds, the acid was first converted to a tbutyl ester 4.6a using tert-butyl-2,2,2-trichloroacetimidate in the presence of BF3&Et2O,
and then N-methylation was performed as described above using MeI and NaH to provide
4.6b (Scheme 4.2). Monoalkylated t-butyl esters 4.7a-c were obtained by treatment of
4.6b with lithium hexamethyldisilylazide (LHMDS) in the presence of LiCl at -78 °C,
followed by the addition of the alkyl halide. In marked contrast to the formation of the
benzyl

and

allyl

derivatives

which

suffered

from

partial

over-alkylation,

monomethylation was cleanly achieved even when a large excess of both LHMDS and
MeI were used, simplifying purification and increasing its yield relative to the other
compounds. The substituted t-butyl esters were then converted to the free acids by first
removing both the Boc group and the ester using 1:1 TFA:CH2Cl2, and then reinstalling
the Boc group on the amine. This process worked very efficiently for all substrates, with
all products being obtained with yields in excess of 90%. The final step was formation of
the phenyl ester. When DCC was used as described above for the preparation of 4.4a and
4.4b, unsatisfactory yields of the desired products were obtained, likely due to steric
hindrance at the # carbon. To circumvent this problem, the acid was converted to a
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mixed anhydride using pivaloyl chloride, and this anhydride was then treated with
phenol. This afforded phenyl esters 4.9a-c in good yields, ranging from 78 – 86%.
R-X
LHMDS

4.6b

O

THF
-78°C MeI
LDA
THF
-78°C
4.7a

BocN
R

R

1. TFA/CH2Cl2
OtBu

2. Boc2O, NaOH
H2O/dioxane

4.10a R = Me 95%
4.10b R = allyl 93%
4.10c R = Bn 93%
4.10d R = -CH2(CH2)2CH2 = R 46%
NMe2
Cl

4.12
PhOH

O
BocN
R

R

OH

NEt3
CH2Cl2

4.11a R = Me 97%
4.11b R = allyl 90%
4.11c R = Bn 94%
4.11d R = -CH2(CH2)2CH2 = R 88%

O
BocN
R

R

OPh

4.13a R = Me 90%
4.13b R = allyl 74%
4.13c R = Bn 60%
4.13d R = -CH2(CH2)2CH2 = R 76%

Scheme 4.3. Synthesis of #,#-disubstituted derivatives.
The #,#-dialkylated compounds were similarly derived from the intermediate 4.6b
(Scheme 4.3). Diallyl and dibenzyl tert-butyl esters 4.10b & 4.10c were synthesized
directly from 4.6b by treatment first with 1 eq of LHMDS and then the alkyl halide
followed an hour later by 2 eq of each, which gave clean conversion to the disubstituted
products. Synthesis of the cyclopentyl ring was done similarly except with a single
addition of the alkyl dihalide. Following the same protocol as allylation and benzylation
to generate 4.10a did not prove successful, and the products obtained were a mixture of
the mono and disubstituted compounds. Resubjection of this material also did not prove
successful, even after removal of byproducts.

Similarly, 4.7a could not be further

methylated under these conditions. However, when the base was switched to lithium
diisopropylamide (LDA), the second methylation occurred cleanly, affording 4.10a in
very good yield. Curiously, when LDA was used on 4.6b, a mixture of mono and
dialkylated products was once again obtained, so it appears for this particular substrate
the dimethyl tert-butyl ester could only be obtained by doing successive methylations of
4.6b and then 4.7a, using LHMDS for the first methylation and LDA for the second.
At this point a global deprotection and reinstallation of the Boc group was carried
out, again producing the N-Boc acids in very good yields. To install the phenyl ester, it
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was evident that a mixed pivaloyl anhydride would be ineffective as there would be little
steric differentiation between the two carbonyls of the anhydride. Therefore, the best
option appeared to be conversion of the acid to an acid chloride. As the acid sensitivity
of the Boc groups was incompatible with conventional methods for generating acid
chlorides, the Ghosez reagent, 1-chloro-N,N,2-trimethylpropenylamine, which generates
the acid chloride with no acidic byproducts, was used.

This method proved quite

effective, providing the desired phenyl esters in yields ranging from 60 – 90% after
isolation.
MeI
Cs2CO3

O
BocHN

OH

DMF
87%

OH

O
BocHN

4.14
R
BocN

4.16a R = H 91%
4.16b R = Me 74%

OMe
OH

Boc2O
DMAP
THF

4.15
LiOH.H2O

O
OMe
OBoc
MeI, NaH
DMF, 0°C

1.
THF/H2O

R
BocN

2. Piv-Cl
PhOH, DMAP
NEt3
CH2Cl2

O
OPh
OBoc

4.17a R = H 70%
4.17b R = Me 58%

Scheme 4.4. Synthesis of #-hydroxy substituted derivatives.
As shown in Scheme 4.4, the synthesis of the #-hydroxy targets began with Bocprotected (S)-4-amino-2-hydroxybutyric acid54 4.14. This acid was treated with MeI in
the presence of Cs2CO3 to afford the desired methyl ester 4.15 in very good yield. The
next step was protection of the 2-hydroxy group, for which we selected a second Boc
group. This group was chosen because it could be attached easily in high yields, and
cleavage could occur simultaneously with the N-Boc group, thus removing an additional
deprotection step from the reaction sequence. This Boc group was installed using Boc2O
in the presence of catalytic DMAP, affording di-Boc protected compound 4.16a in 90%
yield. To generate the target lacking an N-methyl group, 4.16a was treated with LiOH to
cleave the methyl ester, and the corresponding acid was converted to phenyl ester 4.17a
in 70% yield using the mixed anhydride method described above.

The N-methyl

derivative was synthesized by first methylating 4.16a using MeI and NaH, and then
following the same procedure as above to obtain the phenyl ester 4.17b.

119

4.2.3 Kinetics

Figure 4.4. Normalized UV-visible absorption spectra of phenol and a representative
phenyl ester 4.1a·TFA.
UV-visible spectroscopy was evaluated as a possible analytical tool for measuring the
cyclization kinetics. The UV-visible spectra of phenol and a representative phenyl ester
4.1a·TFA are shown in Figure 4.4. While there is some overlap between the two spectra,
at 276 nm the phenol is strongly absorbing, with a molar extinction coefficient of 1100
M-1cm-1 while the phenyl ester is only weakly absorbing, with a molar extinction
coefficient of just 65 M-1cm-1. Therefore, it was possible to perform kinetic studies
measuring the phenol released upon cyclization by monitoring the absorbance at 276 nm,
as the change in absorbance at this wavelength throughout the course of the reaction was
expected to be due almost exclusively to the increase in concentration of phenol while the
decreasing phenyl ester concentration was expected to have negligible impact on the
absorbance.
R1
BocN

O
R2

R3

TFA
OPh

4.4a-b, 4.9a-c
4.13a-d, 4.17a-b

CH2Cl2

O
R1H2N
TFA

R2

R3

4.1a-k!TFA

OPh

10 v% iPrOH
0.1M phosphate
pH 7.4
37 °C

O
R2
R3

N

R1

4.18a-k

Scheme 4.5. Deprotection and subsequent cyclization of 4-aminobutyric acid derivatives.

120

All of the target molecules were stored in their Boc-protected forms and were
deprotected immediately prior to kinetic studies by treatment with TFA as shown in
Scheme 4.5. Removal of the Boc group was verified by 1H NMR spectroscopy. In most
cases, protonation of the amine in the form of the TFA salt was sufficient to inhibit
cyclization prior to and during NMR spectroscopy, but occasionally some cyclization was
observed (see appendix).

The kinetic studies were performed by dissolving the

deprotected substrates in iPrOH, then diluting this solution ten-fold with pH 7.4 0.1 M
phosphate buffer. The measurements were carried out at the physiological temperature of
37 °C. The pH was verified after cyclization, and no change was observed. Due to the
rapid rates of cyclization observed for certain spacers, it was found to be necessary to
begin monitoring the change in absorbance at 276 nm immediately prior to addition of
phosphate buffer. To compensate for initial mixing effects, the point at which a steady
increase in the absorbance at 276 nm began was taken to be t = 0. The linearity of
ln[A]0/[A] versus time graphs where [A] is the concentration of the starting material
suggested that the cyclizations followed first order or pseudo first order kinetics (see
appendix). Rate constants were calculated as the slopes of these graphs. The reported
rate constants are the average of those obtained over a minimum of 3 experimental runs
(Table 4.1). Reported errors correspond to the calculated standard deviations of these
runs. From the average rate constant, the half-life for each spacer was also calculated.
In each case, the structure of the cyclized product was verified by NMR spectroscopy and
mass spectrometry (see appendix).

There was no evidence of background ester

hydrolysis for any of the substrates.
All of the spacers cyclized quite rapidly with the half-lives ranging from 2 to 39 s.
When comparing 4.1a and 4.1b, it is clear that methylating the amine had a dramatic
effect on the rate, with the half-life being reduced by a factor of approximately four.
Consistent with the Thorpe-Ingold50,51 and reactive rotamer effects,52 # substitution
further increased the rate of cyclization, as all of the monosubstituted spacers 4.1c, 4.1d,
and 4.1e reacted faster than the unsubstituted spacer 4.1b and cyclized at similar rates.
The #,#-disubstituted spacers 4.1f and 4.1g cyclized at similar rates to their
monosubstituted analogues. However, the #,#-dibenzyl substituted spacer 4.1h exhibited
a nearly 4-fold decrease in rate, suggesting that steric crowding proximal to the ester
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impedes cyclization. In contrast, the #-cyclopentyl substituted compound 4.1i exhibited
the fastest rate of cyclization, indicating that conformational rigidity can play a role.
Finally, both of the #-hydroxy substituted spacers 4.1j and 4.1k cyclized faster than the
#-aliphatic substituted derivatives. Interestingly, the dramatic increase in rate caused by
N-methylation that was observed for 4.1a versus 4.1b was not noted for 4.1j versus 4.1k.
The rate did increase, indicating that there was still an effect, but it appears that the most
significant contribution was from the #-hydroxy substituent.
Table 4.1. Rate constants and corresponding half-lives for the intramolecular cyclizations
of 4.1a-k.
Substrate

Rate Constant (s-1)

Half-life (s)

4.1a

0.018 ± 0.004

39

4.1b

0.071 ± 0.009

9.8

4.1c

0.12 ± 0.01

6.0

4.1d

0.13 ± 0.02

5.5

4.1e

0.10 ± 0.02

6.7

4.1f

0.13 ± 0.01

5.2

4.1g

0.13 ± 0.01

5.2

4.1h

0.028 ± 0.002

25

4.1i

0.35 ± 0.01

2.0

4.1j

0.17 ± 0.02

4.0

4.1k

0.23 ± 0.01

3.0
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It was also of interest to investigate the effect of pH on the cyclization rate. This
was of interest in considering the potential application of these new spacers in areas such
as drug delivery. For example, certain drug delivery targets such as tumors,55,56 inflamed
tissues,57 and intracellular compartments such as endosomes and lysosomes58 are known
to exhibit mildly acidic pHs. It has been established that aminolysis of esters is a pH
dependent process due to the basicity of the amine functionality.59,60 At lower pH the
equilibrium between the protonated (inactive) and deprotonated (active) states favours the
protonated state and therefore hinders the cyclization. Thus, it was of importance to test
the effect of pH on the rate of intramolecular cyclization. To explore this, the cyclization
of spacer 4.1i was investigated at pHs 4.0, 5.0, 6.0 and 7.0 following the method
previously described. As shown in Table 4.2, there was indeed a pronounced decrease in
the cyclization rate with decreasing pH. Nevertheless, the cyclization was still rapid even
at pH 4.0 with a half-life of 76 s. In comparison, the N,N-dimethylethylenediamine
spacer previously employed44,45 has a reported half-life of greater than 15 days at pH 4.2
and 37 °C.7 Therefore, these 4-aminobutyric acid spacers appear to be more promising
for a wider range of physiological environments.
Table 4.2. Rate constants and corresponding half-lives for the intramolecular cyclizations
of 4.1i at different pHs.
pH

Rate Constant (s-1)

Half-life (s)

7.4

0.35 ± 0.01

2.0

7.0

0.18 ± 0.02

3.8

6.0

0.062 ± 0.009

11

5.0

0.020 ± 0.001

35

4.0

0.0091 ± 0.0012

76
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4.3 Conclusion
A new series of self-immolative spacers derived from 4-aminobutyric acid was
developed.

A modular synthetic approach was used for the preparation of eleven

different derivatives. These derivatives allowed the effects of N-methylation and #substitution to be explored. As expected, N-methylation led to enhanced cyclization
rates. #-Substitution led to enhanced cyclization rates when the substituents were not too
bulky but large groups such as benzyl slowed the cyclization. Electron withdrawing
groups or conformationally restricted groups at the # position accelerated the rate.
Overall, all of the target compounds exhibited rapid cyclization kinetics with half lives of
less than one minute at pH 7.4 and 37 °C. In addition, cyclization still occurred rapidly at
mildly acid pH. This suggests that these spacers should be of great utility in systems
where a rapid release of the substrate even at acidic pHs is required. Furthermore, the
versatile synthetic approach should allow the introduction of additional functionalities
and also for their incorporation into a range of chemical systems, allowing for many new
applications.

4.4 Experimental
General procedures and materials:
All reagents were purchased from commercial sources and used without further
purification unless otherwise noted. Anhydrous DMF and THF were obtained from a
solvent purification system. Anhydrous CH2Cl2 and NEt3 were distilled over CaH2.
Diisopropylamine was distilled over MgSO4. Unless otherwise stated, all reactions were
performed under a N2 atmosphere using flame or vacuum-dried glassware. Column
chromatography was performed using silica gel (0.063–0.200 mm size, 70–230 mesh).
1

H NMR spectra were obtained at 400 MHz and 13C NMR spectra were obtained at 100

MHz. NMR chemical shifts are reported in ppm and are calibrated against residual
solvent signals of CDCl3 (! 7.27, 77.00). Coupling constants are expressed in Hertz (Hz).
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Infrared spectra were obtained as films from CH2Cl2 on NaCl plates using a Bruker
Tensor 27 instrument. High-resolution mass spectrometry (HRMS) was performed using
a Finnigan MAT 8400 electron impact (EI) or a Micromass LCT electrospray ionization
time-of-flight (ESI) mass spectrometer.

UV-visible spectrscopy experiments were

carried out using a Varian Cary 300 Bio UV-visible spectrophotometer.
Synthesis of compound 4.3: To a flask containing 4.253 (0.250 g, 1.23 mmol), DMF (12
mL) and MeI (0.23 mL, 3.69 mmol) were added, and the solution was cooled to 0 °C.
NaH (0.128 g, 3.21 mmol) was suspended in DMF (1 mL) and the suspension was added
dropwise to the reaction mixture. The resulting mixture was stirred for 4 h. A second
portion of MeI (0.10 mL, 1.61 mmol) was then added followed by additional NaH (0.070
g, 2.92 mmol) suspended in DMF (0.5 mL) and the reaction mixture was stirred for 2 h.
The solvent was removed in vacuo, and the crude material was taken up in CH2Cl2 and
poured into H2O. The product was extracted with CH2Cl2. The combined organic layers
were dried over MgSO4, filtered, and the solvent was removed in vacuo. The resulting
oil was taken up in 1:1 THF:H20 (12 mL), LiOH&H2O (0.104 g, 2.48 mmol) was added
and then the solution was stirred overnight under air atmosphere. The solution was
poured into 1 M HCl, and the product was extracted three times into EtOAc. The
combined organic layers were dried over MgSO4, filtered, and the solvent was removed.
The crude product was purified by column chromatography (3:2 cyclohexane:EtOAc),
yielding 4.3 (0.195 g, 73%) as a clear, colorless oil.

1

H NMR (CDCl3): ! 11.08 (br s,

1H), 3.35 – 3.22 (m, 2H), 2.85 (s, 3H), 2.36 (t, J = 7.2, 2H), 1.85 (quintet, J = 6.8, 2H),
1.45 (s, 9H).

13

C NMR (CDCl3): ! 178.1, 155.9, 79.6, 47.9 & 47.5 (rotamers), 34.0, 31.0

& 30.8 (rotamers), 28.2, 22.7. IR (cm-1): 3205, 2980, 2937, 1738, 1698, 1490, 1457,
1401, 1367. HRMS: calc’d [M]+ (C10H19NO4): 217.1314. Found: (EI) 217.1318.
Synthesis of compound 4.4a and general DCC mediated esterification procedure:
Compound 4.253 (0.409 g, 2.01 mmol) was dissolved in CH2Cl2 (20 mL). Phenol (0.228
g, 2.45 mmol), DCC (0.623 g, 3.02 mmol) and DMAP (0.0236 g, 0.193 mmol) were
added, and the solution was stirred for 1 h. The precipitate was filtered off and rinsed
with CH2Cl2. The filtrate was poured into 1 M NaOH and the product was extracted
three times into CH2Cl2. The combined organic layers were dried over MgSO4, filtered,
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and the solvent was removed in vacuo. The crude material was purified by column
chromatography (85:15 cyclohexane:EtOAc), affording 4.2a (0.536 g, 95%) as a white
solid.

1

H NMR (CDCl3): ! 7.42 – 7.35 (m, 2H), 7.27 – 7.22 (m, 2H), 7.12 – 7.07 (m,

1H), 4.67 (br s, 1H), 3.27 (quartet, J = 6.6 Hz, 2H), 2.62 (t, J = 7.4, 2H), 1.95 (quintet, J =
7.0 Hz, 2H), 1.46 (s, 9H).

13

C NMR (CDCl3): ! 171.7, 155.9, 150.5, 129.2, 125.7, 121.4,

79.1, 39.7, 31.5, 28.3, 25.2. IR (cm-1): 3080, 3068, 3010, 2981, 2936, 2866, 1762, 1697,
1596, 1523, 1494, 1483, 1367. HRMS: calc’d [M+H]+ (C15H22NO4): 280.1543. Found:
(EI) 280.1549.
Synthesis of compound 4.4b: The same procedure described above for the preparation
of compound 4.4a was followed except that 4.3 was used as a starting material. The
product was purified by column chromatography (9:1 cyclohexane:EtOAc) to provide
4.4b (0.128 g, 79%) as a clear, colorless oil. 1H NMR (CDCl3): ! 7.42 – 7.36 (m, 2H),
7.26 – 7.21 (m, 2H), 7.12 – 7.07 (m, 1H), 3.35 (t, J = 6.6 Hz, 2H), 2.89 (s, 3H), 2.58 (t, J
= 7.4 Hz, 2H), 1.97 (quintet, J = 7.0 Hz. 2H), 1.48 (s, 9H).

13

C NMR (CDCl3): ! 171.6,

155.7, 150.6, 129.3, 125.7, 121.4, 79.4, 48.0 & 47.4 (rotamers), 34.1, 31.3, 28.4, 23.0 &
22.8 (rotamers). IR (cm-1): 3103, 3074, 3045, 3014, 2979, 2937, 2873, 1762, 1697, 1596,
1494, 1477, 1396, 1366. HRMS: calc’d [M+H]+ (C16H24NO4): 294.1705. Found: (EI)
294.1711.
Synthesis of compound 4.6a: Compound 4.253 (1.00 g, 4.92 mmol) was dissolved in
CH2Cl2 (15 mL).

tert-Butyl-2,2,2-trichloroacetimidate (1.76 mL, 9.83 mmol) and

BF3&Et2O (0.100 mL, 0.707 mmol) were added and the reaction mixture was stirred for 45
min. The solution was then filtered to remove the precipitate and the precipitate was
rinsed with CH2Cl2. The filtrate was poured into 1 M Na2CO3, and the product was
extracted three times into CH2Cl2. The combined organic layers were dried over MgSO4,
filtered, and the solvent was removed in vacuo.

The material was taken up in

cyclohexane and filtered a second time. The solvent was removed in vacuo, yielding
4.6a (1.22 g, 96%) as a clear, colourless oil. 1H NMR (CDCl3): ! 4.73 (br s, 1H), 3.10
(quartet, J = 6.3 Hz, 2H), 2.22 (t, J = 7.4 Hz, 2H), 1.73 (quintet, J = 7.0 Hz, 2H), 1.40 (s,
9H), 1.39 (s, 9H).

13

C NMR (CDCl3): ! 172.6, 155.7, 80.3, 79.0, 39.9, 32.8, 28.3, 28.0,
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25.2. IR (cm-1): 2980, 2937, 1718, 1716, 1525, 1456, 1393, 1368. HRMS: calc’d [M]+
(C13H25NO4): 259.1784. Found: (EI) 259.1779.
Synthesis of compound 4.6b: To a flask containing 4.6a (1.11 g, 4.28 mmol) were
added DMF (20 mL) and MeI (0.29 mL, 4.66 mmol), and the solution was cooled to 0
°C. NaH (0.103 g, 4.31 mmol) was suspended in DMF (2 mL) and added dropwise to the
reaction mixture. The solution was stirred for 1 h, then a second equivalent each of MeI
and NaH were added as above, and the solution was stirred overnight. The solution was
poured into 1:1 H2O:saturated brine, and the product was extracted three times into
CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and the solvent
was

removed

in

vacuo.

Purification

by

column

chromatography

(19:1

cyclohexane:EtOAc followed by 9:1 cyclohexane:EtOAc) yielded 4.6b (0.990 g, 84%) as
a thin, colourless oil. 1H NMR (CDCl3): ! 3.23 (t, J = 7.4 Hz, 2H), 2.85 (s, 3H), 2.22 (t, J
= 7.6 Hz, 2H), 1.79 (quintet, J = 7.6 Hz, 2H), 1.46 (s, 9H), 1.45 (s, 9H).

13

C NMR

(CDCl3): ! 172.4, 155.6, 80.1, 79.1, 48.1 & 47.6 (rotamers), 34.0, 32.5, 28.3, 28.0, 23.3
& 22.9 (rotamers). IR (cm-1): 2979, 2937, 1731, 1700, 1482, 1458, 1395, 1367. HRMS:
calc’d [M]+ (C14H27NO4): 273.1940. Found: (EI) 273.1947.
Synthesis of compound 4.7a: Compound 4.6b (0.188 g, 0.687 mmol) was dissolved in
THF (2 mL), and then LiCl (0.044 g, 0.104 mmol) was added and the solution was cooled
to -78 °C. MeI (0.43 mL, 6.91 mmol) was added, followed by dropwise addition of
LHMDS (1.0 M solution in THF, 2.00 mL, 2.00 mmol). The resulting solution was
stirred for 30 min at -78 °C, then warmed to RT and stirred an additional 90 min. The
reaction mixture was then poured into 1 M HCl and the product was extracted three times
into EtOAc. The combined organic layers were dried over MgSO4, filtered, and the
solvent was removed in vacuo.

The crude material was purified by column

chromatography (19:1 cyclohexane:EtOAc) to afford 4.7a (0.174 g, 88%) as a pale
yellow oil. 1H NMR (CDCl3): ! 3.37 – 3.11 (m, 2H), 2.84 (s, 3H), 2.31 (sextet, J = 7.0
Hz, 1H), 1.88 (sextet, J = 7.0 Hz, 1H), 1.63 – 1.51 (m, 1H), 1.46 (s, 9H), 1.45 (s, 9H),
1.15 (d, J = 7.0 Hz, 3H).

13

C NMR (CDCl3): ! 175.5, 155.6, 80.0, 79.2, 46.9 & 46.5

(rotamers), 37.9, 34.1, 31.7 & 31.2 (rotamers), 28.4, 28.0, 17.1. IR (cm-1): 2979, 2937,
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1729, 1700, 1482, 1460, 1395, 1367.

HRMS: calc’d [M]+ (C15H29NO4): 287.2097.

Found: (EI) 287.2085.
Synthesis of compound 4.7b and general monoalkylation procedure: Compound 4.6b
(0.204 g, 0.747 mmol) was dissolved in THF (3 mL), and then LiCl (0.048 g, 1.128
mmol) was added and the solution was cooled to -78 °C. LHMDS (1.0 M solution in
THF, 0.93 mL, 0.93 mmol) was added slowly, and the solution was stirred 30 min. Allyl
bromide (0.068 mL, 0.786 mmol) was then added dropwise, and the solution was stirred
for 30 min at -78 °C, then warmed to RT and stirred for an additional 90 min. The
reaction mixture was then poured into 1 M HCl, and the product was extracted three
times into EtOAc. The combined organic layers were dried over MgSO4, filtered, and the
solvent was removed in vacuo.

Purification by column chromatography (99:1

cyclohexane:EtOAc followed by 19:1 cyclohexane:EtOAc) to provide 4.7b (0.162 g,
69%) as a thick, colorless oil. 1H NMR (CDCl3): ! 5.81 – 5.68 (m, 1H), 5.15 – 4.98 (m,
2H), 3.39 – 3.06 (m, 2H), 2.84 (s, 3H), 2.40 – 2.17 (m, 3H), 1.88 – 1.76 (m, 1H), 1.69 –
1.57 (m, 1H), 1.46 (s, 9H), 1.45 (s, 9H).

13

C NMR (CDCl3): ! 174.1, 155.5, 135.2, 116.7,

80.3, 79.2, 47.0 & 46.4 (rotamers), 43.3, 36.4, 34.1, 29.6 & 29.3 (rotamers), 28.3, 28.0.
IR (cm-1): 2978, 2935, 1729, 1700, 1482, 1458, 1394, 1367.

HRMS: calc’d [M]+

(C17H31NO4): 313.2253. Found: (EI) 313.2259.
Synthesis of compound 4.7c: The same procedure described above for the preparation of
compound 4.7b was followed except that benzyl bromide was used as the alkyl halide
and only 1.2 eq of LHMDS was used.

The product was purified by column

chromatography (99:1 cyclohexane:EtOAc followed by 19:1 cyclohexane:EtOAc) to
provide 4.7c (0.188 g, 70%) as a thick, colorless oil. 1H NMR (CDCl3): ! 7.32 – 7.24 (m,
2H), 7.23 – 7.15 (m, 3H), 3.43 – 3.08 (m, 2H), 2.99 – 2.67 (m, 2H), 2.81 (s, 3H), 1.93 –
1.79 (m, 1H), 1.73 – 1.60 (m, 1H), 1.54 – 1.38 (m, 9H), 1.38 – 1.28 (m, 9H).

13

C NMR

(CDCl3): ! 174.2, 155.5, 139.1, 128.9, 128.2, 126.2, 80.3, 79.2, 47.2, 45.6, 38.5, 34.1,
29.9, 28.3, 27.9. IR (cm-1): 3090, 3066, 3031, 3006, 2978, 2932, 2892, 1727, 1699, 1483,
1456, 1394, 1367. HRMS: calc’d [M]+ (C21H33NO4): 363.2410. Found: (EI) 363.1924.
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Synthesis of compound 4.8a and general deprotection-N-Boc reprotection
procedure: Under an air atmosphere, a flask was charged with 4.7a (0.108 g, 0.376
mmol), and then 1:1 TFA:CH2Cl2 (2 mL) was added and the solution was stirred for 2 h.
The solvent was then removed in vacuo, and CH2Cl2 was added and removed 3 times to
help further remove residual TFA. After thorough drying, the material was taken up in
1:1 dioxane:0.5 M NaOH solution (2 mL), and the pH was adjusted to approximately 12
using 1 M NaOH. Di-tert-butyldicarbonate (0.103 g, 0.470 mmol) was added, and the
solution was stirred overnight. The material was poured into 1:1 1 M HCl:saturated
brine, and the product was extracted three times into EtOAc. The combined organic
layers were dried over MgSO4, filtered, and the solvent was removed in vacuo. The crude
material was purified by column chromatography (85:15 cyclohexane:EtOAc followed
by 70:30 cyclohexane:EtOAc) to provide 4.8a (0.0795 g, 91%) as a clear, colorless oil.
1

H NMR (CDCl3): ! 10.24 (br s, 1H), 3.52 – 3.11 (m, 2H), 2.85 (s, 3H), 2.46 (sextet, J =

7.0 Hz, 1H), 2.02 – 1.82 (m, 1H), 1.71 – 1.55 (m, 1H), 1.46 (s, 9H), 1.23 (d, J = 7.4 Hz,
3H).

13

C NMR (CDCl3): ! 181.3, 156.0, 79.9, 46.7, 36.7, 34.0, 31.2, 28.3, 17.0. 3472,

3237, 2979, 2941, 1701, 1687, 1488, 1467, 1403, 1368. IR (cm-1): 3472, 3237, 2979,
2941, 1701, 1687, 1488, 1467, 1403, 1368. HRMS: calc’d [M]+ (C11H21NO4): 231.1471.
Found: (EI) 231.1464.
Synthesis of compound 4.8b: The same procedure described above for the preparation
of compound 4.8a was followed except that 4.7b was used as a starting material. The
product was purified by column chromatography (5:1 cyclohexane:EtOAc) to provide
4.8b (0.122 g, 99%) as a thick, colorless oil. 1H NMR (CDCl3): ! 10.77 (s, 1H), 5.80 –
5.67 (m, 1H), 5.14 – 5.10 (m, 2H), 3.40 – 3.16 (m, 2H), 2.81 (s, 3H), 2.46 – 2.35 (m, 2H),
2.33 – 2.22 (m, 1H), 1.90 – 1.78 (m, 1H), 1.75 – 1.64 (m, 1H), 1.43 (s, 9H).

13

C NMR

(CDCl3): ! 180.2, 155.9, 134.7, 117.3, 80.0, 46.9 & 46.5 (rotamers), 42.2, 36.1, 34.1,
29.9, 28.3. IR (cm-1): 3450, 2980, 2941, 1700, 1670, 1489, 1457, 1401, 1368. HRMS:
calc’d [M]+ (C13H23NO4): 257.1627. Found: (EI) 257.1634.
Synthesis of compound 4.8c: The same procedure described above for the preparation of
compound 4.8a was followed except that 4.7c was used as a starting material. The
product was purified by column chromatography (3:1 cyclohexane:EtOAc) to provide
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4.8c (0.143 g, 96%) as a thick, colorless oil. 1H NMR (CDCl3): ! 10.90 (s, 1H), 7.34 –
7.15 (m, 5H), 3.45 – 3.19 (m, 2H), 3.14 – 3.00 (m, 1H), 2.84 – 2.73 (m, 1H), 2.77 (s, 3H),
2.73 – 2.64 (m, 1H), 1.94 – 1.82 (m, 1H), 1.78 – 1.67 (m, 1H), 1.54 – 1.34 (m, 9H).

13

C

NMR (CDCl3): ! 180.2, 156.3, 138.6, 128.8, 128.4, 126.5, 80.5, 47.1 & 46.6 (rotamers),
44.4, 38.0, 34.1, 29.0, 28.2. IR (cm-1): 3092, 3180, 3067, 3032, 2980, 2938, 1735, 1700,
1667, 1488, 1456, 1404, 1368. HRMS: calc’d [M]+ (C17H25NO4): 307.1784. Found: (EI)
307.1783.
Synthesis of compound 4.9a and general pivaloyl chloride-mediated esterification
procedure: Acid 4.8a (0.181 g, 0.783 mmol) was dissolved in CH2Cl2 (8 mL). Freshly
distilled NEt3 (0.27 mL, 1.94 mmol) and pivaloyl chloride (0.12 mL, 0.975 mmol) were
added and the solution was stirred for 30 min. Phenol (0.115 g, 1.22 mmol) and DMAP
(0.012 g, 0.0982 mmol) were added and the solution was stirred overnight. The solution
was poured into 1 M HCl and the product was extracted three times into CH2Cl2. The
combined organic layers were dried over MgSO4, filtered, and the solvent was removed.
The crude material was purified by column chromatography (9:1 cyclohexane:EtOAc) to
provide 4.9a (0.187 g, 78%) as a colorless oil. 1H NMR (CDCl3): ! 7.39 (dd, J = 7.8 &
8.2 Hz, 2H), 7.23 (dd, J = 7.0 & 7.4 Hz, 1H), 7.09 (d, J = 7.8 Hz, 2H), 3.37 – 3.23 (m,
2H), 2.88 (s, 3H), 2.70 (sextet, J = 7.0 Hz, 1H), 2.16 – 2.03 (m, 1H), 1.80 – 1.67 (m, 1H),
1.47 (s, 9H), 1.36 (d, J = 7.0 Hz, 3H).

13

C NMR (CDCl3): ! 174.9, 155.6, 150.7, 129.3,

125.6, 121.4, 79.3, 46.7 & 46.3 (rotamers), 37.0, 31.6 & 31.0 (rotamers), 28.3, 17.1. IR
(cm-1): 3040, 2979, 2940, 1758, 1695, 1495, 1481, 1398, 1366. HRMS: calc’d [M+H]+
(C17H26NO4): 308.1856. Found: (EI) 308.1860.
Synthesis of compound 4.9b: The same procedure described above for the preparation
of compound 4.9a was followed except that 4.8b was used as a starting material. The
product was purified by column chromatography (93:7 cyclohexane:EtOAc) to provide
4.9b (0.128 g, 86%) as a colorless oil. 1H NMR (CDCl3): ! 7.37 (t, J = 7.4 Hz, 2H), 7.22
(t, J = 7.4 Hz, 1H), 7.08 (d, J = 7.8 Hz, 2H), 5.94 – 5.80 (m, 1H), 5.22 – 5.08 (m, 2H),
3.48 – 3.21 (m, 2H), 2.87 (s, 3H), 2.75 – 2.65 (m, 1H), 2.60 – 2.39 (m, 2H), 2.04 (sextet,
J = 7.4 Hz, 1H), 1.80 (sextet, J = 7.4 Hz, 1H), 1.46 (s, 9H).

13

C NMR (CDCl3): ! 173.4,

155.6, 150.6, 134.7, 129.3, 125.7, 121.5, 117.5, 79.5, 47.0 & 46.4 (rotamers), 42.5, 36.5,
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34.1, 29.4, 28.4. IR (cm-1): 3080, 3009, 2979, 2936, 2871, 1758, 1698, 1594, 1493, 1457,
1396, 1367. HRMS: calc’d [M]+ (C19H27NO4): 333.1940. Found: (EI) 333.1932.
Synthesis of compound 4.9c: The same procedure described above for the preparation of
compound 4.9a was followed except that 4.8c was used as a starting material. The
product was purified by column chromatography (93:7 cyclohexane:EtOAc) to provide
4.9c (0.146 g, 82%) as a colorless oil. 1H NMR (CDCl3): ! 7.33 – 7.26 (m, 4H), 7.25 –
7.19 (m, 3H), 7.15 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 7.4 Hz, 2H), 3.52 – 3.18 (m, 2H), 3.13
– 2.84 (m, 3H), 2.81 (s, 3H), 2.04 (sextet, J = 7.8 Hz, 1H), 1.89 – 1.73 (m, 1H), 1.52 –
1.35 (m, 9H).

13

C NMR (CDCl3): ! 173.5, 155.6, 150.4, 138.5, 129.2, 129.0, 128.4,

126.6, 125.7, 121.4, 79.4, 47.1 & 46.3 (rotamers), 45.0, 38.5, 34.1, 29.8, 28.3. IR (cm-1):
3091, 3068, 3033, 2993, 2978, 2931, 2867, 1756, 1696, 1594, 1494, 1481, 1396, 1367.
HRMS: calc’d [M+H]+ (C23H30NO4): 384.2169. Found: (EI) 384.2167.
Synthesis of compound 4.10a: A flask was charged with freshly distilled NH(iPr)2 (0.25
mL, 1.77 mmol) and THF (1 mL), and the solution was cooled to -78 °C. butyllithium
(2.5 M solution in hexane, 0.69 mL, 1.73 mmol) was added and the solution was stirred
for 15 min. This solution was then transferred via canula to a flask containing 4.7a
(0.165 g, 0.574 mmol) and LiCl (0.041 g, 0.967 mmol) in THF (2 mL) and the solution
was stirred for 15 min. MeI (0.22 mL, 3.53 mmol) was added dropwise and the solution
was stirred overnight. The reaction mixture was then poured into 1 M HCl, and the
product was extracted three times into EtOAc. The combined organic layers were dried
over MgSO4, filtered, and the solvent was removed in vacuo. The product was further
purified by column chromatography (19:1 cyclohexane:EtOAc) to afford 4.10a (0.165 g,
95%) as a pale yellow oil. 1H NMR (CDCl3): ! 3.25 – 3.12 (m, 2H), 2.84 (s, 3H), 1.75 –
1.66 (m, 2H), 1.46 (s, 9H), 1.45 (s, 9H), 1.60 (s, 6H).

13

C NMR (CDCl3): ! 176.6, 155.5,

79.9, 79.1, 45.4, 41.2, 37.8, 33.9, 28.4, 27.9, 25.1. IR (cm-1): 2979, 2953, 1700, 1654,
1480, 1458, 1394, 1367.

HRMS: calc’d [M]+ (C16H31NO4): 301.2253. Found: (EI)

301.2246.
Synthesis of compound 4.10b and general dialkylation procedure: Compound 4.6b
(0.232 g, 0.849 mmol) was dissolved in THF (4 mL) and the solution was cooled to -78
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°C. LHMDS (1.0 M solution in THF, 0.85 mL, 0.85 mmol) was added slowly and the
solution was stirred for 15 min. Allyl bromide (0.074 mL, 0.855 mmol) was added
dropwise, and the solution was stirred 1 h. A second addition of LHMDS (1.70 mL, 1.70
mmol) and allyl bromide (0.13 mL, 1.73 mmol) was performed and the solution was
stirred overnight. The solution was poured into 1 M HCl and the product was extracted
three times into EtOAc. The combined organic layers were dried over MgSO4, filtered,
and the solvent was removed in vacuo. Further purification by column chromatography
(97:3 cyclohexane:EtOAc) afforded 4.10b (0.280 g, 93%) as a clear, colorless oil.

1

H

NMR (CDCl3): ! 5.83 – 5.66 (m, 2H), 5.15 – 5.05 (m, 4H), 3.27 – 3.10 (m, 2H), 2.82 (s,
3H), 2.30 (d, J = 7.4 Hz, 4H), 1.76 – 1.68 (m, 2H), 1.46 (s, 18H).

13

C NMR (CDCl3): !

174.4, 155.4, 133.4, 118.3, 80.6, 79.3, 47.7, 44.6 & 44.2 (rotamers), 39.0, 34.0, 32.2 &
31.8 (rotamers), 28.4, 28.0. IR (cm-1): 3081, 2979, 2936, 1723, 1700, 1483, 1458, 1393,
1367. HRMS: calc’d [M]+ (C20H35NO4): 353.2566. Found: (EI) 353.3557.
Synthesis of compound 4.10c: The same procedure described above for the preparation
of compound 4.10b was followed except that benzyl bromide was used as the alkyl
halide. The product was purified by column chromatography (93:7 cyclohexane:EtOAc)
to provide 4.10c (0.384 g, 93%) as a thick, colorless oil. 1H NMR (CDCl3): ! 7.27 – 7.14
(m, 10H), 3.50 – 3.30 (br m, 2H), 3.02 (d, J = 14.1 Hz, 2H), 2.83 (d, J = 14.1 Hz, 2H),
2.66 (s, 3H), 1.78 – 1.65 (br m, 2H), 1.45 (s, 9H), 1.34 (s, 9H).

13

C NMR (CDCl3): !

174.5, 155.5, 137.3, 130.4, 128.0, 126.4, 81.1, 79.5, 50.2, 44.6 & 43.9 (rotamers), 42.0,
33.6, 31.1 & 30.4 (rotamers), 28.5, 27.9. IR (cm-1): 3088, 3065, 3032, 3006, 2978, 2935,
1698, 1496, 1482, 1455, 1395, 1366.

HRMS: calc’d [M]+ (C28H39NO4): 453.2879

Found: (EI) 453.2866.
Synthesis of compound 4.10d: Compound 4.6b (0.142 g, 0.519 mmol) was dissolved in
THF (25 mL) and the solution was cooled to -78 °C. LHMDS (1.0 M soln in THF, 0.84
mL, 0.84 mmol) was added and the solution was stirred for 15 min. 1,4-Dibromobutane
(0.070 mL, 0.586 mmol) was added dropwise and the solution was stirred 30 min. A
second equivalent of LHMDS was added and the solution was stirred overnight. The
reaction mixture was poured into 1 M HCl and the product was extracted three times into
EtOAc. The combined organic layers were dried over MgSO4, filtered, and the solvent
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was

removed

in

vacuo.

Purification

by

column

chromatography

(98:2

cyclohexane:EtOAc followed by 97:3 cyclohexane:EtOAc) yielded 4.10d (0.078 g, 46%)
as a clear, colorless oil. 1H NMR (CDCl3): ! 3.22 – 3.08 (m, 2H), 2.83 (s, 3H), 2.14 –
2.02 (m, 2H), 1.86 – 1.74 (m, 2H), 1.69 – 1.58 (m, 4H), 1.53 – 1.39 (m, 2H), 1.46 (s, 9H),
1.45 (s, 9H).

13

C NMR (CDCl3): ! 176.3, 155.4, 79.8, 79.0, 52.7, 46.2 & 45.9 (rotamers),

35.6, 36.1, 34.0, 28.4, 27.9, 24.8. IR (cm-1): 2976, 2953, 2875, 1724, 1701, 1482, 1456,
1393, 1367. HRMS: calc’d [M+H]+ (C18H34NO4): 328.2482. Found: (EI) 328.2482.
Synthesis of compound 4.11a: The same procedure described above for the preparation
of compound 4.8a was followed except that 4.10a was used as a starting material. The
product was purified by column chromatography (85:15 cyclohexane:EtOAc) to provide
4.11a (0.166 g, 97%) as a thick, colorless oil. 1H NMR (CDCl3): ! 3.24 (br t, J = 7.8 Hz,
2H), 2.83 (s, 3H), 1.82 – 1.74 (m, 2H), 1.46 (s, 9H), 1.25 (s, 6H).

13

C NMR (CDCl3): !

182.9, 155.6, 79.4, 45.4 & 44.9 (rotamers), 40.6, 37.7, 34.0, 28.3, 24.9. IR (cm-1): 3454,
3200, 2980, 2935, 1700, 1694, 1481, 1405, 1368. HRMS: calc’d [M]+ (C12H23NO4):
245.1627. Found: (EI) 245.1618.
Synthesis of compound 4.11b: The same procedure described above for the preparation
of compound 4.8a was followed except that 4.10b was used as a starting material. The
product was purified by column chromatography (5:1 cyclohexane:EtOAc) to provide
4.11b (0.092 g, 90%) as a thick, colorless oil. 1H NMR (CDCl3): ! 5.84 – 5.70 (m, 2H),
5.19 – 5.11 (m, 4H), 3.25 (br t, J = 7.4 Hz, 2H), 2.82 (s, 3H), 2.38 (d, J = 7.4 Hz, 4H),
1.84 – 1.76 (m, 2H), 1.46 (s, 9H).

13

C NMR (CDCl3): ! 181.0, 155.6, 132.6, 118.8, 80.3,

47.6, 38.7, 34.1, 32.1, 28.3. IR (cm-1): 3430, 3270, 3080, 3010, 2980, 2935, 1730, 1700,
1488, 1454, 1404, 1368.

HRMS: calc’d [M]+ (C16H27NO4): 297.1940. Found: (EI)

297.1949.
Synthesis of compound 4.11c: The same procedure described above for the preparation
of compound 4.8a was followed except that 4.10c was used as a starting material. The
product was purified by column chromatography (85:15 cyclohexane:EtOAc) to provide
4.11c (0.139 g, 94%) as a sticky white solid. 1H NMR (CDCl3): ! 7.33 – 7.19 (m, 10H),
3.55 – 3.31 (m, 2H), 3.13 (d, J = 13.7 Hz), 2.93 (d, J = 14.0 Hz), 2.69 (s, 3H), 1.80 – 1.70
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(m, 2H), 1.47 (s, 9H).

C NMR (CDCl3): ! 181.2, 155.9, 136.8, 130.2, 128.2, 126.8,

80.1, 50.3, 44.8 & 43.9 (rotamers), 42.1, 43.7, 30.6 & 29.4 (rotamers), 28.5. IR (cm-1):
3460, 3210, 3090, 3067, 3031, 2979, 2935, 1697, 1665, 1497, 1456, 1404, 1368. HRMS:
calc’d [M]+ (C24H31NO4): 397.2253. Found: (EI) 397.2241.
Synthesis of compound 4.11d: The same procedure described above for the preparation
of compound 4.8a was followed except that 4.10d was used as a starting material. The
product was purified by column chromatography (85:15 cyclohexane:EtOAc) to provide
4.11d (0.095 g, 88%) as a thick, colorless oil. 1H NMR (CDCl3): ! 3.30 – 3.13 (m, 2H),
2.83 (s, 3H), 2.22 – 2.10 (m, 2H), 1.92 – 1.80 (m, 2H), 1.76 – 1.63 (m, 4H), 1.62 – 1.50
(m, 2H), 1.45 (s, 9H).

13

C NMR (CDCl3): ! 182.4, 155.5, 79.3, 51.7, 46.2 & 45.7

(rotamers), 36.4, 36.1, 34.0, 28.3, 24.9. IR (cm-1): 3470, 2975, 2876, 1698, 1674, 1468,
1454, 1403, 1368. HRMS: calc’d [M]+ (C14H25NO4): 271.1784. Found: (EI) 271.1776.
Synthesis of compound 4.13a and general Ghosez reagent-mediated esterification
procedure: Compound 4.11a (0.153 g, 0.624 mmol) was dissolved in CH2Cl2 (6 mL). 1Chloro-N,N,2-trimethylpropenylamine (0.12 mL, 0.907 mmol) was added and the
solution was stirred for 1 h. Phenol (0.118 g, 1.25 mmol) and distilled NEt3 (0.18 mL,
1.29 mmol) were added and the solution was stirred overnight. The reaction mixture was
poured into 1 M HCl and the product was extracted three times into CH2Cl2. The
combined organic layers were dried over MgSO4, filtered, and the solvent was removed.
Purification by column chromatography (97:3 cyclohexane:EtOAc) yielded 4.13a (0.181
g, 90%) as a colorless oil. 1H NMR (CDCl3): ! 7.39 (dd, J = 7.8 & 8.2 Hz, 2H), 7.25 (dd,
J = 8.2 & 7.4 Hz, 1H), 7.07 (d, J = 7.8 Hz, 2H), 3.37 – 3.29 (m, 2H), 2.88 (s, 3H), 1.97 –
1.87 (m, 2H), 1.47 (s, 9H), 1.38 (s, 6H).

13

C NMR (CDCl3): ! 175.7, 155.4, 150.8, 129.3,

125.6, 121.4, 79.3, 45.3 & 45.0 (rotamers), 41.1, 37.8 & 37.0 (rotamers), 34.1, 28.4, 25.1.
IR (cm-1): 3107, 3078, 3073, 2978, 2934, 2898, 1752, 1699, 1594, 1494, 1485, 1471,
1428, 1394, 1368.

HRMS: calc’d [M+H]+ (C18H28NO4): 322.2013. Found: (EI)

322.2013.
Synthesis of compound 4.13b: The same procedure described above for the preparation
of compound 4.13a was followed except that 4.11b was used as a starting material. The
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product was purified by column chromatography (97:3 cyclohexane:EtOAc) to provide
4.13b (0.085 g, 74%) as a colorless oil.

1

H NMR (CDCl3): ! 7.38 (t, J = 7.4 Hz, 2H),

7.23 (t, J = 7.4 Hz, 1H), 7.06 (br d, J = 7.4 Hz, 2H), 5.94 – 5.78 (m, 2H), 5.26 – 5.16 (m,
4H), 3.42 – 3.26 (m, 2H), 2.86 (s, 3H), 2.52 (d, J = 7.8 Hz, 4H), 1.98 – 1.87 (m, 2H), 1.47
(s, 9H).

13

C NMR (CDCl3): ! 174.0, 155.5, 150.7, 132.8, 129.4, 125.8, 121.6, 119.1,

79.6, 48.0, 44.7 & 44.3 (rotamers), 39.1, 34.1, 32.2 & 31.9 (rotamers), 28.5. IR (cm-1):
3080, 2979, 2934, 1752, 1697, 1642, 1594, 1494, 1457, 1396, 1367. HRMS: calc’d [M]+
(C22H31NO4): 373.2253. Found: (EI) 373.2267.
Synthesis of compound 4.13c: The same procedure described above for the preparation
of compound 4.13a was followed except that 4.11c was used as a starting material. The
product was purified by column chromatography (97:3 cyclohexane:EtOAc) to provide
4.13c (0.092 g, 60%) as a colorless oil. 1H NMR (CDCl3): ! 7.44 – 7.26 (m, 12H), 7.23
(t, J = 7.4 Hz, 1H), 6.88 (d, J = 7.4 Hz), 3.66 – 3.44 (m, 2H), 3.28 (d, J = 13.7 Hz, 2H),
3.05 (d, J = 14.0 Hz, 2H), 2.73 (s, 3H), 2.02 – 1.86 (m, 2H), 1.49 (s, 9H).

13

C NMR

(CDCl3): ! 173.9, 155.5, 150.5, 136.8, 130.3, 129.3, 128.3, 126.9, 125.8, 121.4, 79.6,
50.8, 44.7 & 43.7 (rotamers), 42.3, 36.7, 30.5 & 29.5 (rotamers), 28.5. IR (cm-1): 3091,
3066, 3032, 2980, 2934, 2874, 1750, 1693, 1594, 1495, 1456, 1398, 1367. HRMS:
calc’d [M]+ (C30H35NO4): 473.2566. Found: (EI) 473.2557.
Synthesis of compound 4.13d: The same procedure described above for the preparation
of compound 4.13a was followed except that 4.11d was used as a starting material. The
product was purified by column chromatography (98:2 cyclohexane:EtOAc followed by
97:3 cyclohexane:EtOAc) to provide 4.13d (0.135 g, 76%) as a colorless oil.

1

H NMR

(CDCl3): ! 7.38 (t, J = 7.8 Hz, 2H), 7.22 (t, J = 7.4 Hz, 1H), 7.07 (br d, J = 7.4 Hz, 2H),
3.38 – 3.24 (m, 2H), 2.87 (s, 3H), 2.38 – 2.26 (m, 2H), 2.00 (br t, J = 7.8 Hz, 2H), 1.83 –
1.60 (m, 6H), 1.46 (s, 9H).

13

C NMR (CDCl3): ! 175.8, 155.5, 150.9, 129.3, 125.6,

121.4, 79.4, 52.3, 46.3 & 45.9 (rotamers), 36.6 & 36.2 (rotamers), 36.4, 34.2, 28.4, 25.0.
IR (cm-1): 3103, 3095, 3047, 2974, 2934, 2878, 1750, 1699, 1597, 1494, 1458, 1399,
1367. HRMS: calc’d [M+H]+ (C20H30NO4): 348.2169. Found: (EI) 348.2169.
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Synthesis of compound 4.15: Compound 4.1454 (3.31 g, 15.1 mmol) was dissolved in
DMF (150 mL). Cs2CO3 (6.17 g, 18.9 mmol) was added, and then MeI (0.99 mL, 15.9
mmol) was added slowly and the solution was stirred for 90 min. The reaction mixture
was poured into 1:1 H2O:saturated brine, and the product was extracted three times into
CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and the solvent
was removed in vacuo. Column chromatography (7:3 cyclohexane:EtOAc followed by
1:1 cyclohexane:EtOAc) yielded 4.15 (3.05 g, 87%) as a yellow oil. 1H NMR (CDCl3): !
4.89 (br s, 1H), 4.26 (dd, J = 3.9 & 8.1 Hz, 1H), 3.79 (s, 3H), 3.43 – 3.20 (m, 2H), 2.07 –
1.96 (m, 1H), 1.89 – 1.77 (m, 1H), 1.44 (s, 9H).

13

C NMR (CDCl3): ! 174.9, 156.2, 79.1,

-1

68.4, 52.1, 36.5, 33.7, 28.1. IR (cm ): 3390, 2980, 2952, 1754, 1697, 1527, 1455, 1394,
1368. HRMS: calc’d [M+H]+ (C10H20NO5): 234.1336. Found (EI) 234.1335.
Synthesis of compound 4.16a: Compound 4.15 (0.491 g, 2.11 mmol) was dissolved in
THF (20 mL). Di-tert-butyldicarbonate (0.577 g, 2.64 mmol) and DMAP (0.030 g, 0.25
mmol) were added and the solution was stirred for 1 h. The solution was then poured
into 1 M HCl and the product was extracted three times into CH2Cl2. The combined
organic layers were dried over MgSO4, filtered, and the solvent was removed in vacuo.
Purification by column chromatography (9:1 cyclohexane:EtOAc) afforded 4.16a (0.635
g, 91%) as a thick, colorless oil. 1H NMR (CDCl3): ! 4.90 (br s, 1H), 4.80 (dd, J = 5.0 &
7.0 Hz, 1H), 3.64 (s, 3H), 3.23 – 3.04 (m, 2H), 2.02 – 1.83 (m, 2H), 1.37 (s, 9H), 1.31 (s,
9H).

13

C NMR (CDCl3): ! 170.3, 155.4, 152.5, 82.7, 78.9, 72.0, 52.0, 36.2, 31.1, 28.1,

27.3. IR (cm-1): 3408, 2982, 2958, 1749, 1718, 1521, 1458, 1369. HRMS: calc’d
[M+H]+ (C15H28NO7): 334.1866. Found: (EI) 334.1874.
Synthesis of compound 4.16b: Compound 4.16a (0.133 g, 0.399 mmol) was dissolved
in DMF (2 mL), and the solution was cooled to 0 °C. MeI (0.25 mL, 4.01 mmol) was
added, and NaH (0.010 g, 0.429 mmol) suspended in DMF (0.5 mL) was added dropwise
to the reaction mixture. The solution was stirred for 1 h and then a second equivalent of
NaH was added as above and the solution was stirred a second hour. The reaction
mixture was then poured into 1:1 1 M HCl:saturated brine, and the product was extracted
three times into CH2Cl2. The combined organic layers were dried over MgSO4, filtered,
and the solvent was removed in vacuo. Further purification by column chromatography
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(96:4 cyclohexane:EtOAc) yielded 4.16b (0.103 g, 74%) as a colourless oil.

1

H NMR

(CDCl3): ! 4.81 (dd, J = 4.3 & 8.6 Hz, 1H), 3.71 (s, 3H), 3.56 – 3.31 (m, 1H), 3.26 – 3.15
(m, 1H), 2.80 (s, 3H), 2.14 – 1.89 (m, 2H), 1.44 (s, 9H), 1.40 (s, 9H).

13

C NMR (CDCl3):

! 170.4, 155.4, 152.7, 82.9, 79.5, 72.0, 52.2, 44.9, 34.5 & 34.2 (rotamers), 29.5 & 29.1
(rotamers), 28.2, 27.5. IR (cm-1): 2981, 2937, 1748, 1700, 1483, 1460, 1396, 1369.
HRMS: calc’d [M+H]+ (C16H30NO7): 348.2017. Found: (EI) 348.2015.
Synthesis of compound 4.17a and general procedure for conversion from a methyl
to phenyl ester: Under an air atmosphere, a flask was charged with 4.16a (0.168 g, 0.503
mmol) and the material was dissolved in 1:1 THF:H2O (5 mL). LiOH&H2O (0.0264 g,
0.629 mmol) was added, and the solution was stirred overnight. The reaction mixture
was then poured into 1:1 1 M HCl:saturated brine and the product was extracted three
times into CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and
the solvent was removed in vacuo. The flask was then fully evacuated, refilled with N2,
and the material was dissolved in CH2Cl2 (5 mL). Pivaloyl chloride (0.077 mL, 0.626
mmol) and NEt3 (0.18 mL, 1.29 mmol) were added and the solution was stirred for 30
min. Phenol (0.0724 g, 0.769 mmol) and DMAP (0.0073 g, 0.060 mmol) were then
added and the solution was stirred overnight. The reaction mixture was poured into 1 M
HCl and the product was extracted three times into CH2Cl2. The combined organic layers
were dried over MgSO4, filtered, and the solvent was removed in vacuo. The crude
material was purified by column chromatography (9:1 cyclohexane:EtOAc) to yield
4.17a (0.140 g, 70%) as a colorless oil.

1

H NMR (CDCl3): ! 7.37 (t, J = 7.4 Hz, 2H),

7.23 (t, J = 7.4 Hz, 1H), 7.11 (d, J = 7.8 Hz, 2H), 5.11 (dd, J = 5.1 & 7.4 Hz, 1H), 4.84 (br
s, 1H), 3.45 – 3.27 (m, 2H), 2.31 – 2.13 (m, 2H), 1.51 (s, 9H), 1.44 (s, 9H).

13

C NMR

(CDCl3): ! 168.8, 155.7, 152.8, 150.1, 129.4, 126.1, 121.2, 83.3, 79.4, 72.3, 36.5, 31.3,
28.3, 27.6. IR (cm-1): 3460, 2983, 2962, 1747, 1695, 1653, 1521, 1495, 1369. HRMS:
calc’d [M+H]+ (C20H30NO7): 396.2017. Found: (EI) 396.2016.
Synthesis of compound 4.17b: The same procedure described above for the preparation
of compound 4.17a was followed except that 4.16b was used as a starting material. The
product was purified by column chromatography (93:7 cyclohexane:EtOAc) to provide
4.17b (0.096 g, 58%) as a colorless oil.

1

H NMR (CDCl3): ! 7.38 (t, J = 7.8 Hz, 2H),
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7.23 (t, J = 7.4 Hz, 1H), 7.11 (d, J = 7.8 Hz, 2H), 5.05 (dd, J = 4.3 & 8.6 Hz, 1H), 3.64 –
3.48 (m, 1H), 3.43 – 3.29 (m, 1H), 2.89 (s, 3H), 2.38 – 2.13 (m, 2H), 1.51 (s, 9H), 1.46
(s, 9H).

13

C NMR (CDCl3): ! 168.7, 155.6, 152.8, 150.2, 129.5, 126.1, 121.2, 83.3, 79.8,

72.2, 45.0, 34.5, 29.7, 28.4, 27.7. IR (cm-1): 3120, 3084, 3024, 3008, 2982, 2938, 2898,
1778, 1747, 1698, 1593, 1493, 1476, 1396, 1369. HRMS: calc’d [M+H]+ (C21H31NO7):
410.2173. Found: (EI) 410.2173.
Kinetic Studies: Absorption spectra for phenol and 4.1a&TFA were obtained by
preparing a 0.1 mg/mL solution of each in 1 M HCl and measuring the absorbance
between 320 and 230 nm, and the molar extinction coefficients were calculated using the
Beer-Lambert equation, A = $c!"# To measure the cyclization rate, the Boc protected
compound was dissolved in 1:1 TFA:CH2Cl2 (approximately 4 mL) and the resulting
solution was stirred for 2 h. The solvent was removed in vacuo, and CH2Cl2 was added
and removed three times to remove residual TFA, after which the flask was fully
evacuated. The material was then suspended in H2O, frozen in liquid nitrogen, and dried
on a lyophilizer. 1.5 mg of the target 4.1a-k was then dissolved in iPrOH (0.2 mL) and
the solution was transferred to the cuvette and preheated within the spectrometer to 37
°C. To this solution was then added, with stirring, pH 7.4 0.1 M phosphate buffer
solution (1.8 mL), preheated to 37 °C. The change in absorbance at 276 nm with respect
to time was measured. Due to the rapid rates of cyclization observed for certain spacers,
the measurement of absorbance values at 276 nm was started immediately prior to the
addition of phosphate buffer solution, and was continued throughout the course of the
reaction. The value of t = 0 was taken to be the point of onset of steady increase of
absorbance, and this time was taken as 0% conversion, while the absorbance value after
the absorbance had stabilized was taken as 100% conversion (verified by NMR). From
this, the % conversion with respect to time was calculated. To obtain the first order rate
constants, ln[A]0/[A] versus time was plotted where [A]0/[A] effectively corresponds to
100/(100-% conversion). Phosphate buffers (0.1 M) were used for pHs 6.0, 7.0, and 7.4.
Acetate buffers (0.1 M) were used for pHs 4.0 and 5.0.
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Chapter 5
Progress Toward Rapidly Degrading Self-Immolative
Polymers Based on 4-Aminobutyric Acid

5.1 Introduction
The development of self-immolative polymers is a new and promising field of research.18

Originally inspired by self-immolative dendrimers that fragmented via a series of

intramolecular reactions, resulting in the release of molecules on the dendrimer
periphery,9-14 these polymers are the most recent advancement in the study and
application of self-immolative spacers. Self-immolative polymers offer numerous unique
and attractive features, making them valuable synthetic targets.

First, they can be

accessed in an efficient manner, with commercially available materials often requiring
just a few functional group manipulations to be converted into polymerizable monomers.
Once prepared, these monomers can then be polymerized in a single step to afford the
desired target. This offers a significant improvement over stepwise, iterative dendrimer
synthesis, which can be costly and time-consuming. Second, it has been demonstrated
that it is possible to obtain supramolecular structures,4,6,7 such as microcapsules or
micelles with these materials.4,6 These structures could then be non-covalently loaded
with a small molecule payload, which could be subsequently released upon polymer
degradation.4,6 Third, a variety of end caps have been reported,1-8 which allow polymer
degradation to be initiated in a variety of ways, such as in acidic or basic media,1,3,6,8 via
enzymatic or hydrolytic cleavage,2,4 or under reducing conditions.5 Such diversity allows
the researcher to tailor the polymer to best suit the desired application.
While such diversity exists in the design and incorporation of end caps, there is
surprisingly little variety in the self-immolative spacers that have been employed in selfimmolative polymers. By using different spacers, one can change the physical properties,
such as the physical form of the polymer (crystalline, globular, etc), solubility in different
media, and the possible formation of supramolecular structures. In addition, differences
in monomer degradation kinetics should allow access to a wide range of polymer
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degradation timelines. The majority of reports thus far have utilized derivatives of 4aminobenzyl alcohol.2,3,6 While these spacers have been modified to form cross-linked
microcapsules,6 release reporter molecules3 or act as fluorescent probes themselves,2 the
core aminobenzyl alcohol structure, and therefore the depolymerization mechanism,
remain the same.
In an effort to explore this dimension and gain access to a rich variety of polymer
backbones, our group has focused on the design and syntheses of heterodimeric repeat
units as polymerizable monomers. Two examples have been reported thus far that use
N,N’-dimethylethylenediamine in conjunction with first 4-hydroxybenzyl alcohol4 and
then 2-mercaptoethanol (Chapters 2 and 3).5 This led to two polymeric structures with
distinctly different physical properties, as well as degradation profiles. Although these
polymers possessed numerous attractive features, they both suffered from the limitation
of relying on the relatively slow cyclization of the diamine spacer, which resulted in
degradation times ranging from 6 – 10 days in a mixed acetone/aqueous phosphate buffer
solvent system and up to a month at the core of a degradable micelle in pure phosphate
buffer.
While these are certainly useful for slow release applications, it was desirable to
gain access to more rapidly degrading polymers. To this end, our lab developed and
tested a series of self-immolative spacers based on 4-aminobutyric acid (Chapter 4).15 By
introducing substituents at the amine and at the % position, 11 different spacers were
synthesized and demonstrated to cyclize on a phenyl ester very rapidly, with half-lives
ranging from 2 – 39 s (Figure 5.1a). When compared to N,N’-dimethylethylenediamine,
reported to cyclize on a 4-methoxyphenyl carbamate with a half-life of 36 min in pH 7.4
phosphate at 37 °C (Figure 5.1b),16 and found in our previous work (Chapter 2) to have a
similar rate when derivatized with a hydroxymethyl carbamate and studied in a mixed
acetone-phosphate solution (Figure 5.1c), the 4-aminobutyric acid derivatives exhibited
between 55 and over 1000-fold increases in cyclization rates. This was a very promising
result, and based on this it was hypothesized that these would be excellent candidates as
spacers in new, rapidly degrading polymeric systems.
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Figure 5.1. Comparison of half-lives of cyclization for a) 4-aminobutyric acid phenyl
ester derivatives, and b) and c) dimethylethylenediamine aryl carbamates.
With these spacers in hand, two new general polymeric structures were
envisioned comprising heterodimeric repeat units with a 4-aminobutyric acid linked to a
second self-immolative spacer. The first is based on 4-hydroxybenzyl alcohol (Figure
5.2a), previously employed in our lab, and the second would employ a 2’hydroxyhydrocinnamic acid spacer designed to undergo spontaneous cyclization (Scheme
5.1) that had been previously reported by Amsberry and Borchardt in 1990 (Figure
5.2b).17 This spacer contains a so called “trimethyl lock” system, referring to the methyl
group on the phenol and the two methyl groups on the sidechain, which bias the
conformation of the molecule to favour cyclization. This conformational bias proved
extremely effective, as the authors demonstrated its capability to cyclize on amides with a
half-life of 65 s in pH 7.5 0.3 M PBS:acetonitrile (5:1) at 30 °C, compared to a half-life
of greater than 19 days for the non-methylated substrate. Based on this information, it
was proposed that this 2’-hydroxyhydrocinnamic acid spacer would be an ideal partner
for a 4-aminobutyric acid derivative in the development of a polymeric system.
Described here is work towards the synthesis and degradation studies of these target
polymers.
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Scheme 5.1. Degradation mechanism of polymer 5.5.

5.2 Results and Discussion
5.2.1 Design
In contrast to the heterodimers described in Chapters 2 and 3, which polymerized
smoothly via nucleophilic attack of the aliphatic amine of N,N’-dimethylethylenediamine
on the 4-nitrophenyl carbonate, there was concern that the more rapidly cyclizing 4aminobutyric acid spacer would favour intramolecular monomer fragmentation to form
the corresponding #-lactam and hydroxybenzyl alcohol, thus preventing polymerization
(Scheme 5.2). With this in mind, a flexible approach was taken toward the synthesis of
both polymeric systems.
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Figure 5.3 illustrates the two potential monomer units envisioned for the synthesis
of polymer 5.4.

First, following our previous polymerization strategy, both a 4-

nitrophenyl carbonate and a chloroformate were considered as activating groups for the
oxygen.

The nitrophenyl carbonate was chosen as this activating group has been

successfully employed in our lab for polymerization, and its synthesis was expected to be
straightforward. The chloroformate was proposed as a more electrophilic activating
group should the nitrophenyl carbonate prove to be unable to induce polymerization in
preference to the competing intramolecular cyclization reaction to form the #-lactam.
Alternatively, the amine could be converted to an electrophilic functionality such as a
phenyl carbamate or chloroformamide, which could react with a free benzyl alcohol to
generate the polymer.
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For polymer 5.5, two possibilities were also considered. First, the heterodimer
could be formed via an amide bond, and polymerization would then follow via
esterification reactions (Scheme 5.3a). Alternatively, the ester could be made first and
polymerization could be carried out via amide bond formation reactions (Scheme 5.3b).
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Scheme 5.3. Alternative synthetic strategies to access polymer 5.5 utilizing a) amide
heterodimer; or b) ester heterodimer.
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5.2.2 Polymer 5.4
5.2.2.1

First Generation Synthesis
H
N

O

O

OH
O

O

n
5.4a

Figure 5.4. First generation target polymer 5.4a.
Our target 5.4 involved the use of unsubstituted 4-aminobutyric acid in conjunction with
4-hydroxybenzyl alcohol. The rationale behind this was twofold. First, our previous
studies had demonstrated that 4-aminobutyric acid can cyclize rapidly enough to be
potentially useful in a polymeric system, and second, the number of synthetic steps
required to access the target polymer is minimized. The synthesis, outlined in Scheme
5.4, commenced with the DCC-mediated coupling of previously reported acid 4.2 and
phenol 2.6 to afford ester 5.17. Following this, the TBS protecting group was removed in
acidic isopropanol, and the resultant alcohol was treated with 4-nitrophenyl
chloroformate in the presence of pyridine to provide carbonate 5.9a.

While model

studies had revealed that a 4-nitrophenyl carbonate was less reactive than the
corresponding chloroformate and would therefore suffer from increased competition from
intramolecular cyclization, its facile synthesis made it a good test substrate, which could
be further improved upon if necessary.
The final step prior to polymerization was removal of the Boc protecting group,
achieved by treatment of 5.9a with 1:1 TFA:CH2Cl2. Following this, 0.05 equivalents of
Boc-protected 5.9a was added to serve as an end cap, and then the material was
polymerized with the addition of DIPEA and catalytic DMAP.
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Scheme 5.4. First generation synthesis of polymer 5.4a.
While the results of the polymerization were not ideal, analysis of the reaction
mixture proved quite instructive.

As expected, there was a substantial amount of

intramolecular cyclization to form #-lactam 4.18a, demonstrating that a 4-nitrophenyl
carbonate was not electrophilic enough to induce preferential intermolecular attack of the
amine at that site over intramolecular attack on the ester, yet there was still a small
amount of polymeric material formed. However, this material proved to be insoluble in a
wide array of solvents tested. While the material obtained was not useful, it proved that
polymerization was indeed possible, and with slight modification to the 4-aminobutyric
acid spacer polymer 5.4 should be obtainable.

5.2.2.2

Second Generation Synthesis
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O

n
5.4b

Figure 5.5. Second generation target polymer 5.4b.
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The first modification carried out was methylation of the amine. This methyl group was
introduced with the aim of preventing hydrogen bonding, which was hypothesized to be
the cause of polymer insolubility. As an added benefit, based on the cyclization kinetics
described in Chapter 4, this would increase the rate of cyclization and therefore lead to
faster polymer degradation times. The synthesis of the modified polymer, outlined in
Scheme 5.3, was analogous to the first generation synthesis. The N-methylated acid
derivative 4.3 was coupled to phenol 2.6 using DCC and catalytic DMAP to afford ester
5.19. TBS removal proceeded as previously described, revealing the benzylic alcohol
5.20. Due to the previous polymerization results with a nitrophenyl carbonate, combined
with the fact that N-methyl-4-aminobutyric acid was found to cyclize substantially faster
than unfunctionalized 4-aminobutyric acid, it was decided to convert the hydroxyl group
into the more reactive chloroformate in an effort to increase the electrophilicity of this
site and therefore bias the reaction to favour polymerization instead of the previously
observed cyclization on the phenyl ester.
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Scheme 5.5. Second generation synthesis of unactivated monomer 5.20.
While in theory a straightforward transformation, installation of the chloroformate
proved particularly challenging with substrate 5.20, as highlighted in Scheme 5.6.
Initially, standard conditions of triphosgene (5.21) and pyridine were employed, but the
sole product isolated was the benzyl chloride rather than the desired chloroformate.
When the reaction was carried out in the absence of base, the chloroformate was obtained
as the major product along with a small amount of the undesired chloride and some
starting material, but attempts to purify the material via column chromatography proved
detrimental as substantial conversion to the benzyl chloride occurred.

While

polymerization was attempted on the reaction mixture, only oligomeric products were
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obtained, likely due to the low monomer purity. Further attempts to optimize the
synthesis and purification of chloroformate 5.9b proved unsuccessful.
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Scheme 5.6. Attempted formation of chloroformate 5.9b.
Having been unable to produce polymer 5.4 utilizing a nucleophilic amine and
electrophilic alcohol derivative, attention was turned to developing a heterodimer
possessing an electrophilic amine derivative in conjunction with a nucleophilic benzyl
alcohol.

While previous reports involving this methodology made use of a phenyl

carbamate as an electrophilic amine derivative,2 this approach is applicable to primary
amines only, as secondary amines cannot undergo the requisite elimination to form the
isocyanate. Therefore, an alternative eletrophilic group was required, and a
chloroformamide was selected as it had been demonstrated to be compatible with
secondary amines.18
The approach to this activated heterodimer began with the TBS protected ester
5.19.

This material was first treated with TFA to remove the Boc group, which

simultaneously removed the TBS ether and replaced it with a trifluoroacetate group.
While not initially anticipated, this trifluoroacetate proved advantageous, as it allowed
the next step, treatment of the amine with triphosgene to install the chloroformamide, to
proceed without risk of competitive chloroformate formation.

Following this, the

trifluoroacetate was removed using NaHCO3 in a mixture of THF and H2O.
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Unfortunately, attempts to isolate this material proved unsuccessful, as the reaction
sequence led to the formation of a number of byproducts, which proved to be inseparable
from the desired product on a column, and additional methods of purification led to
hydrolysis of the sensitive chloroformamide functionality.
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Scheme 5.7. Synthesis of chloroformamide monomer 5.10a.
Having unsuccessfully attempted two methods to generate N-methylated polymer
5.4b, this strategy was abandoned in favour of pursuing an alternative solubilizing group.

5.2.2.3

Third Generation Synthesis
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Figure 5.6. Third generation target polymer 5.4c.
The third variant of polymer 5.4 involved using (S)-4-amino-2-hydroxybutyric acid as the
starting material and functionalizing the 2-hydroxy group. To this end, the synthetic
route outlined in Scheme 5.8 was developed. Beginning from previously reported methyl
ester 4.15, the secondary alcohol was converted to the corresponding N,N-diethyl
carbamate 5.25 in two steps, first by forming active carbonate 5.24 and then displacing 4nitrophenol with diethylamine. It should be noted that while a diethyl carbamate seems
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like an unusual choice for a solubilizing group, several different possible solubilizing
groups including various ethers and a pivalate ester were evaluated initially and proved
unsuitable. The methyl ester was then removed using LiOH to reveal the free acid, which
was subsequently coupled with phenol 2.6 via a mixed anhydride to afford ester 5.27.
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Scheme 5.8. Synthesis of monomer 5.10b.
In order to provide an electrophilic amine derivative and nucleophilic free
alcohol, TBS protected ester 5.27 was first treated with 1:1 TFA:CH2Cl2 to remove the
Boc group while simultaneously converting the silyl ether to a trifluoroacetate. A phenyl
carbamate was then installed using phenyl chloroformate with excess NEt3, and finally
the trifluoroacetate was cleaved under mildly basic conditions using NaHCO3 in a
mixture of THF and H2O to afford monomer 5.10b.
Before polymerization could be carried out, an end cap needed to be prepared,
and for initial studies a Boc group was selected. To this end, free alcohol 5.29 was
synthesized by treatment of 5.27 with dilute HCl in iPrOH to remove the silyl protecting
group. With this material in hand, polymerization of phenyl carbamate 5.7b was carried
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out using catalytic dibutyltin dilaurate (DBTL) in refluxing dioxane with 0.05 equivalents
of 5.29 serving as the Boc end cap source (Scheme 5.9).
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Scheme 5.9. a) Deprotection of 5.27 to form Boc-protected end cap 5.29; and b)
polymerization of monomer 5.10b in the presence of end cap 5.29.
Polymerization of the material was indeed successful; however, an unexpected
product was also formed in the course of the reaction. Analysis of the 1H NMR spectrum
revealed that in addition to the expected aromatic peaks corresponding to the esterfunctionalized hydroxybenzyl alcohol, a new set of aromatic protons of approximately
equal intensity were present that resembled unsubstituted hydroxybenzyl alcohol (Figure
5.7a). When the sample was doped with 4-hydroxybenzyl alcohol, however, the two
signals did not overlap, indicating that the peaks observed in the polymer arise from a
different, unidentified compound (Figure 5.7b).

Repeated dialyses with increasing

molecular weight cutoffs were carried out (Figure 5.7c), but it was found that the
additional aromatic peaks persisted, indicating that this species had been incorporated
into the polymeric backbone.

Carrying out preliminary degradation studies, the

additional aromatic peaks persisted, as shown by the overlapping doublets near 7 ppm,
suggesting that this phenolic species was covalently bound to the 4-aminobutyric acid
backbone in such a way that either prevented cyclization or was unaffected by it.
Unfortunately, as a number of different routes to the polymer had already been
unsuccessfully explored and that the source of the problem was not evident, this polymer
was not explored further.
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Figure 5.7. 1H NMR spectra of the aromatic region of polymer 5.4c a) following dialysis
with 3500 MWCO; b) following addition of hydroxybenzyl alcohol; c) following dialysis
with 6000-8000 MWCO; and d) after 24 h in pH 7.4 0.1 M phosphate (D2O):methanol-d4
(1:1) (spectrum taken in pH 7.4 0.1 M phosphate (D2O):methanol-d4 (1:1)).

5.2.3 Polymer 5.5
5.2.3.1

Synthesis

As described above (Scheme 5.3), two strategies were envisioned to synthesize target
polymer 5.5. Initially it was thought that the strategy depicted in Scheme 5.3a would be
the more successful route, as Amsberry and Borchardt had successfully employed this
strategy in their syntheses of prodrugs containing a 2’-hydroxyhydrocinnamic acid selfimmolative spacer.17 However, it was found that while the two components could be
coupled, deprotection of the phenol resulted in spontaneous lactonization, with no
intermediate phenol observed in the reaction mixture (Scheme 5.10). Based on this
subsequent efforts were then focused on the strategy depicted in Scheme 5.3b.
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Scheme 5.10. Deprotection of heterodimer 5.13 followed by spontaneous lactonization.
The synthesis of carboxylic acid 5.33, outlined in scheme 5.11, followed a similar
protocol to that used by Greenwald and coworkers.18 It began with the EDC-mediated
coupling of Boc protected acid 4.2 and previously reported phenol 5.15a (EDC = 1-ethyl3-(3-dimethylaminopropyl)carbodiimide).18 TBS deprotection of the resulting ester was
achieved using 3:1:1 HOAc:THF:H2O.

The free alcohol was then oxidized to a

carboxylic acid in a two-step process, first converting it to aldehyde 5.32 with pyridinium
chlorochromate (PCC), and then completing the oxidation with Oxone", affording acid
5.33.
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Scheme 5.12. Activation and polymerization of acid 5.33.
In order to complete the polymerization, the acid had to be first converted to an
active ester. A brief screening of potential candidates revealed that a pentafluorophenyl
ester was the most viable option and thus was selected for the polymerization. This
group was readily installed using an EDC coupling with pentafluorophenol to form active
ester 5.34. Following Boc group removal with TFA, polymerization was carried out at 0
°C in toluene with excess DIPEA, catalytic DMAP, and 0.05 equivalents of Boc
protected 5.34 as an end cap. The final polymer was then purified via dialysis using a
3500 MWCO membrane.
Analysis of the purified polymer was carried out using NMR and SEC. NMR
revealed that the desired end cap-to-repeat unit ratio of approximately 1:20 had been
obtained, corresponding to an Mn of 5900, and SEC in DMF indicated an Mn of 4500, Mw
of 6100 and a resulting PDI of 1.4 relative to polystyrene standards.

5.2.3.2

Degradation Studies

The increased hydrophobic character of polymer 5.5b rendered it insoluble in the
previously used degradation conditions of pH 7.4 0.1 M phosphate:acetone (3:2), and
therefore alternative conditions needed to be employed. A mixture of pH 7.4 acetone:0.1
M HEPES buffer (3:2) was found to be the most suitable. Due to the substantial change
in solvent composition relative to what was previously used for 4-aminobutyric acid
cyclization studies, it was deemed prudent to perform monomer degradation kinetics
under these conditions to determine what effect this had on the rate of cyclization.
Additionally, it was not inherently obvious which of the cyclization reactions would be
rate limiting. In order to probe this, modified monomer 5.36 was prepared by coupling
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acid 5.33 with 4-aminobutyric acid methyl ester 5.12a&HCl.20

Once prepared, the

monomer was deprotected using TFA and the resulting material was dissolved in the
buffered solution and incubated at 37 °C (Scheme 5.13).

Reaction progress was

monitored by 1H NMR, measuring the formation of lactone 5.7. The results are shown in
Figure 5.8.
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Scheme 5.13. a) Synthesis of modified monomer 5.36; b) deprotection and degradation
of monomer 5.36 into lactam 4.18a, lactone 5.7 and free amine 5.12a.
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Figure 5.8. Plot of conversion of monomer 5.36 into lactone 5.7 over time.
While the data highlighted in Figure 5.8 effectively shows the timeline for
complete monomer degradation, it is in fact an oversimplification of the reaction process.
As shown in Scheme 5.9b, monomer 5.36 fragments into three different components,
lactam 4.18a, lactone 5.7 and amine 5.12a. It is noteworthy that while in theory amine
5.12a could cyclize to generate additional 4.18a, previous studies in our lab on similar
substrates have revealed this process to be slow enough that negligible conversion would
be expected to occur throughout the course of this study. Based on this, the assumption
was made that the percent composition of amine 5.12a would be equal to that of lactone
5.7.
To more accurately probe the reaction and follow the course of events leading to
formation of the final degradation products (Scheme 5.14), a more thorough analysis of
the aromatic region of the spectra was carried out, the results of which are highlighted in
Figure 5.9. At t = 0, two singlets are present, arising from deprotected monomer 5.37.
As the reaction progressed, two new sets of singlets began to emerge, first one set higher
upfield, followed by a second set in between those assigned to 5.37. The first set, higher
upfield than the other two, was presumed to from an intermediate species produced from
the first cyclization event. The second set, which emerged in between the two singlets
assigned to the monomer, was assigned to lactone 5.7. As shown in Figure 5.10b, after

159

10 h the major component in the reaction mixture was lactone 5.7, but there was still a
significant amount of 5.37 as well as a small amount of phenol 5.38 present in solution.
By 28 h (Figure 5.8c), only trace amounts of starting material and intermediate were
detected, with the vast majority of the material having converted to the final lactone.

Figure 5.9. Aromatic region of the 1H NMR spectra of monomer degradation reaction
after a) 4 min; b) 10 h; and c) 28 h showing conversion of 5.37 into phenolic intermediate
5.38 and then lactone 5.7.
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Scheme 5.14. Degradation pathway of deprotected monomer 5.37, with the first
cyclization event generating lactone 4.18a and intermediate phenol 5.38 which then
undergoes a second cyclization event to form lactone 5.7 and amine 5.12a.

160

An analysis of the percent composition of the degradation products over time is
shown in Figure 5.10. What is immediately apparent is that the cyclizations of both 4aminobutyric acid and 2’-hydroxyhydrocinnamic acid were significantly slower than in
previously reported examples. As shown, the cyclizations required more than 24 h to
proceed to completion, versus just minutes for the same spacers to cyclize under
previously reported conditions, namely pH 7.4 0.1 M phosphate:iPrOH (9:1) at 37 °C for
4-aminobutyric acid and pH 7.5 PBS:acetonitrile (4:1) at 30 °C for 2’hydroxyhydrocinnamic acid.17

While the substrates under investigation in this

experiment were not identical to the previous examples and therefore were expected to
have somewhat different reaction rates, the processes themselves are fundamentally quite
similar (the amine cyclizing on a phenyl ester and the phenol cyclizing on an amide), and
therefore would be expected to occur at a somewhat similar rate. Because of the orders
of magnitude in difference for the observed cyclizations in this study relative to previous
work, it is apparent that the higher organic content in the solvent mixture played a key
role in suppressing the cyclization rate of these spacers.

Figure 5.10. Change in percent composition of the degradation products over the course
of the reaction.
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Kinetic analysis of the reaction was carried out using nonlinear regression. The
two rate constants were solved using the concentration of intermediate phenolic species
5.38, according to the equation [B] = [A]0(k1/k2 – k1)(e-k1t - e-k2t), where B is intermediate
5.38, A is ester 5.37, k1 is the rate constant corresponding to the initial cyclization to form
lactam 4.18a and phenol 5.38 and k2 is the rate constant corresponding to the second
cyclization to form 5.7 and 5.12a. Additionally, based on NMR data obtained for the
reaction, the assumptions were made that the starting concentration of 5.38 was zero, and
k1 $ k2. The rate constant k1 was calculated to be 3.03 x 10-5s-1, corresponding to a halflife of 6.4 h. The second rate constant was 8.08 x 10-5s-1, with a corresponding half-life
of 2.4 h. From these values, it has been shown that the two cyclization reactions do
indeed occur on a similar timeline, as was expected, and furthermore the first cycization
was demonstrated to be the rate limiting step in the overall monomer degradation process.
Due to the relatively slow kinetics of cyclization observed for monomer 5.37, it
was predicted that polymer 5.5b would require a significant amount of time to degrade.
A thorough kinetic study of the degradation of polymer 5.5b was not undertaken and will
be the subject of ongoing investigation in the laboratory.

5.3 Conclusions
In conclusion, significant progress has been made toward the synthesis of self-immolative
polymers containing 4-aminobutyric acid spacers. Two general polymeric structures, 5.4
and 5.5, were targeted. While 5.4 proved to be very challenging to prepare, much
valuable insight was gained into the potential synthesis of this polymer, as well as other
similar polymeric structures.

Polymer 5.5b was successfully synthesized, and

investigation of the kinetics of monomer cyclization revealed that monomer 5.37
underwent conversion to lactam 4.18a and lactone 5.7. In the solvent required for the
dissolution of polymer 5.5b, the rates observed for each cyclization event were
significantly slowed relative to previous studies due to the increased organic content of
the solvent medium. An investigation of the kinetics of polymer degradation was not
undertaken, but will be the focus of future work.

162

5.4 Experimental
All reagents were purchased from commercial suppliers and used without further
purification unless otherwise noted.

Anhydrous DMF, toluene and dioxane were

obtained from a solvent purification system. CH2Cl2, pyridine and NEt3 were distilled
from CaH2.

Unless otherwise stated, all reactions were performed under an argon

atmosphere using flame or oven dried glassware.

Column chromatography was

performed using silica gel (0.063-0.200 mm particle size, 70-230 mesh). Thin layer
chromatography was performed using Macherney-Nagel Polygram® SIL G/UV254 plates.
1

H NMR spectra were obtained at 400 MHz and 13C NMR spectra were obtained at 100

MHz using a Varian Inova spectrometer. NMR chemical shifts are reported in ppm and
are calibrated against residual solvent signal of CDCl3 (! 7.27, 77.00) or D2O (! 4.75).
Coupling constants (J) are expressed in Hertz (Hz).

Infrared spectra were obtained as

films from CH2Cl2 on NaCl plates using a Bruker Tensor 27 instrument. High-resolution
mass spectrometry (HRMS) was performed using a Finnigan MAT 8400 electron impact
(EI) or a Micromass LCT electrospray ionization time-of-flight (ESI) mass spectrometer.
Size exclusion chromatography was carried out at a flow rate of 1 mL/min in N,Ndimethylformamide (DMF) with 10 mM LiBr and 1% (v/v) NEt3 at 85 °C using a Waters
2695 separations module equipped with a Waters 2414 differential refractometer and two
PLgel 5 !m mixed-D (300 mm " 7.5 mm) columns from Polymer Laboratories connected
in series. The calibration was performed using polystyrene standards.
Synthesis of compound 5.17 and general DCC-mediated ester synthesis: Acid 4.2
(0.980 g, 4.11 mmol) and phenol 2.6 (1.03 g, 5.06 mmol) were dissolved in CH2Cl2 (40
mL). DCC (1.28 g, 6.20 mmol) and DMAP (0.100 g, 0.819 mmol) were added and the
solution was stirred 90 min. The precipitate was filtered off and rinsed with CH2Cl2. The
solution was then poured into 1 M Na2CO3, and the product was extracted three times
into CH2Cl2. The organic layers were dried over MgSO4, filtered, and the solvent was
removed. Purification via column chromatography (90:10 cyclohexane:EtOAc for 600
mL followed by 80:20 cyclohexane:EtOAc) afforded 5.17 (1.58 g, 91%) as a colourless
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oil. 1H NMR (CDCl3): ! 7.33 (d, J = 8.6 Hz, 2H), 7.05 (d, J = 8.6 Hz, 2H), 4.73 (s, 2H),
4.67 (br s, 1H), 3.27 (quartet, J = 6.6 Hz, 2H), 2.61 (t, J = 7.0 Hz, 2H), 1.94 (quintet, J =
7.0 Hz, 2H), 1.46 (s, 9H), 0.94 (s, 9H), 0.10 (s, 6H).

13

C NMR (CDCl3): ! 171.8, 155.9,

149.4, 138.9, 126.9, 121.1, 79.2, 64.3, 39.8, 31.6, 28.3, 25.9, 25.2, 18.3, -5.4. IR (cm-1):
2959, 2933, 2883, 2860, 1760, 1702, 1676, 1508, 1463, 1367. HRMS: calc’d [M+H]+
(C22H38NO5Si): 424.2514. Found (EI): 424.2519.
Synthesis of compound 5.18 and general HCl/iPrOH-mediated TBS deprotection:
Under air atmosphere, ester 5.17 (1.44 g, 3.40 mmol) was dissolved in 1 vol% 12 M HCl
in iPrOH (30 mL), and the solution was stirred for 2 h. The reaction was quenched with
saturated NaHCO3 solution, and the product was extracted three times with CH2Cl2. The
organic layers were dried over MgSO4, filtered, and the solvent was removed. Column
chromatography (80:20 cyclohexane:EtOAc followed by 1:1 cyclohexane:EtOAc)
afforded 5.18 (0.957 g, 91%) as a colourless oil. 1H NMR (CDCl3): ! 7.39 (d, J = 8.6 Hz,
2H), 7.09 (d, J = 8.6 Hz, 2H), 4.70 (s, 2H), 4.66 (br s, 1H), 3.27 (quartet, J = 6.6 Hz, 2H),
2.62 (t, J = 7.4 Hz, 2H), 1.95 (quintet, J = 7.0 Hz, 2H), 1.72 (br s, 1H), 1.46 (s, 9H).

13

C

NMR (CDCl3): ! 171.9, 156.0, 149.8, 138.7, 127.9, 121.4, 79.3, 64.3, 39.7, 31.5, 28.3,
25.1. IR (cm-1): 3450, 2985, 2940, 2882, 1756, 1653, 1509, 1367. HRMS: calc’d
[M+H]+ (C16H24NO5): 310.1649. Found (EI): 310.1647
Synthesis of compound 5.9a: Ester 5.18 (0.422 g, 1.36 mmol) was dissolved in CH2Cl2
(13 mL). Pyridine (0.33 mL, 4.08 mmol) and 4-nitrophenyl chloroformate (0.552 g, 2.74
mmol) were added, and the solution was stirred 3 h. 1 M HCl was added, and the product
was extracted three times into CH2Cl2. The organic layers were dried over MgSO4,
filtered,

and

the

solvent

was

removed.

Column

chromatography

(90:10

cyclohexane:CH2Cl2 followed by 1:1 CH2Cl2:EtOAc) afforded 5.9a (0.617 g, 95%) as a
colourless oil.

1

H NMR (CDCl3): ! 8.29 (d, J = 9.4 Hz, 2H), 7.47 (d, J = 8.6 Hz, 2H),

7.39 (d, J = 9.4 Hz, 2H), 7.15 (d, J = 8.6 Hz, 2H), 5.29 (s, 2H), 4.72 (br s, 1H), 3.28
(quartet, J = 6.6 Hz, 2H), 2.64 (t, J = 7.0 Hz, 2H), 1.95 (quintet, J = 7.0 Hz, 2H), 1.47 (s,
9H).

13

C NMR (CDCl3): ! 171.5, 155.9, 155.3, 152.2, 151.0, 145.3, 131.7, 129.9, 125.1,

121.9, 121.7, 79.1, 70.1, 39.6, 31.4, 28.3, 25.1. IR (cm-1): 2980, 2935, 2873, 1765, 1703,
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1653, 1528, 1367, 1350. HRMS: calc’d [M+H]+ (C23H27N2O9): 475.1711. Found (EI):
475.1712.
Synthesis of compound 5.19: The same general DCC-mediated coupling procedure was
followed except acid 4.3 (2.28 g, 10.5 mmol) was used as the starting material.
Purification via column chromatography (95:5 cyclohexane:EtOAc followed by 85:15
cyclohexane:EtOAc) afforded 5.19 (3.27 g, 86%) as a colourless oil. 1H NMR (CDCl3):
! 7.33 (d, J = 8.2 Hz, 2H), 7.05 (d, J = 8.6 Hz, 2H), 4.73 (s, 2H), 3.34 (t, J = 6.6 Hz, 2H),
2.88 (s, 3H), 2.57 (t, J = 7.4 Hz, 2H), 1.97 (quintet, J = 7.4 Hz, 2H), 1.47 (s, 9H), 0.94 (s,
9H), 0.10 (s, 9H).

13

C NMR (CDCl3): ! 171.6, 155.7, 149.4, 138.8, 126.8, 121.1, 79.3,

64.3, 48.0, 34.0, 31.3, 28.3, 25.8, 23.0 18.3, -5.4. IR (cm-1): 2957, 2934, 2858, 1761,
1699, 1508, 1471, 1394, 1365. HRMS: calc’d [M+H]+ (C23H40NO5Si): 438.2670. Found
(EI): 438.2667.
Synthesis of compound 5.20: The same procedure was followed for general HCl/iPrOHmediated deprotection except ester 5.19 (0.582 g, 1.33 mmol) was used as the starting
material.

Column chromatography (85:15 cyclohexane:EtOAc followed by 1:1

cyclohexane:EtOAc) afforded 5.20 (0.396 g, 92%) as a colourless oil. 1H NMR (CDCl3):
! 7.39 (d, J = 8.6 Hz, 2H), 7.09 (d, J = 8.6 Hz, 2H), 4.70 (s, 2H), 3.35 (t, J = 6.6 Hz, 2H),
2.88 (s, 3H), 2.58 (t, J = 7.4 Hz, 2H), 1.97 (quintet, J = 7.4 Hz, 2H), 1.47 (s, 9H).

13

C

NMR (CDCl3): ! 171.7, 155.8, 149.8, 138.7, 127.8, 121.4, 79.5, 64.3, 48.0. 34.0, 31.3,
28.3, 23.0. IR (cm-1): 3450, 2976, 2934, 2876, 1757, 1693, 1508, 1398, 1367. HRMS:
calc’d [M+H]+ (C17H26NO5): 324.1805. Found (EI): 324.1809.
Synthesis of compound 5.24: Ester 4.15 (2.02 g, 8.64 mmol) was dissolved in CH2Cl2
(60 mL). Pyridine (2.10 mL, 26.0 mmol) and 4-nitrophenyl chloroformate (3.48 g, 17.3
mmol) were added, and the solution was stirred 90 min. The reaction was quenched with
1 M HCl, and then the aqueous phase was extracted three times with CH2Cl2. The
organic layers were dried over MgSO4, filtered, and the solvent was removed.
Purification via column chromatography (CH2Cl2 followed by 3:1 CH2Cl2:EtOAc)
afforded carbonate 5.24 (3.23 g, 94%) as a white solid. 1H NMR (CDCl3): ! 8.29 (d, J =
9.0 Hz, 2H), 7.44 (d, J = 9.0 Hz, 2H), 5.13 (dd, J = 6.4 & 5.9 Hz, 1H), 4.72 (br. s, 1H),
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3.83 (s, 3H), 3.48 - 3.36 (m, 1H), 3.34 – 3.24 (m, 1H), 2.25 – 2.13 (m, 2H) 1.45 (s, 9H).
13

C NMR (CDCl3): ! 169.4, 155.7, 155.1, 151.7, 145.2, 125.0, 121.5, 79.1, 73.7, 52.5,

35.9, 31.1, 28.0. IR (cm-1): 3435, 2980, 2935, 1763,1757, 1709, 1528, 1350. HRMS:
calc’d [M+H]+ (C17H23N2O9): 399.1404. Found (EI): 399.1544.
Synthesis of compound 5.25: Carbonate 5.24 (5.04 g, 12.6 mmol) was dissolved in
toluene (60 mL). Diethylamine (4.00 mL, 38.5 mmol) and DMAP (0.161 g, 1.32 mmol)
were added, and the solution was stirred 24h. The solvent was removed in vacuo, and
then the crude material was taken up in CH2Cl2. 1 M HCl was added, and the aqueous
phase was extracted three times with CH2Cl2. The combined organic layers were then
washed with 1 M Na2CO3, and the aqueous layer was further extracted twice with
CH2Cl2. The organic phases were dried over MgSO4, filtered, and the solvent was
removed.

The product was purified via silica gel chromatography (65:35

Cyclohexane:EtOAc), affording carbamate 5.25 (4.09 g, 97%) as a colourless oil.

1

H

NMR (CDCl3): ! 5.11 (dd, J = 4.3 & 7.8 Hz, 1H), 4.81 (br. s, 1H), 3.75 (s, 3H), 3.40 –
3.24 (m, 5H), 3.23 – 3.12 (m, 1H), 2.14 – 1.96 (m, 2H), 1.44 (s, 9H), 1.19 (t, J = 7.0 Hz,
3H), 1.14 (t, J = 7.0 Hz, 3H).

13

C NMR (CDCl3): ! 170.7, 155.1, 154.2, 78.3, 69.9, 51.4,

41.3, 40.8, 36.0, 30.9, 27.6, 13.3, 12.7. IR (cm-1): 3373, 2978, 2937, 1759, 1711, 1522,
1479, 1433, 1367. HRMS: calc’d [M]+ (C15H28N2O6): 332.1947. Found (EI): 332.1953.
Synthesis of compound 5.26: Under an air atmosphere, compound 5.25 (4.09 g, 12.3
mmol) was dissolved in 1:1 THF:H2O (100 mL). LiOH&H2O (0.778 g, 18.5 mmol) was
added, and the solution was stirred for 24 h. The solution was acidified with 1 M HCl,
and the solution was extracted four times with CH2Cl2. The organic layers were dried
with MgSO4, filtered, and the solvent was removed to provide acid 5.26 (3.63 g, 92%) as
a thick, colourless oil. 1H NMR (CDCl3): % 5.10 (dd, J = 5.5 & 6.4 Hz, 1H), 4.90 (br. s,
1H), 3.45 – 3.17 (m, 6H), 2.37 – 1.90 (m, 2H), 1.44 (s, 9H), 1.19 (t, J = 7.4 Hz, 3H), 1.14
(t, J = 7.4 Hz, 3H).

13

C NMR (CDCl3): % 173.4, 155.9, 155.0, 79.1, 70.5, 41.8, 41.3, 36.4,

31.2, 28.1, 13.6, 13.0. IR (cm-1): 3369, 2980, 2937, 1699, 1527, 1481, 1435, 1367.
HRMS: calc’d [M]+ (C14H26N2O6): 318.1791. Found (EI): 318.1781.
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Synthesis of compound 5.27: Acid 5.26 (3.60 g, 11.3 mmol) was dissolved in CH2Cl2
(50 mL). NEt3 (4.00 mL, 28.7 mmol) and pivaloyl chloride (1.67 mL, 13.6 mmol) were
added and the solution was stirred for 15 min. Phenol 2.6 (3.78 g, 15.8 mmol) was
dissolved in CH2Cl2 (10 mL) and added via syringe to the reaction mixture, which was
then stirred for 24 h. The solution was poured into 1 M HCl, and the product was
extracted three times into CH2Cl2. The organic layers were dried over MgSO4, filtered,
and the solvent was removed.

Column chromatography (9:1 cyclohexane:EtOAc

followed by 3:1 cyclohexane:EtOAc) afforded ester 5.27 (5.38 g, 88%) as a colourless
oil. 1H NMR (CDCl3): ! 7.43 (d, J = 8.6 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 5.30 (dd, J =
4.7 & 7.8 Hz, 1H), 4.87 (br. s, 1H), 4.73 (s, 2H), 3.52 – 3.23 (m, 6H), 2.30 – 2.13 (m,
2H), 1.45 (s, 9H), 1.20 (t, J = 7.0 Hz, 3H), 1.18 (t, J = 7.0 Hz, 3H).

13

C NMR (CDCl3): !

169.6, 155.7, 154.8, 149.0, 139.2, 126.9, 121.0, 79.2, 70.6, 64.3, 42.1, 41.5, 36.6, 31.5,
28.3, 18.3, 13.9, 13.3, -5.4. IR (cm-1): 3371, 2959, 2934, 2958, 1776, 1711, 1508,1431,
1367. HRMS: calc’d [M+H]+ (C27H47N2O7): 539.3147. Found (EI): 539.3133.
Synthesis of compound 5.10b: Under an air atmosphere, 5.27 (1.01 g, 1.87 mmol) was
dissolved in 1:1 TFA:CH2Cl2 (10 mL) and the solution was stirred 2 h. The solvent was
removed, and CH2Cl2 was then added and removed three times to remove residual TFA.
The flask was then fully evacuated and refilled with Ar. CH2Cl2 (9 mL) was added, and
the solution was cooled to 0°C. Phenyl chloroformate (0.35 mL, 279 mmol) was added,
followed by NEt3 (1.00 mL, 7.19 mmol), and the solution was stirred for 1 h. The
reaction was quenched with 1 M HCl and the aqueous phase was extracted three times
with CH2Cl2. The combined organic layers were dried over MgSO4, filtered, and the
solvent was removed. The material was then taken up in 2:1:1 THF:H2O:1 M NaHCO3
(16 mL), and the solution was stirred for 2 h under an air atmosphere. Saturated NaHCO3
solution was then added, and the product was extracted three times into CH2Cl2. The
organic layers were dried over MgSO4, filtered, and the solvent was removed.
Purification via column chromatography (2:1 cyclohexane:EtOAc followed by 1:1
cyclohexane:EtOAc) afforded 5.10b (0.673 g, 81%) as a thick, colourless oil. 1H NMR
(CDCl3): ! 7.39 (d, J = 8.8 Hz, 2H), 7.36 (t, J = 8.2 Hz, 2H), 7.20 (t, J = 7.4 Hz 1H), 7.15
– 7.12 (m, 4H), 5.43 (t, J = 5.9 Hz, 1H), 5.40 (dd, J = 4.7 & 8.2 Hz, 1H), 4.70 (d, J = 5.3
Hz, 2H), 3.64 – 3.57 (m, 1H), 3.47 – 3.29 (m, 5H), 2.40 – 2.34 (m, 1H), 2.33 – 2.25 (m,
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1H), 1.67 (t, J = 5.3 Hz, 1H), 1.22 (t, J = 7.0 Hz, 3H), 1.17 (t, J = 7.0 Hz, 3H).

13

C NMR

(CDCl3): ! 169.5, 169.1, 154.8 & 154.7 (rotamers),149.3 & 149.2 (rotamers), 139.2 &
139.0 (rotamers), 129.2, 127.9, 125.2, 121.4, 121.1 & 121.0 (rotamers), 70.5 & 70.4
(rotamers), 64.12 & 64.08 (rotamers), 42.2, 41.6, 37.2 & 35.9 (rotamers), 31.2 & 30.6
(rotamers), 13.9, 13.2. IR (cm-1): 3350, 3074, 2980, 2937, 2880, 1772, 1709, 1699, 1483,
1435, 1383. HRMS: calc’d [M+H]+ (C23H29N2O7): 445.1969. Found (EI): 445.1979.
Synthesis of compound 5.29: The same procedure was followed for general HCl/iPrOHmediated deprotection except ester 5.27 (0.129 g, 0.240 mmol) was used as the starting
material. Purification via column chromatography (3:1 cyclohexane:EtOAc followed by
1:1 cyclohexane:EtOAc) afforded 5.29 (0.0905 g, 89%) as a colourless oil.

1

H NMR

(CDCl3): ! 7.39 (d, J = 8.6 Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 5.30 (dd, J = 4.7 & 7.8 Hz,
1H), 4.86 (br s, 1H), 4.70 (d, J = 5.9 Hz, 2H), 3.50 – 3.24 (m, 6H), 2.32 – 2.14 (m, 2H),
1.70 (t, J = 5.9, 1H), 1.45 (s, 9H), 1.20 (t, J = 7.0 Hz, 3H), 1.16 (t, J = 7.0 Hz, 3H).

13

C

NMR (CDCl3): ! 169.6, 155.7, 154.8, 149.4, 139.0, 127.9, 121.2, 79.4, 70.7, 64.3, 42.1,
41.6, 36.6, 31.5, 28.3, 13.9, 13.3. IR (cm-1): 3440, 2978, 2936, 1772, 1695, 1503, 1433,
1367. HRMS: calc’d [M+H]+ (C21H32N2O7): 425.2282. Found (EI): 425.2286.
Synthesis of compound 5.16a: A flask was charged with acid 4.2 (1.57 g, 4.88 mmol)
and previously reported phenol 5.15a (1.98 g, 9.72 mmol). CH2Cl2 (20 mL) was added,
followed by EDC&HCl (2.80 g, 14.6 mmol) and DMAP (4.16 g, 34.0 mmol), and then the
solution was stirred for 24 h. The solution was poured into saturated NaHCO3 solution,
and the product was extracted twice into CH2Cl2. The organic extracts were then washed
with 1 M HCl, and the aqueous phase was further extracted twice with additional CH2Cl2.
The combined organic layers were dried over MgSO4, filtered, and the solvent was
removed.

Purification of the crude material by column chromatography (19:1

cyclohexane:EtOAc followed by 9:1 cyclohexane:EtOAc) afforded 5.16a (2.09 g, 85%)
as a colourless oil. 1H NMR (CDCl3): ! 6.81 (s, 1H), 6.55 (s, 1H), 4.72 (br. s, 1H), 3.48
(t, J = 7.4 Hz, 2H), 3.26 (quartet, J = 6.6 Hz, 2H), 2.59 (t, J = 7.4 Hz, 2H), 3.52 (s, 3H),
2.23 (s, 3H), 2.02 (t, J = 7.4 Hz, 2H), 1.94 (quintet, J = 7.0 Hz, 2H), 1.46 (s, 15H), 0.85
(s, 9H), -0.02 (s, 6H).

13

C NMR (CDCl3): ! 172.3, 155.9, 149.6, 138.3, 135.8, 134.0,

132.2, 123.0, 79.1, 60.9, 45.9, 39.8, 39.0, 32.2, 31.8, 28.4, 25.9, 25.2, 24.9, 20.1, 18.2, -
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5.4. IR (cm-1): 3380, 2959, 2930, 2858, 1759, 1718, 1520, 1474, 1365. HRMS: calc’d
[M+H]+ (C28H50NO5Si): 508.3453. Found (EI): 508.3459.
Synthesis of compound 5.31: Under an air atmosphere, 5.16a (2.08 g, 4.10 mmol) was
dissolved in 3:1:1 HOAc:THF:H2O (20 mL), and the solution was stirred for 2 h.
Removal

of

the

solvent

and

purification

by

column

chromatography

(3:1

cyclohexane:EtOAc followed by 1:1 cycohexane:EtOAc) afforded 5.31 (1.48 g, 91%) as
a colourless oil. 1H NMR (CDCl3): ! 6.83 (d, J = 1.6 Hz, 1H), 6.56 (d, J = 1.6 Hz, 1H),
4.73 (br. s, 1H), 3.54 (t, J = 7.4 Hz, 2H), 3.27 (quartet, J = 6.3 Hz, 2H), 2.61 (t, J = 7.4
Hz, 2H), 2.53 (s, 3H), 2.24 (s, 3H), 2.05 (t, J = 7.4 Hz, 2H), 1.94 (quintet, J = 7.0 Hz,
2H), 1.49 (s, 6H), 1.45 (s, 9H).

13

C NMR (CDCl3): ! 172.2, 155.9, 149.2, 137.8, 135.4,

133.4, 131.8, 122.7, 78.5, 59.3, 45.2, 39.2, 38.4, 31.6, 31.4, 28.0, 24.8, 24.4, 19.7. IR
(cm-1): 3410, 2976, 2934, 1753, 1697, 1524,1456, 1366.

HRMS: calc’d [M+H]+

(C22H36NO5): 394.2588. Found (EI): 394.2603.
Synthesis of compound 5.32: Under an air atmosphere, 5.31 (1.45 g, 3.69 mmol) was
dissolved in CH2Cl2 (40 mL), and PCC (1.79 g, 8.32 mmol) was added. The solution was
stirred for 2 h, at which time the material was filtered through a silica plug, and the
product was eluted using Et2O. Removal of the solvent afforded aldehyde 5.32 (1.26 g,
87%) as a brown oil. 1H NMR (CDCl3): ! 9.54 (t, J = 2.7 Hz, 1H), 6.85 (s, 1H), 6.60 (s,
1H), 4.69 (br. s, 1H), 3.27 (quartet, J = 6.6 Hz, 2H), 2.82 (d, J = 2.7 Hz, 2H), 2.60 (t, J =
7.4 Hz, 2H), 2.54 (s, 3H), 2.25 (s, 3H), 1.94 (quintet, J = 7.0 Hz, 2H), 1.56 (s, 6H), 1.46
(s, 9H).

13

C NMR (CDCl3): ! 201.6, 171.3, 155.3, 148.5, 136.8, 135.7, 131.7, 131.6,

122.5, 77.9, 55.6, 38.8, 37.1, 31.3, 30.6, 27.5, 24.4, 24.1, 19.3. IR (cm-1): 3410, 2978,
2932, 1751,1718, 1522, 1366. HRMS: calc’d [M]+ (C22H33NO5): 391.2359. Found (EI):
391.2359.
Synthesis of compound 5.33: Under an air atmosphere, 5.32 (1.33 g, 3.40 mmol) was
dissolved in DMF (35 mL). Oxone" (2.64 g, 4.28 mmol) was added and the solution was
stirred for 24 h. The solution was poured into 1:1 H2O:saturated brine, and the product
was extracted four times into CH2Cl2. The organic layers were dried over MgSO4,
filtered, and the solvent was removed. Purification via column chromatography (8:2
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cyclohexane:EtOAc followed by 6:4 cyclohexane:EtOAc) afforded acid 5.33 (1.26 g,
91%) as a pale yellow oil. 1H NMR (CDCl3): ! 6.83 (d, J = 2.0 Hz, 1H), 6.58 (d, J = 2.0
Hz, 1H), 4.77 (br. s, 1H), 3.24 (br. s, 2H), 2.82 (s, 2H), 2.61 (t, J = 7.0 Hz, 2H), 2.55 (s,
3H), 2.23 (s, 3H), 1.93 (quintet, J = 7.0 Hz, 2H), 1.58 (s, 6H), 1.46 (s, 9H).

13

C NMR

(CDCl3): ! 176.3, 172.1, 156.0, 149.2, 137.8, 135.9, 133.3, 132.2, 122.8, 79.1, 47.3, 39.6,
38.4, 32.0, 31.1, 28.2, 25.0, 24.7, 20.0. IR (cm-1): 3385, 2978, 2934, 1755, 1713, 1522,
1367. HRMS: calc’d [M+H]+ (C22H33NO6): 407.2381. Found (EI): 408.2378.
Synthesis of compound 5.34: 5.33 (1.18 g, 2.89 mmol) was dissolved in CH2Cl2 (15
mL).

Pentafluorophenol (0.64 g, 3.46 mmol), EDC&HCl (0.69 g, 3.62 mmol) and

pyridine (0.46 g, 5.81 mmol) were then added and the solution was stirred for 24 h. The
solution was poured into 1 M HCl and the product was extracted three times into CH2Cl2.
The organic layers were dried over MgSO4, filtered, and the solvent was removed. The
crude material was purified via column chromatography (9:1 cyclohexane:EtOAc
followed by 3:1 cyclohexane:EtOAc), affording ester 5.34 (1.57 g, 95%) as a pale yellow
oil. 1H NMR (CDCl3): ! 6.84 (d, J = 2.0 Hz, 1H), 6.62 (d, J = 2.0 Hz, 1H), 4.68 (br s,
1H), 3.27 (quartet, J = 6.6 Hz, 2H), 3.20 (s, 2H), 2.65, (t, J = 7.4 Hz, 2H), 2.57 (s, 3H),
2.24 (s, 3H), 1.96 (quintet, J = 7.0 Hz, 2H), 1.64 (s, 6H), 1.45 (s, 9H).

13

C NMR

(CDCl3): ! 172.1, 167.3, 156.1, 149.4, 142.4, 139.8, 138.9, 137.7, 136.6, 132.40, 132.36,
124.9, 123.1, 79.0, 46.7, 39.7, 38.9, 32.1, 31.0, 28.2, 25.03, 24.97, 20.0. IR (cm-1): 2981,
2934, 2898, 1792, 1763, 1716, 1620, 1521, 1368.

HRMS: calc’d [M+H]+

(C28H33F5NO6): 574.2223. Found (EI): 574.2242.
Synthesis of polymer 5.5b: Under an air atmosphere, 5.34 (1.41 g, 2.46 mmol) was
dissolved in 1:1 TFA:CH2Cl2 (16 mL), and the solution was stirred for 2 h. The solvent
was removed, and CH2Cl2 was then added and removed three times to remove residual
TFA.

Additional 5.34 (0.0717 g, 0.133 mmol) was added and the flask was fully

evacuated and refilled with Ar. Toluene (5 mL) was added and the solution was cooled
to 0 °C. DIPEA (1.80 mL, 10.3 mmol) and DMAP (63.2 mg, 0.517 mmol) were added,
and the solution was stirred 24 h. The solution was poured into 1 M HCl, and the product
was extracted three times into CH2Cl2. The organic layers were dried over MgSO4,
filtered, and the solvent was removed. The crude material was dialyzed against DMF
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(200 mL, 1 solvent change) using a regenerated cellulose membrane (Spectrum
Laboratories Spectra/Por, 3500 MW cutoff). The recovered polymer was then dissolved
1:1 dioxane:H2O (1 mL) and fully dried on a lyophilizer to afford 5.5b (0.132 g, 17%) as
a powdery white solid. 1H NMR (CDCl3): ! 6.85 – 6.79 (m, 1H), 6.57 – 6.52 (m, 1H),
6.18 – 5.93 (m, 1H), 3.25 – 3.06 (m, 2H), 2.58 – 2.47 (m, 3H), 2.47 – 2.37 (m, 2H), 2.35
– 2.27 (m, 2H), 2.25 – 2.18 (m, 3H), 1.83 – 1.67 (m, 1H), 1.66 – 1.58 (m, 7H), 1.43 (s,
0.3H). SEC: Mn = 4469, Mw = 6053, PDI = 1.4.
Synthesis of compound 5.12a&HCl: This compound was prepared following a literature
procedure.20 Under an air atmosphere, 5.35 (1.00 g, 9.73 mmol) was dissolved in MeOH
(50 mL). SOCl2 (3.50 mL, 49.5 mmol) was added, and the solution was heated to reflux
and stirred for 24 h. The solution was cooled to RT and then the solvent was removed,
affording 5.12a&HCl (1.50 g, 99%) as a white crystalline solid. 1H NMR (D2O): % 3.68
(s, 3H), 3.01 (t, J = 7.8 Hz, 2H), 2.50 (t, J = 7.8 Hz, 2H), 1.93 (quintet, J = 7.8 Hz, 2H).
Synthesis of compound 5.36: Acid 5.33 (0.0728 g, 0.179 mmol) was dissolved in
CH2Cl2 (1 mL). Pivaloyl chloride (0.030 mL, 0.244 mmol) and NEt3 (0.10 mL, 0.718
mmol) were added and the solution was stirred for 15 min. 5.12a&HCl (0.0566 g, 0.368
mmol) was added, and the solution was stirred for 24 h. The reaction mixture was then
poured into 1 M HCl, and the product was extracted three times into CH2Cl2. The
organic layers were dried over MgSO4, filtered, and then the solvent was removed.
Columm chromatography (3:1 cyclohexane:EtOAc followed by 1:1 cyclohexane:EtOAc)
afforded 5.36 (0.0511 g, 56%) as a colourless oil. 1H NMR (CDCl3): ! 6.82 (s, 1H), 6.59
(s, 1H), 5.64 (br s, 1H), 4.73 (br s, 1H), 3.65 (s, 3H), 3.28 (quartet, J = 6.3 Hz, 2H), 3.05
(quartet, J = 6.6 Hz, 2H), 2.65 (t, J = 7.0 Hz, 2H), 2.51 (s, 3H), 2.43 (s, 2H), 2.24 (s, 3H),
2.03 – 1.91 (m, 4H), 1.62 (s, 6H), 1.50 (quintet, J = 7.4 Hz, 2H), 1.46 (s, 9H).

13

C NMR

(CDCl3): ! 173.6, 173.4, 171.1, 156.0, 149.9, 138.7, 136.7, 133.2, 132.6, 123.1, 79.1,
51.3, 49.5, 39.9, 39.6, 38.3, 32.1, 32.0, 30.9, 28.2, 25.4, 25.0, 24.2, 20.0. IR (cm-1): 3381,
2977, 2933, 1738, 1713, 1656, 1533, 1440, 1367. HRMS: calc’d [M]+ (C27H42N2O7):
507.3065. Found (EI): 507.3072.
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Kinetics Studies
Buffer preparation: HEPES (0.119 g, 0.500 mmol) was dissolved in D2O (5.0 mL). To
this, a saturated solution of NaOH in D2O was added dropwise with stirring, while
monitoring with a pH meter until the desired pH of 7.4 was obtained.
NMR Kinetics Study: Compound 5.36 (7.5 mg) was dissolved in 1:1 TFA:CH2Cl2 (1
mL), and the solution was stirred for 2 h under an air atmosphere. The solvent was
removed, and CH2Cl2 was added and removed three times to remove residual TFA. The
material was then taken up in H2O and dioxane (approximately 2:1 H2O:dioxane, 2 mL)
and freeze-dried to remove all solvents. The material was then dissolved in pH 7.4
acetone-d6:0.1 M HEPES (D2O) (3:2) and incubated at 37 °C. Reaction progress was
monitored using 1H NMR spectroscopy by comparing the relative integrations of the
aromatic peaks arising from ester 5.37, intermediate phenol 5.38 and lactone 5.7.
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Chapter 6
Conclusions and Future Directions

The work described in this thesis represents a significant expansion of the relatively new
but rapidly growing field of self-immolative polymers. The primary focus was on the
development of amine-based self-immolative spacers for use in heterodimers to form
novel polymeric structures with unique degradation profiles. In the first study, it was
found that N,N’-dimethylethylenediamine could be combined with the aromatic spacer 4hydroxybenzyl alcohol to form a linear self-immolative polycarbamate. An initial model
polymer containing a Boc group as an end cap was shown to undergo end-to-end
depolymerization following end cap removal in the predicted manner, generating N,N’dimethylimidazolidinone and 4-hydroxybenzyl alcohol as the sole detectable degradation
products. When the polymer was studied under the same conditions without prior end
cap removal, minimal degradation was observed, indicating that depolymerization was a
specific process and required end cap removal in order to occur. This was the first
example involving the incorporation of cyclization spacers into self-immolative linear
polymers and demonstrated that they could be used to alter the depolymerization rate.
Utilizing the same polymer backbone with a PEG end cap, an amphiphilic block
copolymer was formed, which was found to undergo self-assembly into nanoparticles in
an aqueous environment.

These nanoparticles were capable of encapsulating a

hydrophobic molecule and gradually releasing it as degradation progressed,
demonstrating the potential for drug delivery applications. This was the first example
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involving the development of supramolecular assemblies of self-immolative linear
polymers.
The N,N’-dimethylethylenediamine spacer was also combined with 2mercaptoethanol to generate a linear self-immolative polymer that degraded entirely via
intramolecular cyclization reactions. This was of interest due to the potential toxicity of
the quinone methide degradation intermediates that would be generated from the
depolymerization of the polymers comprising 4-hydroxybenzyl alcohol.

By

incorporating a disulfide end cap, polymer degradation was initiated under reducing
conditions. Indeed, when the polymer was incubated in a phosphate buffered solution in
the presence of DTT as a reducing agent, polymer degradation occurred over the course
of 10 days, producing N,N’-dimethylimidazolidinone and 1,3-oxathiolan-2-one.
Analyzing this process using SEC revealed a gradual decrease in the molecular weight of
the polymer, further supporting the proposed end-to-end degradation mechanism. When
the polymer was studied under the same conditions in the absence of a reducing agent, no
degradation was observed, indicating that depolymerization was once again an
intramolecular process requiring end cap removal.
At this stage, it was of interest to demonstrate that self-immolative linear
polymers with a broad range of depolymerization rates could be developed. If this could
be achieved, it would eventually allow different polymer backbones, and thus
degradation rate to be selected according to their desired applications.

While the

backbones based on 4-aminobenzyl alcohol depolymerized very rapidly, the above
described backbones degraded slowly over periods of days.

To access polymer

backbones with different depolymerization rates, it would be necessary to develop new
monomers. To further broaden the scope of self-immolative spacers and gain access to
more rapidly cyclizing amine-based monomers, a series of 4-aminobutyric acid
derivatives were developed. Varying substituents were incorporated at the N- and %positions to probe the effects of sterics, rigidity and electronics on the rate of cyclization
of the amine on a phenyl ester. The findings suggested that 4-aminobutyric acid was
indeed a viable candidate as a self-immolative spacer, with half-lives of cyclization in the
range of 2 – 39 s. Furthermore, substitution was found to have a positive effect on the
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rate, as N-alkylated substrates cyclized more rapidly, and further substitution at the %position provided greater enhancement of cyclization rate. Additionally, further tests
were carried out under moderately acidic conditions utilizing the most rapidly cyclizing
spacer. As expected, the cyclization rate slowed as pH decreased, but even at pH 4.0,
well outside the pH range found within the body, the half-life of cyclization was still
found to be 76 s. Based on this result, it was hypothesized that polymeric systems based
on this spacer could be developed for applications in moderately acidic environments.
Building off of these results, two new polymeric systems were developed utilizing
4-aminobutyric acid in conjunction with either 4-hydroxybenzyl alcohol or 2’hydroxyhydrocinnamic acid. Multiple routes toward the first polymer were investigated
employing a variety of methodologies as well as variations to the 4-aminobutyric acid
backbone. While no usable polymer was ultimately obtained, much groundwork was laid
for future investigations. In the most promising approach, polymeric material was indeed
obtained. However, throughout the course of the polymerization an unexpected and as of
yet unknown side reaction occurred, rendering the polymer unusable. Efforts toward the
second polymer were more fruitful, as usable polymer was obtained. This polymer was
found to be substantially more hydrophobic than those previously studied, and thus
mandated that degradation studies be carried out in a predominantly organic, rather than
aqueous, environment. This modification had a profound effect on the rate of cyclization,
as monomer studies demonstrated that cyclization of the amine occurred orders of
magnitude slower with a half-life of greater than 8 h. Due to this prolonged timeline of
monomer degradation, no investigation of polymer degradation was undertaken at this
point.
Future investigations in this area of study involve the continuing development of
4-aminobutyric acid-based polymers.

First, a thorough kinetic investigation of the

degradation of polymer 5.5b is required. Following that, it would be desirable to increase
the hydrophilic character of such a polymer, first to improve the rate of depolymerization,
but also for potential use in other applications such as drug delivery. To this end, a
solubilizing group such as a triethylene glycol chain could be incorporated into the 4aminobutyric acid backbone. Alternatively, the polymer could be combined with PEG to

176

generate a block copolymer capable of self-assembly in aqueous environment.

By

synthesizing novel PEG end caps with varying functionality, it would be possible to
initiate degradation through alternative mechanisms other than ester hydrolysis.
Additionally, it would be desirable to employ the methodologies developed
toward polymeric structure 5.4 to obtain usable polymeric material.

Each method

employed showed significant potential but suffered from a flaw that could not be readily
overcome. In two of the cases, purity of the activated monomer proved to be the limiting
factor, so if alternative purification procedures could be developed it is likely that these
routes could be used to access polymeric material. In the final case, polymeric material
was obtained but an unwanted side reaction occurred during polymerization. Further
probing of the reaction and further characterization of the polymer obtained and its
degradation products may provide further insight into this side reaction and potentially
prevent it from occurring. Finally, the synthetic routes developed can potentially lay the
groundwork to the synthesis of other 4-aminobutyric acid-based polymers incorporating
alternative spacers.
Over the longer term, the controlled degradation of these self-immolative
polymers makes them of significant interest for biomedical applications where it is
desirable to trigger the breakdown of a biomaterial in order to release drug molecules or
perform other functions. Such applications may involve the use of these polymers as bulk
materials or the preparation of new block copolymers that will assemble into different
nanostructures such as micelles or vesicles in aqueous solution. Thus, future work will
involve further exploration of these areas as well as investigations into the toxicity and
biocompatibilities of these materials in different applications.
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Appendix 2: NMR spectra for compounds 2.6, 2.8, 2.10 –
2.13, 2.15 – 2.18, polymers 2.3a & 2.3b, control degradation
experiment of polymer 2.3a, SEC chromatogram for crude
polymer 2.3a, TEM image of polymer 2.3b stained with
OsO4, DLS spectrum of polymer 2.3b, MS data for
degradation products 1.72 and 1.97.
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Figure A2.1. 1H NMR of compound 2.6 (400 MHz, CDCl3).

Figure A2.2. 13C NMR of Compound 2.6 (100 MHz, CDCl3).
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Figure A2.3. 1H NMR of compound 2.8 (400 MHz, CDCl3).

Figure A2.4. 13C NMR of Compound 2.8 (100 MHz, CDCl3).
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Figure A2.5. 1H NMR of compound 2.10 (400 MHz, CDCl3).

Figure A2.6. 13C NMR of Compound 2.10 (100 MHz, CDCl3).
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Figure A2.7. 1H NMR of compound 2.11 (400 MHz, CDCl3).

185

Figure A2.8. 1H NMR of Compound 2.12 (400 MHz, CDCl3).

Figure A2.9. 13C NMR of Compound 2.12 (100 MHz, CDCl3).
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Figure A2.10. 1H NMR of Compound 2.13 (400 MHz, CDCl3).

Figure A2.11. 13C NMR of Compound 2.13 (100 MHz, CDCl3).
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Figure A2.12. 1H NMR of Compound 2.15 (400 MHz, CDCl3).

Figure A2.13. 1H NMR of Compound 2.16 (400 MHz, CDCl3).
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Figure A2.14. 1H NMR of Compound 2.17 (400 MHz, CDCl3).

Figure A2.15. 1H NMR of Compound 2.18 (400 MHz, CDCl3).

189

Differential Refractive Index (mV)

Figure A2.16. 1H NMR of Compound 2.3a (400 MHz, CDCl3).

Figure A2.17. SEC trace of Compound 2.3a prior to preparative SEC purification
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Figure A2.18. 1H NMR spectrum of polymer 2.3a without end cap removal in pH 7.4 0.1
M phosphate buffer (D2O):acetone-d6 (3:2) after 4 days at 37 °C, showing only trace
degradation into small molecules.

Figure A2.19. 1H NMR of Compound 2.3b (400 MHz, CDCl3).
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Figure A2.20. Transmission electron microscopy image of nanoparticles formed by the
assembly of polymer 2.3b in water. Staining was performed with OsO4. Scale bar = 100
nm.

Figure A2.21. Size distribution of nanoparticles of polymer 2.3b in water as measured by
dynamic light scattering (1 mg/mL, Zetasizer Nano ZS from Malvern Instruments).
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Figure A2.22. Mass spectrometry data further supporting the structures of the proposed
degradation products.
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Appendix 3: NMR spectra for compounds 3.7a, 3.9 – 3.13,
polymers 3.5a & 3.5b, 3.5b dialysiate, control degradation
experiments for polymer 3.5a & 3.5b, SEC chromatogram for
polymer 3.5a.
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Figure A3.1. 1H NMR of Compound 3.9 (400 MHz, CDCl3).

Figure A3.2. 13C NMR of Compound 3.9 (100 MHz, CDCl3).
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Figure A3.3. 1H NMR of Compound 3.10 (400 MHz, CDCl3).

Figure A3.4. 13C NMR of Compound 3.10 (100 MHz, CDCl3).
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Figure A3.5. 1H NMR of Compound 3.11 (400 MHz, CDCl3).

Figure A3.6. 13C NMR of Compound 3.11 (100 MHz, CDCl3).
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Figure A3.7. 1H NMR of Compound 3.12 (400 MHz, CDCl3).

Figure A3.8. 13C NMR of Compound 3.12 (100 MHz, CDCl3).
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Figure A3.9. 1H NMR of Compound 3.13 (400 MHz, CDCl3).

Figure A3.10. 13C NMR of Compound 3.13 (100 MHz, CDCl3).
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Figure A3.11. 1H NMR of Compound 3.7a (400 MHz, CDCl3).

Figure A3.12. 13C NMR of Compound 3.7a (100 MHz, CDCl3).
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Figure A3.13. 1H NMR of Polymer 3.5a (400 MHz, CDCl3).

Figure A3.14. SEC trace of Polymer 3.5a.
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Figure A3.15. 1H NMR of Polymer 3.5b (400 MHz, CDCl3).

HNEt3+

HNEt3+

Figure A3.16. 1H NMR spectrum of dialysate from polymer purification showing the
presence of polymeric species along with reaction byproducts 4-nitrophenol and
triethylammonium salts.
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Figure A3.17. 1H NMR spectrum of a degradation control sample in which the Boc end
cap was not removed from Polymer 3.5a, but the polymer was incubated for 5 days in pH
7.4 0.1 M phosphate buffered D2O:acetone-d6 (3:2). Degradation was not observed.

Figure A3.18. 1H NMR spectrum of a degradation control sample in which Polymer 3.5b
was incubated for 14 days in pH 7.4 0.1 M phosphate buffered D2O:acetone-d6 (3:2) in
the absence of DTT. No detectable degradation was observed.
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Appendix 4: NMR spectra for 4.3 – 4.4b, 4.6a – 4.11d,
4.13a-d, 4.15 – 4.17b, 4.1a-k.TFA, 4.18a-k, graphs of UV-Vis
spectra and ln plots for cyclization of 4.1a-k.
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Figure A4.1. 1H NMR of Compound 4.3 (400 MHz, CDCl3).

Figure A4.2. 13C NMR of Compound 4.3 (100 MHz, CDCl3).
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Figure A4.3. 1H NMR of Compound 4.4a (400 MHz, CDCl3).

Figure A4.4. 13C NMR of Compound 4.4a (100 MHz, CDCl3).
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Figure A4.5. 1H NMR of Compound 4.4b (400 MHz, CDCl3).

Figure A4.6. 13C NMR of Compound 4.4b (100 MHz, CDCl3).
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Figure A4.7. 1H NMR of Compound 4.6a (400 MHz, CDCl3).

Figure A4.8. 13C NMR of Compound 4.6a (100 MHz, CDCl3).
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Figure A4.9. 1H NMR of Compound 4.6b (400 MHz, CDCl3).

Figure A4.10. 13C NMR of Compound 4.6b (100 MHz, CDCl3).
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Figure A4.11. 1H NMR of Compound 4.7a (400 MHz, CDCl3).

Figure A4.12. 13C NMR of Compound 4.7a (100 MHz, CDCl3).
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Figure A4.13. 1H NMR of Compound 4.7b (400 MHz, CDCl3).

Figure A4.14. 13C NMR of Compound 4.7b (100 MHz, CDCl3).

211

Figure A4.15. 1H NMR of Compound 4.7c (400 MHz, CDCl3).

Figure A4.16. 13C NMR of Compound 4.7c (100 MHz, CDCl3).
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Figure A4.17. 1H NMR of Compound 4.8a (400 MHz, CDCl3).

Figure A4.18. 13C NMR of Compound 4.8a (100 MHz, CDCl3).

213

Figure A4.19. 1H NMR of Compound 4.8b (400 MHz, CDCl3).

Figure A4.20. 13C NMR of Compound 4.8b (100 MHz, CDCl3).
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Figure A4.21. 1H NMR of Compound 4.8c (400 MHz, CDCl3).

Figure A4.22. 13C NMR of Compound 4.8c (100 MHz, CDCl3).
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Figure A4.23. 1H NMR of Compound 4.9a (400 MHz, CDCl3).

Figure A4.24. 13C NMR of Compound 4.9a (100 MHz, CDCl3).
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Figure A4.25. 1H NMR of Compound 4.9b (400 MHz, CDCl3).

Figure A4.26. 13C NMR of Compound 4.9b (100 MHz, CDCl3).
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Figure A4.27. 1H NMR of Compound 4.9c (400 MHz, CDCl3).

Figure A4.28. 13C NMR of Compound 4.9c (100 MHz, CDCl3).
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Figure A4.29. 1H NMR of Compound 4.10a (400 MHz, CDCl3).

Figure A4.30. 13C NMR of Compound 4.10a (100 MHz, CDCl3).
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Figure A4.31. 1H NMR of Compound 4.10b (400 MHz, CDCl3).

Figure A4.32. 13C NMR of Compound 4.10b (100 MHz, CDCl3).
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Figure A4.33. 1H NMR of Compound 4.10c (400 MHz, CDCl3).

Figure A4.34. 13C NMR of Compound 4.10c (100 MHz, CDCl3).
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Figure A4.35. 1H NMR of Compound 4.10d (400 MHz, CDCl3).

Figure A4.36. 13C NMR of Compound 4.10d (100 MHz, CDCl3).
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Figure A4.37. 1H NMR of Compound 4.11a (400 MHz, CDCl3).

Figure A4.38. 13C NMR of Compound 4.11a (100 MHz, CDCl3).
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Figure A4.39. 1H NMR of Compound 4.11b (400 MHz, CDCl3).

Figure A4.40. 13C NMR of Compound 4.11b (100 MHz, CDCl3).
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Figure A4.41. 1H NMR of Compound 4.11c (400 MHz, CDCl3).

Figure A4.42. 13C NMR of Compound 4.11c (100 MHz, CDCl3).
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Figure A4.43. 1H NMR of Compound 4.11d (400 MHz, CDCl3).

Figure A4.44. 13C NMR of Compound 4.11d (100 MHz, CDCl3).
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Figure A4.45. 1H NMR of Compound 4.13a (400 MHz, CDCl3).

Figure A4.46. 13C NMR of Compound 4.13a (100 MHz, CDCl3).
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Figure A4.47. 1H NMR of Compound 4.13b (400 MHz, CDCl3).

Figure A4.48. 13C NMR of Compound 4.13b (100 MHz, CDCl3).
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Figure A4.49. 1H NMR of Compound 4.13c (400 MHz, CDCl3).

Figure A4.50. 13C NMR of Compound 4.13c (100 MHz, CDCl3).
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Figure A4.51. 1H NMR of Compound 4.13d (400 MHz, CDCl3).

Figure A4.52. 13C NMR of Compound 4.13d (100 MHz, CDCl3).
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Figure A4.53. 1H NMR of Compound 4.15 (400 MHz, CDCl3).

Figure A4.54. 13C NMR of Compound 4.15 (100 MHz, CDCl3).
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Figure A4.55. 1H NMR of Compound 4.16a (400 MHz, CDCl3).

Figure A4.56. 13C NMR of Compound 4.16a (100 MHz, CDCl3).
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Figure A4.57. 1H NMR of Compound 4.16b (400 MHz, CDCl3).

Figure A4.58. 13C NMR of Compound 4.16b (100 MHz, CDCl3).
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Figure A4.59. 1H NMR of Compound 4.17a (400 MHz, CDCl3).

Figure A4.60. 13C NMR of Compound 4.17a (100 MHz, CDCl3).
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Figure A4.61. 1H NMR of Compound 4.17b (400 MHz, CDCl3).

Figure A4.62. 13C NMR of Compound 4.17b (100 MHz, CDCl3).
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Figure A4.63. 1H NMR of Compound 4.1a&TFA (400 MHz, CDCl3).

Figure A4.64. 1H NMR of Compound 4.18a (400 MHz, CDCl3).
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Figure A4.65. 1H NMR of Compound 4.1b&TFA (400 MHz, CDCl3).

Figure A4.66. 1H NMR of Commercial NMP and compound 4.18b (400 MHz, CDCl3).
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Figure A4.67. 1H NMR of Compound 4.1c&TFA (400 MHz, CDCl3).

Figure A4.68. 1H NMR of Compound 4.18c (400 MHz, CDCl3).
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Figure A4.69. 1H NMR of Compound 4.1d&TFA (400 MHz, CDCl3).

Figure A4.70. 1H NMR of Compound 4.18d (400 MHz, CDCl3).
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Figure A4.71. 1H NMR of Compound 4.1e&TFA (400 MHz, CDCl3).

Figure A4.72. 1H NMR of Compound 4.18e (400 MHz, CDCl3).
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Figure A4.73. 1H NMR of Compound 4.1f&TFA (400 MHz, CDCl3).

Figure A4.74. 1H NMR of Compound 4.18f (400 MHz, CDCl3).
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Figure A4.75. 1H NMR of Compound 4.1g&TFA (400 MHz, CDCl3).

Figure A4.76. 1H NMR of Compound 4.18g (400 MHz, CDCl3).
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Figure A4.77. 1H NMR of Compound 4.1h&TFA (400 MHz, CDCl3).

Figure A4.78. 1H NMR of Compound 4.18h (400 MHz, CDCl3).
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Figure A4.79. 1H NMR of Compound 4.1i&TFA (400 MHz, CDCl3).

Figure A4.80. 1H NMR of Compound 4.18i (400 MHz, CDCl3).
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Figure A4.81. 1H NMR of Compound 4.1j&TFA (400 MHz, CDCl3).

Figure A4.82. 1H NMR of Compound 4.18j (400 MHz, CDCl3).
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Figure A4.83. 1H NMR of Compound 4.1k&TFA (400 MHz, CDCl3).

Figure A4.84. 1H NMR of Compound 4.18k (400 MHz, CDCl3).
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Figure A4.85. Cyclization kinetics for compounds 4.1a and 4.1b.

Figure A4.86. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compounds 4.1a and 4.1b.
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Figure A4.87. Cyclization kinetics for compounds 4.1c, 4.1d and 4.1e.

Figure A4.88. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compounds 4.1c, 4.1d, and 4.1e.
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Figure A4.89. Cyclization kinetics for compounds 1.4f, 1.4g and 1.4i.

Figure A4.90. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compounds 3f, 3g, and 3i.
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Figure A4.91. Cyclization kinetics for compound 4.1h.

Figure A4.92. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compound 4.1h.
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Figure A4.93. Cyclization kinetics for compounds 4.1j and 4.1k.

Figure A4.94. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compounds 4.1j and 4.1k.
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Figure A4.95. Cyclization rate of compound 4.1i at pH 7.0 and 6.0.

Figure A4.96. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compound 4.1i at pH 7.0 and 6.0.
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Figure A4.97. Cyclization of compound 4.1i and pH 5.0 and 4.0.

Figure A4.98. Determination of first order rate constant by ln[A]0/[A] vs t graph for
compound 4.1i at pH 5.0 and 4.0.
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Appendix 5: NMR spectra for compounds 5.9a, 5.10b, 5.12a,
5.16a – 5.20, 5.24 – 5.27, 5.29, 5.31 – 5.34, 5.36, polymer
5.5b, SEC chromatogram for polymer 5.5b.
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Figure A5.1. 1H NMR of Compound 5.17 (400 MHz, CDCl3).
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Figure A5.2. 13C NMR of Compound 5.17 (100 MHz, CDCl3).
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Figure A5.3. 1H NMR of Compound 5.18 (400 MHz, CDCl3).
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Figure A5.4. 13C NMR of Compound 5.18 (100 MHz, CDCl3).
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Figure A5.5. 1H NMR of Compound 5.9a (400 MHz, CDCl3).
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Figure A5.6. 13C NMR of Compound 5.9a (100 MHz, CDCl3).
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Figure A5.7. 1H NMR of Compound 5.19 (400 MHz, CDCl3).
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Figure A5.8. 13C NMR of Compound 5.19 (100 MHz, CDCl3).
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Figure A5.9. 1H NMR of Compound 5.20 (400 MHz, CDCl3).
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Figure A5.10. 13C NMR of Compound 5.20 (100 MHz, CDCl3).
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Figure A5.11. 1H NMR of Compound 5.24 (400 MHz, CDCl3).
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Figure A5.12. 13C NMR of Compound 5.24 (100 MHz, CDCl3).
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Figure A5.13. 1H NMR of Compound 5.25 (400 MHz, CDCl3).
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Figure A5.14. 13C NMR of Compound 5.25 (100 MHz, CDCl3).
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Figure A5.15. 1H NMR of Compound 5.26 (400 MHz, CDCl3).
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Figure A5.16. 13C NMR of Compound 5.26 (100 MHz, CDCl3).
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Figure A5.17. 1H NMR of Compound 5.27 (400 MHz, CDCl3).
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Figure A5.18. 13C NMR of Compound 5.27 (100 MHz, CDCl3).
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Figure A5.19. 1H NMR of Compound 5.10b (400 MHz, CDCl3).
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Figure A5.20. 13C NMR of Compound 5.10b (100 MHz, CDCl3).
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Figure A5.21. 1H NMR of Compound 5.29 (400 MHz, CDCl3).
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Figure A5.22. 13C NMR of Compound 5.29 (100 MHz, CDCl3).
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Figure A5.23. 1H NMR of Compound 5.16a (400 MHz, CDCl3).
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Figure A5.24. 13C NMR of Compound 5.16a (100 MHz, CDCl3).
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Figure A5.25. 1H NMR of Compound 5.31 (400 MHz, CDCl3).
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Figure A5.26. 13C NMR of Compound 5.31 (100 MHz, CDCl3).
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Figure A5.27. 1H NMR of Compound 5.32 (400 MHz, CDCl3).
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Figure A5.28. 13C NMR of Compound 5.32 (100 MHz, CDCl3).
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Figure A5.29. 1H NMR of Compound 5.33 (400 MHz, CDCl3).
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Figure A5.30. 13C NMR of Compound 5.33 (100 MHz, CDCl3).
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Figure A5.31. 1H NMR of Compound 5.34 (400 MHz, CDCl3).
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Figure A5.32. 13C NMR of Compound 5.34 (100 MHz, CDCl3).
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Figure A5.33. 1H NMR of Polymer 5.4b (400 MHz, CDCl3).
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Figure A5.34. SEC trace of Polymer 5.4b.
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Figure A5.35. 1H NMR of Compound 5.12a&HCl (400 MHz, D2O).
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Figure A5.36. 1H NMR of Compound 5.36 (400 MHz, CDCl3).
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Figure A5.37. 13C NMR of Compound 5.36 (100 MHz, CDCl3).
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